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Chapter 1 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
2 Chapter 1  
 
1.1 Malignant brain tumors 
 
1.1.1  Classification 
 
Malignant brain tumors comprise various groups of CNS neoplasms that can be divided into 
primary tumors, originating from cells physiologically present in the brain and secondary 
tumors, derived from extracranial neoplasms which have metastasized to the brain. Primary 
brain tumors are classified by the predominant cell type of the respective neoplasm according 
to clearly defined histopathological and clinical criteria. More than 30 years ago, the 
international classification of diseases for oncology (ICD-O) was established, which serves as 
an indispensable guideline for the grading of cancers by providing histopathology and 
mortality data for epidemiological as well as oncological studies [Louis et al., 2007]. In 1979, 
the first edition of histological typing of CNS tumors was published [Zülch, 1979] and since 
that time continuously updated, e.g. by the introduction of immunohistochemistry and genetic 
profiling as well as clinical signs, symptoms, imaging and many other aspects, aiming at a 
refined classification [Kleihues et al., 1993; Kleihues and Sobin, 2000]. Quite recently, the 
latest version of the WHO (World Health Organization) classification of tumors of the central 
nervous system was published [Louis et al., 2007]. It contains, amongst several new entities 
and histological variants the updated WHO grading scheme for malignant brain tumors. 
 
Up to date, the so-called group of “glioma” represents a good portion of the primary 
malignant brain tumors, including astrocytomas, oligodendrogliomas, ependymomas and 
oligoastrocytomas. Gliomas constitute malignancies of the supporting tissue, which 
physiologically acts as a kind of protector and supporter for the nerve cells in the brain. 
Hence, the classification of different glioma types depends on the similarity of the tumor cells 
compared to healthy glial cells, namely astrocytes, oligodendrocytes and ependymal cells. 
Furthermore, several kinds of mixed gliomas contain great fractions of different cell types, for 
example astrocytes and oligodendrocytes or astrocytes and ependymal cells. According to the 
Central Brain Tumor Registry of the United States (CBTRUS), gliomas amount to 33 % of all 
brain tumors and even 80 % of the malignant brain neoplasms of addults. Moreover, 77 % of 
all primary malignant brain tumors belong to the astrocytoma class  [CBTRUS, Online 2009].  
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1.1.2  Diagnosis procedure of brain tumors 
 
At the beginning of brain tumor diagnosis, usually typical parameters such as vision, hearing, 
balance, coordination and reflexes are checked. Results of these preliminary enquiries rule the 
further procedure, which can contain the use of special imaging methods, such as CT, MRI or 
PET, to affirm the existence of a tumor. Furthermore, visualization of the brain by 
aforementioned techniques allows localizing the putative neoplasm as well as distinguishing 
the tumor from healthy tissue and, depending on the method, gives information on impaired 
brain activity and function caused by the tumor. 
 
1.1.2.1 Imaging techniques 
 
Computed X-ray Tomography (CT) describes the measurement of X-ray attenuation (≈ 40-80 
keV) as the basis for a 2-dimensional imaging procedure. Despite of high spatial resolution 
(20 µm), simple applicability and relatively low costs, CT implies several drawbacks such as 
low sensitivity, high radiation doses, lack of functional information as well as poor soft tissue 
contrast (might be enhanced by contrast agents) [Laboratory for Preclinical Imaging 
Technologies, 2007].  
 
Magnetic Resonance Imaging (MRI) represents an alternative method of noninvasive tumor 
imaging. MRI is characterized by high spatial resolution (50-500 µm) and the use of non-
ionizing radiation. However, the low sensitivity (micromolar range) and mainly the high costs 
limit the application of Magnetic Resonance Imaging as a standard procedure in preclinical 
oncology [Laboratory for Preclinical Imaging Technologies, 2007]. 
 
 
An excellent technique for the visualization of metabolic and functional processes, e.g. in 
cardiology, immunology but also particularly in oncology, is Positron Emission Tomography 
(PET). For PET measurements, positron emitting short-lived radionuclides (half-life ideally 
several hours) are injected into the specimen. Thereby, the positron-electron annihilation leads 
to the generation of two 511 keV gamma rays which are emitted in an angle of 180° and are 
determined by a static detector. The path-length of the positrons depends on tissue density as 
well as positron energy.  
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Due to differences in metabolic processes in tumors and healthy tissues, PET techniques are 
very valuable methods in diagnostics, therapy planning and therapy control. Complex 
processing of radiotracers, limited resolution and little information on the correlation of 
morphology and PET signals restrict the application of PET imaging [Laboratory for 
Preclinical Imaging Technologies, 2007]. 
 
In view of the benefits and disadvantages of the aforementioned imaging techniques, the 
combination of different methods is a promising approach to improve noninvasive imaging. 
Such “Multi Modality Imaging” can be realized for example by combining Positron Emission 
Tomography with CT or MRI, respectively. Thereby, morphological information from CT / 
MRI can be connected with functional data obtained by the PET technique [Laboratory for 
Preclinical Imaging Technologies, 2007]. 
 
1.1.2.2 Histopathology 
 
In order to confirm a putative brain tumor, suggested from preliminary imaging explorations, 
biopsy of the tissue for histopathology is essential. Moreover, biopsy is the prerequisite to 
distinguish between different subtypes of neoplasms and to grade malignancy. For example, 
the astrocytic origin of a tumor becomes obvious by the detection of star-shaped cells. 
Astrocytomas have been shown to extensively infiltrate into the healthy brain tissue, and 
especially glioblastoma multiforme proved to display a great variety in the extent, the 
geometry and the character of the infiltrating margin [Burger et al., 1988].  
 
Brain tumors are classified according to histological grading which is considered as a 
“malignancy scale”. The WHO classification contains 4 different grades representing 
ascending malignancy of the intracranial neoplasms. Whereas grade I tumors are 
characterized by a low proliferative potential and offer the chance of cure after resection, 
neoplasms ranked in grade II show infiltrative growth and tend to recur. Furthermore, some 
types of grade II tumors can progress to high grade malignancies, for instance, low-grade 
diffuse astrocytomas can develop to anaplastic astrocytoma or even glioblastoma. The 
classification of tumors as WHO grade III corresponds to histological evidence of malignancy 
such as vigorous mitotic activity or nuclear atypia.  
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Finally, the category WHO grade IV is applied to tumors characterized by microvascular 
proliferation and / or necrosis in addition to the aforementioned features [Louis et al., 2007].  
An example of WHO grad IV classification includes glioblastoma as a subtype of 
astrocytomas, which account for more than 3 quarter of all astrocytic tumors. A synopsis of 
the current grading of the predominating group of brain neoplasms, namely the astrocytic 
tumors, is given in Table 1.1. 
 
 
 
 
Astrocytic tumors I II III IV 
Subependymal giant cell astrocytoma ●    
Pilocytic astrocytoma ●    
Pilomyxoid astrocytoma  ●   
Diffuse astrocytoma  ●   
Pleomorphic xanthoastrocytoma  ●   
Anaplastic astrocytoma   ●  
Glioblastoma    ● 
Giant cell glioblastoma    ● 
Gliosarcoma    ● 
 
 
However, the classification as well as the grading of the malignancy by means of 
histopathology is associated with several limitations. Since only small biopsy samples are 
taken, it is possible that the neoplasm is classified into the false subtype of CNS tumor. This 
can be explained by different histological grades of malignancy, which are found in various 
areas of the same tumor [Kepes, 1994]. Hence, inaccurate diagnosis might be responsible for 
underestimation of the degree of malignancy [Glantz et al., 1991] and cause suboptimal 
therapy of the malignant brain tumor [Jackson et al., 2001].  
 
 
Table 1.1: WHO grading (I-IV) of astrocytic tumors according to “The 2007 WHO 
Classification of Tumours of the Central Nervous System”. Modified from Louis et al. [Louis 
et al., 2007]  
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1.1.2.3 Molecular classification of tumor types 
 
In recent years much effort has been spent on developing more accurate methods for the 
grading of CNS neoplasms. Predominantly, the highly specific molecular classification of 
tumor types by identifying genetic abnormalities in different subtypes of neoplasms has 
become a valuable tool for the detailed characterization of various malignancies. Such gene 
expression profiling studies were performed by several workgroups to distinguish between 
non-neoplastic brain tissue and gliomas of different pathology. Moreover, these methods 
might be helpful for identifying new therapeutic targets in the therapy of malignant brain 
tumors. For example, Shai et al. could characterize the key molecular differences between 
healthy brain tissue, grade II and III astrocytomas, oligodendrogliomas and glioblastomas by 
means of 170 selected genes [Shai et al., 2003]. Quite recent studies, using oligonucleotide 
microarrays and real-time quantitative PCR, indicated the presence of 18 over-expressed 
genes in human primary glioblastoma compared to non-neoplastic brain tissues. These 
investigations suggest a significant role of such over-expressed genes in the pathogenesis of 
brain tumors and might be promising starting points in the search for new targets in 
glioblastoma treatment [Scrideli et al., 2008].  
 
 
 
Taken together, in addition to highly efficient noninvasive imaging techniques (e.g. CT, MRI 
and PET) for the early diagnosis of brain tumors, reliable histopathological examinations are 
indispensable for the confirmation as well as for the grading of the tumor. Beyond that, the 
genetic profiling of different tumor types demonstrating specific mutations and / or 
overexpression of genes in various neoplasms has become an alternative strategy to classify 
tumors and to identify putative new targets for cancer therapy.  
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1.1.3  Prognosis 
 
The tumor grade is of critical prognostic value, but other criteria including age of the patient, 
tumor location, proliferation indices, genetic alterations and many more are to be considered 
in the prediction of survival time [Louis et al., 2007]. Despite extensive search for new 
approaches in the therapy of gliomas over the last 3 decades, the median survival time could 
not be appreciably enhanced.  
 
Typically, patients bearing WHO grade II gliomas (diffuse astrocytoma, oligodendroglioma 
and mixed oligoastrocytoma) survive 5 to 7 years after diagnosis. For grade III gliomas (e.g. 
anaplastic astrocytoma), an averaged survival of 2-3 years is typical, whereas patients with 
high-grade glioblastoma multiforme (WHO grade IV) succumb to the disease in large part 
within 1 year after diagnosis [Rees, 2002; Louis et al., 2007]. A prolongation of the survival 
period from 12 to 15 months was recently achieved by concomitant and adjuvant application 
of temozolomide plus radiotherapy [Stupp et al., 2005]. Nevertheless, the increase by 3 
months in the median survival reflects the deflating situation in the therapy of glioblastoma 
during the last 30 years. Only 3-5 percent of glioma patients are classified as long-term 
survivors who outlive the disease for more than 5 years. Definite reasons for such long-term 
survivals are still unclear, although several clinical factors seem to be beneficial, in particular 
a young age at the point of diagnosis [Krex et al., 2007].  
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1.1.4  Management of WHO grade III and grade IV gliomas 
 
The current recommendations for the treatment of high grade (WHO grade III and IV) glioma, 
including anaplastic astrocytoma and glioblastoma, consider several different therapeutic 
strategies [Alberta Provincial CNS Tumor Team, 2009]: 
 
(1) Aiming at both, debulking of the malignancy and obtaining of tissue for diagnosis, 
surgery represents the accepted starting point in the therapy of glioma. Moreover, 
neurosurgical literature advocates the maximally possible resection of tumor 
tissue [Quigley and Maroon, 1991; Alberta Provincial CNS Tumor Team, 2009], 
since, according to this approach, a survival benefit for glioma patients was 
proven in many studies [Ammirati et al., 1987; Nitta and Sato, 1995; Kiwit et al., 
1996; Lacroix et al., 2001]. 
 
(2) Already in 1978, Walker et al. demonstrated the efficacy of postoperative 
radiotherapy (RT) in the treatment of anaplastic glioma [Walker et al., 1978]. 
Using a dose of 50-60 Gy, the median survival was increased to 8.4 months 
compared to the best supportive therapy [Alberta Provincial CNS Tumor Team, 
2009]. Still today, a total dose of 60 Gy in 30 fractions is standard in external 
beam radiation therapy. Dose-effect studies on patients bearing anaplastic 
astrocytoma or glioblastoma multiforme revealed an increased median survival 
using a dose of 60 Gy compared to 45 Gy [Walker et al., 1979]. Despite several 
trials, using higher doses [Nelson et al., 1988; Chan et al., 2002], no significant 
improvement in survival time was reported so far [Alberta Provincial CNS Tumor 
Team, 2009]. Furthermore, trials with alternative fractionation regimens such as 
hyper-fractionation and super-fractionation, did not statistically significantly 
improve survival outcome [Alberta Provincial CNS Tumor Team, 2009]. 
 
(3) Due to poor brain penetration, the applicability of cytostatic agents in the therapy 
of malignant brain tumors is extremely limited. The most utilized chemo-
therapeutics are the nitrosoureas carmustine (BCNU) and lomustine (CCNU) as 
well as the alkylating benzamide procarbazine.  
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Since 2005, the concomitant and adjuvant chemotherapy using the alkylating 
agent temozolomide (TMZ) combined with radiotherapy (RT) represents the 
standard regimen in the treatment of WHO grade IV glioma after surgery [Alberta 
Provincial CNS Tumor Team, 2009]. Temozolomide is an orally available 
prodrug which penetrates into the brain and spontaneously undergoes hydrolysis 
to its active metabolite MTIC [5-(3-dimethyl-1-triazenyl)imidazole-4-carbox-
amide]. Subsequently, MTIC breaks down to methyldiazonium which causes 
methylation of guanine residues in the DNA [Koukourakis et al., 2009]. An 
overview of the metabolism of temozolomide is shown in Figure 1.1. 
 
In contrast to other combined chemotherapy and radiation regimens, which 
showed no survival benefit, e.g. radiotherapy plus mitomycin [Halperin et al., 
1996], the concomitant and adjuvant temozolomide application proved to result in 
survival advantage. Athanassiou et al. performed a multicenter randomized phase 
II study to compare the concomitant temozolomide RCT (radiochemotherapy) 
with RT alone, in newly diagnosed glioblastoma multiforme [Athanassiou et al., 
2005]. For this purpose, 57 patients received TMZ (75 mg/m²/d; orally) 
concomitantly with RT (60 Gy in 30 fractions). Furthermore, the treatment 
consisted of 6 consecutive cycles of TMZ (150 mg/m² on days 1 through 5 and 15 
to 19 every 28 days). In contrast, the second group (53 patients) was treated with 
RT alone (60 Gy in 30 fractions). These investigations revealed that the 
concomitant and adjuvant temozolomide radiochemotherapy (RCT) caused not 
only an increase of the median time to progression (10.8 months RCT vs. 5.2 
months RT) but also yielded a higher 1-year progression-free survival rate (36.6% 
RCT vs. 7.7% RT). In addition, the median survival time (13.4 months RCT vs. 
7.7 months RT) as well as the 1-year overall survival (56.3% RCT vs. 15.7% RT) 
proved to be significantly enhanced [Athanassiou et al., 2005].  
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A similar trial on 573 patients with newly diagnosed glioblastoma multiforme was 
conducted by Stupp et al. [Stupp et al., 2005]. The study showed a median 
survival of 14.6 months, when treated with radiotherapy plus temozolomide, 
whereas patients who received radiotherapy alone survived at an average of 12.1 
months [Stupp et al., 2005]. 
 
Quite recently, investigations on the mechanism of action as well as on resistance 
effects of temozolomide were reviewed in detail by Koukourakis et al. 
[Koukourakis et al., 2009]. In addition, this review presents current clinical 
studies and applications of temozolomide. 
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Figure 1.1: Metabolism of the alkylating chemotherapeutic temozolomide to its active 
metabolite MTIC and generation of the DNA alkylating methyldiazonium ion (modified 
from [Koukourakis et al., 2009]). 
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1.2  New approaches to the therapy of glioblastoma 
 
Despite extensive oncological research aiming at improved therapy of malignant brain 
tumors, the prognosis, especially for glioblastoma multiforme (GBM) patients still remains 
unfavorable. Over the last 3 decades, the median survival of GBM patients could be only 
marginally prolonged. The concomitant and adjuvant temozolomide treatment combined with 
radiotherapy proved to be a survival benefit [Athanassiou et al., 2005; Stupp et al., 2005], but 
nevertheless yielded only a slight increase in average survival from 12 to 15 months. Hence, 
new approaches to the therapy of glioblastoma are still required. Some current aspects are 
discussed in more detail in the following. Prior to this, essential features of the blood-brain 
barrier (BBB) are summarized since many problems and limitations in the therapy of 
malignant brain tumors are caused by the morphology and functionality of the BBB. 
 
    
1.2.1  Architecture and function of the blood-brain barrier (BBB) 
 
Both, endogenous and exogenous toxins are prevented from entering the brain by 2 
physiological barriers, namely the blood-brain barrier (BBB) and the blood-cerebrospinal 
fluid barrier (BCSFB). Whereas the BBB is formed by tight junctions connecting the cerebral 
endothelial cells, the blood-cerebrospinal fluid barrier represents a network of associated 
epithelial cells from the choroid plexus [Sugiyama et al., 1999]. However, the BCSFB is 
estimated to have a 5000-fold smaller area than the blood-brain barrier [Deeken and Löscher, 
2007] and, consequently, plays a less important role in the homeostasis of the brain.  
 
1.2.1.1 Characteristics of the cerebral endothelium 
 
The cerebral endothelial cells at the blood-brain barrier are unique in their appearance since 
they show continuous tight junctions and lack of fenestration. Moreover, they possess low 
pinocytotic activity [Wolburg and Lippoldt, 2002]. Several transmembrane proteins, mainly 
occludine, claudins and the so-called JAM’s (junctional adhesion molecules), interact with the 
brain endothelial cells and thereby contribute to the complexity of the tight junctions at the 
BBB [Cecchelli et al., 2007]. Hence, all these specifics arrange for an effective seal of the 
paracellular pathway into the brain.  
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In addition, the cerebral endothelial cells are not only surrounded by extracellular matrix and 
basal membrane but also by astrocytic and pericytic end-feets. More than 90 % of the cell 
surface of brain endothelial cells are covered by astrocytes, which have the ability to partially 
control the permeability of the BBB by releasing a great number of different chemical 
substances [Abbott et al., 2006; Deeken and Löscher, 2007]. Another characteristic of the 
brain capillaries is their 100-200 fold higher electrical resistance compared to the vasculature 
in the periphery (1000-2000 Ω · cm-2 vs. 10 Ω · cm-2) [Deeken and Löscher, 2007], which is 
thought to be reasoned by the great variability of transmembrane protein composition, mainly 
the high occludine expression [Hirase et al., 1997]. This electrical resistance mediates an 
additional prevention against the penetration of polar and ionic substances.  
 
1.2.1.2 Physicochemical criteria of drugs to access to the brain 
 
Due to the highly effective compartmentalization of the brain by the blood-brain barrier, 
drugs administered to target the brain, e.g. cytostatics in the therapy of malignant brain 
tumors, have to fulfill specific physicochemical criteria with respect to membrane permeation 
and access to the brain [Doan et al., 2002]. Whereas small (<400 Da) nonpolar compounds 
should be able to passively diffuse via the transcellular pathway [Pardridge, 2003], water-
soluble or polar substances can only cross the BBB via transport systems [Deeken and 
Löscher, 2007].  
 
1.2.1.3 Drug efflux transporters at the BBB 
 
However, despite fulfilling the aforementioned criteria in terms of molecular weight and 
lipophilicity, many compounds including cytostatics show only limited brain penetration 
since they are actively extruded by a vast number of drug efflux transporters which are 
expressed at the blood-brain barrier. ATP-Binding Cassette (ABC) transporters represent a 
major family of such efflux pumps which compromise the efficacy of many anticancer drugs 
in the chemotherapy of malignant brain tumors. Predominantly, expression of the subtypes 
ABCB1 (MDR1, p-glycoprotein 170), ABCC2 (MRP2, multidrug related protein 2) and 
ABCG2 (MXR, breast cancer resistance protein) at the BBB were shown to play an important 
role in the resistance of CNS neoplasms. These transporters use the energy of ATP-hydrolysis 
to actively pump out a vast number of structurally unrelated compounds. Further details on 
ABC efflux pumps are given in chapter 4.  
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In recent years, a second class of drug efflux transporters, organic anion and cation 
transporters (OAT’s and OCT’s), has gained interest with respect to expression at the blood-
brain barrier. Nevertheless, the research on OAT’s and OCT’s in the chemoresistance of 
malignant brain tumors is still at the beginning [Deeken and Löscher, 2007]. 
 
 
1.2.2  Strategies to overcome the blood-brain barrier 
 
1.2.2.1 Osmotic opening of the BBB  
 
An interesting approach to increase intracerebral levels of water-soluble and high molecular 
weight molecules represents the intermittent opening of the BBB by direct infusion of 
hypertonic solutions, e.g. arabinose or mannitol, into the carotid artery. More than 30 years of 
extensive pre-clinical studies have contributed to a more detailed understanding of the 
mechanism of action during osmotic opening [Bellavance et al., 2008]. Current opinions 
postulate that the tight junctions between the cerebral endothelial cells are widened by several 
processes, including endothelial cell shrinkage, vascular dilation as well as modulation of the 
endothelial cytoskeleton and junctional proteins [Rapoport, 2001]. These effects on the 
cytoskeleton and junctional proteins are caused by increased intracellular Ca2+ levels after 
administration of the hyperosmotic solution [Nagashima et al., 1997], and there is strong 
evidence that the duration of opening can be prolonged by pre-treatment with  Na+/Ca2+ 
exchange blockers [Nagashima et al., 1997; Bhattacharjee et al., 2001; Rapoport, 2001].  
 
The procedure of osmotic opening has been utilized in the treatment of various malignant 
brain tumors [Bellavance et al., 2008]. For example, in a clinical study cyclophosphamide was 
intravenously administered to 41 patients bearing astrocytomas. Subsequently, osmotic 
opening of the BBB was performed on 28 patients, followed by intra-arterial application of 
carboplatin and etoposide (group A), whereas 13 patients obtained the chemotherapeutics 
without blood-brain barrier disruption (group B). The median survival of patients of group A 
turned out to be 90 weeks while the survival time of patients of group B was 50 weeks 
[Kraemer et al., 2002], suggesting a benefit from BBB disruption prior to chemotherapy. 
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Quite recently, osmotic opening of the BBB was applied to a small group of patients with 
diffuse pontine gliomas (DPG), a subtype of high grade astrocytoma, which typically occurs 
in children. The patients were treated monthly by osmotic BBB opening followed by intra-
arterial application of carboplatin or methotrexate as well as intravenous injection of 
cyclophosphamide and etoposide. Efficiency of the therapy was monitored by MRI imaging, 
which demonstrated 2 partial responses, 5 cases of stable diseases and 1 patient with 
progressing disease. The median time to tumor progression was 15 months and the survival 
time averaged 27 months, indicating improved impact on both parameters compared to 
previous DPG studies [Hall et al., 2006]. 
 
The disruption of the BBB turned out to be a promising pre-treatment to improve the response 
to cytostatic agents in brain tumor patients. However, since this procedure represents a drastic 
and non-selective intervention, which facilitates the access of putative neurotoxic compounds 
to the brain, osmotic BBB opening must be carefully considered in each individual case. 
 
1.2.2.2 Immunoliposomes 
 
Certain endogenous large molecules such as insulin, the insulin-like growth factors IGF-1 and 
IGF-2, LDL (low density lipoprotein) and transferrin are transported into the brain by 
receptor-mediated trans- and / or endocytosis [Pardridge, 2007]. The underlying mechanisms 
pave the way to another interesting approach of drug delivery to the central nervous system. 
Drug-containing liposomes can be tagged with antibodies against suitable receptors 
(immunoliposomes) to induce endo- and / or transcytosis after recognition of the drug carrier 
as a receptor ligand [Deeken and Löscher, 2007].  
 
1.2.2.2.1 Immunoliposomes targeting the transferrin receptor 
 
Transferrin is a glycoprotein and represents the major iron binding carrier in the serum of 
vertebrates [Yang et al., 1984]. The transferrin receptor 1 (CD71, TfR) possesses a molecular 
mass of 85 kDa and affiliates to type II transmembrane proteins [Kasibhatla et al., 2005]. The 
expression of TfR on brain capillaries, which was already shown in 1984 [Jefferies et al., 
1984], might be relevant due to extensive oxidative metabolism in neuronal cells.  
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After binding of transferrin to TfR, the iron ions can be channeled into the cell by either endo- 
and / or transcytosis. Both mechanisms were discussed by several workgroups on the basis of 
in vitro and in vivo results [Broadwell et al., 1996; Li and Qian, 2002].  
 
This efficient uptake pathway of iron into the brain has already been exploited in the approach 
of site-specific drug delivery into the CNS by linking liposomes with incorporated drugs to 
specific antibodies against the transferrin receptor, which is expressed at the BBB [Qian et al., 
2002]. OX26, a monoclonal antibody against TfR, was attached to the surface of daunomycin 
incorporated in liposomes [Huwyler et al., 1996]. The drug containing immunoliposomes, 
free daunomycin and non-functionalized daunomycin-loaded liposomes, respectively, were 
intravenously injected into rats, and the daunomycin concentrations in the brain of the animals 
were determined. Comparing daunomycin attached to OX26 immunoliposomes with 
administered free drug, the authors found increased brain delivery by using the drug carrier 
system resulting in about 10,000 fold higher brain concentrations of daunomycin [Huwyler et 
al., 1996; Deeken and Löscher, 2007]. Furthermore, OX26 immunoliposomes were also 
successfully applied in vitro to circumvent ABCB1 mediated digoxin resistance. In 
immortalized rat brain capillary endothelial cells, digoxin uptake was enhanced by a factor of 
25 by incorporating the drug into OX26-immunoliposomes. The authors concluded that this 
immunoliposome-based drug delivery system might be generally useful to by-pass ABCB1, 
and thereby, to increase the levels of ABCB1 substrates in target cells [Huwyler et al., 2002].   
 
These studies on immunoliposomes demonstrate the prospect of the drug-delivery system to 
increase drug concentrations in the brain and to circumvent efflux pump mediated drug 
resistance. Thus, with respect to chemotherapy of brain tumors, the application of cytostatics 
incorporated in immunoliposomes seems to be a promising approach to obtain sufficient drug 
levels in the brain.  
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1.2.2.3 Nanoparticles  
 
The use of nanoparticles (NP) as carrier systems is another attractive strategy to deliver drugs 
across the blood-brain barrier. This approach can also be applied to compounds, which are 
physicochemically and / or biochemically unstable, e.g. due to enzymatic- or pH-dependent 
cleavage, as such drugs are efficiently protected by encapsulation into NP [Kawashima, 
2001]. 
 
Nanoparticles consist of chemically different biodegradable macromolecules, which form 
nano-sized solid, colloidal drug carrier systems. The pharmacologically active compound is 
dissolved, entrapped or encapsulated in the NP or alternatively attached / adsorbed to the 
surface of the particles [Chopra et al., 2008]. Typically, their size ranges from 10 to 1000 nm 
with an average size of 50-300 nm [Olivier, 2005]. Polymers mostly used for the preparation 
of nanoparticulate systems are poly(D,L-lactide), poly(lactic acid), poly(D,L-glycolide), 
poly(lactide-co-glycolide), poly(lactic-co-glycolic acid) (PLGA) and poly(cyanoacrylate). 
However, nanoparticles have also been generated by using gelatin [Farrugia and Groves, 
1999], chitosan [Fernández-Urrusuno et al., 1999] and sodium alginate [Aynie et al., 1998]. 
Additionally, in many cases the nanoparticles are coated with different kinds of surfactants 
such as poloxamers, polysorbates or cremophors [Kreuter et al., 1997]. This surface 
modification has been proven to significantly influence the effective targeting of particular 
tissues, predominantly the delivery to the brain [Kreuter et al., 1997]. Moreover, it was shown 
that surfactant coating reduced the adverse effects of toxic compounds to several organs 
[Gelperina et al., 2002]. 
 
Drug release and biodegradation of the nanoparticles are key issues. Desorption of the 
surface-bound / adsorbed drug, diffusion through the nanoparticle matrix, diffusion through 
the polymer wall (nanocapsules), erosion of the NP matrix and combined erosion / diffusion 
processes dictate the rate of drug release in vivo [Soppimath et al., 2001]. Many ideas, 
explaining the overcoming of the BBB, have been discussed over the recent decades. Current 
opinions suggest that the coated nanoparticles adsorb apolipoproteins on their surface 
enabling a receptor (e. g. LDL receptor) mediated uptake of the drug-loaded particles into the 
brain [Petri et al., 2007]. 
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Nanoparticle drug carrier systems have been proven to transport a vast number of compounds 
including opioids [Alyautdin et al., 1997], growth factors [Kurakhmaeva et al., 2009] and 
cytostatics [Gulyaev et al., 1999; Huang et al., 2008] to the brain. Hence, the use of 
nanoparticles as delivery systems represents an attractive approach to improve the 
chemotherapy of malignant brain tumors. The suitability of drug-loaded and surfactant-coated 
poly(butylcyanoacrylate) nanoparticles is elaborately discussed in chapter 3.  
 
1.2.2.4 Modulation of ABC-efflux transporters at the BBB 
 
The activity of ATP-binding cassette transporters at the blood-brain barrier, predominantly 
ABCB1 and ABCG2 [Dauchy et al., 2008], limits the access of cytostatics to the central 
nervous system. Therefore, the chemotherapy of malignant brain tumors is strongly restricted. 
In order to improve the brain penetration of cytotoxic compounds, which are known to be 
ABC-transporter substrates, the inhibition of these efflux pumps by selective modulators 
represents an attractive strategy.  
 
By means of this approach, an enhanced brain uptake of the ABCB1 substrate vinblastine was 
demonstrated by Cisternino et al. [Cisternino et al., 2001]. CF-1 mice were pre-treated with 
the ABCB1 modulators PSC 833 (valspodar) and GF 120918 (elacridar) respectively. 
Subsequently, radiolabeled vinblastine was administered via in situ brain perfusion techniques 
and the intracerebral drug transport was determined. Mice, pre-treated with the efflux pump 
inhibitors, showed a 3-fold increase in the brain transport of vinblastine compared the non-
treated controls. Moreover, in a laborious proof-of-concept study with nude mice bearing 
intracerebral human glioblastoma, the co-administration of the 2nd generation ABCB1 
inhibitor valspodar with the cytostatic paclitaxel yielded 6-8 fold higher brain levels of 
paclitaxel as obtained without valspodar application [Fellner et al., 2002]. The increased drug 
levels resulted in a decrease of tumor volume by approximately 90 %. Similarly, the brain 
penetration of the ABCG2 substrate imatinib mesylate in mice could be significantly 
enhanced by co-administration of an ABCG2 efflux pump inhibitor [Breedveld et al., 2005]. 
For this purpose, the animals obtained imatinib either alone or combined with the ABCG2 
modulator pantoprazol, which is approved as a proton pump inhibitor. Mice, treated with both 
imatinib and pantoprazol showed 5.2-fold higher brain levels of imatinib, suggesting 
improved drug delivery to the CNS due to ABCG2 modulation.  
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Thus, compounds acting as modulators of ABC-efflux transporters are promising drug 
candidates in combination with cytostatics in order to improve the therapy of malignant brain 
tumors. In view of the clinically available chemotherapeutics, which are in principle 
applicable in the therapy of CNS neoplasms, but which are excluded from the brain by 
transporters, the development of potent inhibitors for different ABC-efflux pumps is of 
particular interest. Only a few potent inhibitors of the recently discovered ABCG2 transporter 
are known so far, including the dual ABCB1 / ABCG2 inhibitor elacridar [de Bruin et al., 
1999] and the fumitremorgin C analog Ko143[Allen et al., 2002]. For this reason, the 
identification of highly potent ABCG2 modulators as appropriate candidates for combination 
treatment might contribute to the progress in the pharmacotherapy of malignant brain tumors. 
Further details on ABCB1 and ABCG2 modulators are given in chapter 4. 
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Up to date, the treatment of malignant brain tumors, especially high grade gliomas, constitutes 
a major problem in cancer therapy. For more than 30 years, the prognosis of patients with 
glioblastoma multiforme (GBM), one of the most aggressive astrocytic gliomas, has not been 
substantially improved. Despite the recent combination of radiotherapy with temozolomide, 
the increase in median survival from 12 to 15 months represents only a minor step in search 
of effective therapy regimens for glioblastoma multiforme. Hence, there is still a great need 
for new strategies in the treatment of GBM. One of the most important reasons for the failure 
of the chemotherapy of malignant brain tumors is the restricted access of anticancer drugs to 
the CNS. In this context, the activity of ATP-binding cassette transporters at the blood-brain 
barrier (BBB), especially the efflux pumps ABCB1 and ABCG2, play a crucial role in the 
failure of the clinically available chemotherapeutics.  
 
For example, doxorubicin is highly cytotoxic against human glioblastoma cells in vitro, but as 
an ABCB1 / ABCG2 substrate does not penetrate across the BBB to reach therapeutically 
active concentrations in the brain. Doxorubicin-loaded poly(butylcyanoacrylate) (PBCA) 
nanoparticles (NPs) are considered as a promising approach to overcome the BBB. It has been 
reported that by means of such PBCA NPs, coated with the surfactant polysorbate 80, 
doxorubicin concentrations were elevated in the brain [Gulyaev et al., 1999]. Thus, the 
objective of the first part of this thesis was to evaluate the in vitro toxicity profile for various 
doxorubicin formulations against 3 different human glioblastoma cell lines. For this purpose, 
the chemosensitivity of these ABCB1 and ABCG2 negative cells against doxorubicin in 
solution, doxorubicin loaded to PBCA NPs and polysorbate 80-coated doxorubicin-loaded 
PBCA NPs had to be investigated. To study interactions of such particles with drug efflux 
transporters, and to compare the antiproliferative activity of different nanoparticle 
formulations, ABCB1 overexpressing Kb-V1 cells and ABCG2 overexpressing MCF-7/Topo 
cells were selected as in vitro models. Aiming at the identification of new anticancer agents 
for the treatment of malignant brain tumors, new doxorubicin derivatives were considered as 
promising candidates for initial in vitro cytotoxicity assays against different human 
glioblastoma cell types. 
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Another interesting strategy to enhance the brain penetration of cytostatics, which are known 
to be substrates of ATP-binding cassette transporters, is the inhibition of these efflux pumps 
at the BBB. In continuation of previous work on the co-administration of ABC modulators 
with cytostatics [Fellner et al., 2002; Hubensack et al., 2008], the ABCB1 inhibitor tariquidar 
served as a starting point for the synthesis of a series of analogs, accomplished in the group of 
Prof. Dr. Burkhard König, Institute of Organic Chemistry, University of Regensburg. These 
new chemical entities had to be investigated for potency against ABCG2 and selectivity for 
ABCG2 versus ABCB1 (and in part versus ABCC2). To circumvent the time-consuming and 
costly flow cytometric (FACS) assays as well as to substantiate the results from FACS 
analysis, alternative methods were sought for routine studies. For this purpose, the ABCG2 
substrates Hoechst 33342 and pheophorbide a were chosen for fluorescence readout in the 96-
well plate format. Confocal-laser scanning microscopy, using fluorescence-labeled ABCG2 
modulators, which had to be characterized with respect to their ability to modulate ABCG2, 
should provide information, if the tariquidar analogs are substrates or inhibitors of this 
transporter. 
 
In view of intended in vivo studies, on the one hand, sufficient stability of the tariquidar 
analogs is a prerequisite. To assess stability, HPLC-MS was regarded as the appropriate 
methodology. On the other hand, a predictive orthotopic glioblastoma model is indispensible. 
Hence, the main part of this thesis focused on the refinement of an existing orthotopic 
glioblastoma model in nude mice by monitoring tumorigenicity and tumor growth using 
noninvasive optical imaging technology, namely bioluminescence and fluorescence. 
Therefore, human glioblastoma cell variants, had to be stably transfected with the genes 
encoding the enzyme luciferase2 (luc2) and the recently discovered far-red protein Katushka, 
respectively. The transfectants should ideally show identical growth kinetics, 
chemosensitivity and tumorigenicity compared with the respective wildtypes. The cardinal 
question was the feasibility of optical in vivo imaging to monitor take rates and the 
progression of intracerebral human glioblastomas in nude mice. 
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3.1  Introduction 
 
The transport of drugs into the brain, e.g. in the therapy of CNS diseases, is often limited by 
the architecture and function of the blood-brain barrier (BBB). Numerous physiological, 
morphological and functional properties of the BBB such as the continuous tight epithelium 
of the brain capillaries, the tight junctions between the cerebral endothelial cells and the 
activity of many different transporter proteins, for example ABC-efflux pumps (e.g. p-
glycoprotein, breast cancer resistance protein) as well as organic anion and cation transporters 
(OAT’s and OCT’s), protect the brain from the uptake of numerous xenobiotics [Deeken and 
Löscher, 2007].  
 
3.1.1  Drug delivery to the brain by nanoparticles (NPs) 
 
Over the recent decades the use of nanoparticle formulations was described as a novel 
strategy for the delivery of drugs across the blood-brain barrier. Such nanoparticles (NPs) are 
colloidal structures with diameters up to 1000 nm [De Jong and Borm, 2008], consisting of 
biodegradable polymer matrices, e.g. poly(D,L-lactide) or poly(D,L-glycolide). These 
nanoparticles can be loaded with appropriate pharmacologically active compounds. 
Investigations by Gao and Jiang revealed a correlation between particle size and brain uptake. 
Methotrexate loaded polysorbate 80-coated nanoparticles were i.v. injected into mice. 
Thereby, coated particles smaller than 100 nm delivered more drug (according to Cmax and 
AUC) to CSF and brain than observed for particles with an average diameter of 100-400 nm 
[Gao and Jiang, 2006].  
 
In an early study, poly(butyl)cyanoacrylate (PBCA) nanoparticles were loaded with the Leu-
enkephalin analog dalargin [Kreuter et al., 1995], which cannot penetrate into the brain, when 
injected as a solution. In addition, the drug-loaded particles were coated with surfactants such 
as polysorbate 20, 40, 60 and 80, various poloxamers, poloxamine 908, Cremophor EL, 
Cremophor RH 40 and Brij 35 [Kreuter et al., 1997]. Mice studies on the analgesic effect of 
different dalargin formulations showed that only polysorbate-coated, dalargin-loaded PBCA 
nanoparticles produced analgesia in the tail flick [Kreuter et al., 1995] and the hot plate test 
[Schroeder et al., 1998].  
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Similar results were reported for the intravenous administration of different formulations of 
the opioid loperamide [Alyautdin et al., 1997]: a long-lasting analgesic effect was only 
achieved by the application of polysorbate 80-coated loperamide loaded nanoparticles. 
Furthermore, the hydrophilic quaternary ammonium salt tubucurarine induced epileptiform 
spikes in EEG, when formulated as polysorbate 80-coated tubucurarine-loaded NPs 
[Alyautdin et al., 1998] in perfusion studies using rat brains. Very recently, 
poly(butyl)cyanoacrylate particles were used for brain targeting of nerve growth factor (NGF) 
[Kurakhmaeva et al., 2009]. In an acute-amnesia model in mice, scopolamine-induced 
amnesia was successfully reversed by the intravenous injection of polysorbate 80-coated NPs 
loaded with NGF. The outcome was measured via the passive avoidance reflex (PAR) test in 
which mice treated with the coated and drug-loaded particles showed a significant increase in 
the mean latent period. Moreover, in mice with provoked parkinsonian syndrome by 
intraperitoneal injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, NGF adsorbed to 
polysorbate 80-coated PBCA NPs produced a decrease in rigidity and a simultaneous increase 
in locomotor activity compared to non-treated control animals [Kurakhmaeva et al., 2008].  
 
3.1.2  NPs as drug delivery systems for the treatment of malignant brain 
tumors 
 
Another challenging application of drug-loaded nanoparticles is the therapy of malignant 
brain tumors. One of the first anticancer drugs, used for loading PBCA NPs, was the 
anthracycline doxorubicin. In investigations on the body distribution of the nanoparticle 
formulations, 4 preparations of doxorubicin were intravenously injected into rats [Gulyaev et 
al., 1999]. The polysorbate 80-coated and uncoated doxorubicin-loaded NPs as well as 
solutions of doxorubicin in saline with and without polysorbate 80 (1 %) were compared. The 
most important result of the studies by Gulyaev et al. [Gulyaev et al., 1999] was an over 60-
fold higher concentration of doxorubicin in the brain of mice treated with polysorbate 80-
coated nanoparticles (6 µg/g vs. < 0.1 µg/g in the other test groups). The therapeutic potential 
of the increased brain uptake of doxorubicin via the surface-modified drug carrier system was 
investigated by Steiniger et al. [Steiniger et al., 2004]. Rats bearing intracranial 101/8 
glioblastomas were treated with different formulations of doxorubicin including the 
surfactant-coated loaded PBCA nanoparticles. In case of the latter formulation, the longest 
survival (100-180 days vs. 50 days) and the highest long-term remissions (over 20 %) were 
observed.  
34 Chapter 3  
 
Lately, Hekmatara et al. [Hekmatara et al., 2009] investigated the therapeutic effects of coated 
doxorubicin-loaded nanoparticles in the orthotopic 101/8 glioblastoma model. Slower 
proliferating and less necrotic tumors were reported, when the animals were treated with the 
polysorbate 80-coated doxorubicin-loaded nanoparticles compared to the administration of 
doxorubicin in solution [Hekmatara et al., 2009]. Due to distinctive effects on vascularization, 
the authors suggest an antiangiogenic mechanism of action.  
 
Recently, polysorbate 80-coated NPs were loaded with the antimetabolite gemcitabin (GCTB) 
and injected into a C6 glioblastoma model in Sprague Dawley rats [Wang et al., 2009]. The 
injection of these gemcitabin-loaded nanoparticles, coated with 1 % polysorbate 80, into the 
tail vein, yielded increased gemicitabin brain levels, determined by HPLC, compared to mice 
treated with GCTB solution, non-coated GCTB nanoparticles or a mixture of “empty” 
nanoparticles plus 1 % polysorbate 80 and gemcitabin [Huang et al., 2008]. These elevated 
GCTB concentrations in the brain resulted in an increase in survival time compared to vehicle 
treated control mice [Wang et al., 2009].  
 
3.1.3  Tolerability of NP drug delivery systems 
  
Toxicology studies by Gelperina et al. on healthy and glioblastoma bearing rats showed that 
non-loaded NPs were tolerated, when administered at a dose of 100-400 mg/kg. Doxorubicin 
associated toxicity was not increased by loading the drug to the surface of nanoparticles or by 
the presence of polysorbate 80 [Gelperina et al., 2002]. On the contrary, HPLC analysis of 
various tissue samples proved a drastic decrease in heart concentrations of doxorubicin, when 
the drug was adsorbed to the nanoparticles [Gulyaev et al., 1999]. This observation was of 
great value, since the cardiotoxicity of doxorubicin limits its therapeutic use. A very recent 
toxicology study, using male and female Wistar rats, confirmed the reduced doxorubicin-
associated cardiotoxicity, when the cytostatic was administered intravenously as the coated 
nanoparticle formulation and, additionally, demonstrated a decreased testicular toxicity of 
surfactant-coated doxorubicin-loaded particles in male rats [Pereverzeva et al., 2008]. 
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3.1.4  Mechanism of NP penetration across the BBB 
 
In theory, there are only few mechanisms, namely transcellular passive diffusion, receptor-
mediated transcytosis or the use of specific carrier systems, by which drugs can enter the 
brain, [Deeken and Löscher, 2007]. As described above, obviously only nanoparticles, coated 
with detergents, in particular with polysorbate 80, were able to overcome the blood-brain 
barrier. The mechanisms by which the polysorbate 80-coated PBCA nanoparticles enter the 
brain have been a matter of discussion. Kreuter [Kreuter, 2001] suggested various single and 
combined mechanisms including endocytosis, mimicry of LDL (low density lipoproteins) 
after adsorption of apolipoprotein E from blood plasma to the surface of the particles and 
subsequent interaction via LDL receptors as well as modulation of tight junctions or ABCB1 
transporters. In recent studies, Petri et al. performed incubation experiments with rat plasma 
containing poloxamer 188 and polysorbate 80-coated doxorubicin-loaded nanoparticles [Petri 
et al., 2007]. Both types of nanoparticles showed high adsorption of apolipoprotein ApoA-I 
prompting the authors to assume a putative in vivo interaction of the particles with the 
scavenger receptor SR-BI expressed at the BBB.  
 
3.1.4.1 Entry into cells 
 
In spite of all these investigations, cellular uptake of polysorbate 80-coated doxorubicin-
loaded nanoparticles remained unproven for a long period of time. Studies by Dr. Dietmar 
Gross using confocal laser scanning microscopy and flow cytometric techniques did not 
support an entry of the surfactant-coated particles into cancer cells [Gross, 2006]. Therefore, 
he speculated, that the drug-loaded nanoparticles might adsorb to the cell surface and 
maintain a high concentration gradient of released doxorubicin around the cell, resulting in 
enhanced diffusion of the drug into the cells [Gross, 2006].  
 
In contrast to these assumptions, recent investigations by Reimold et al. [Reimold et al., 2008] 
proved the brain penetration of polysorbate 80-coated PBCA NP (10 %). The nanoparticles 
were loaded with fluorescein-isothiocyanate-dextran (FITC-dextran), rhodamine-123 or 
doxorubicin and injected intravenously into male Wistar rats. After several time periods, the 
rats were killed by cervical dislocation, and cryosections of the brain tissues were prepared for 
CLSM studies.  
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The investigations gave clear evidence that the particle-associated fluorescence was located 
within microvessels and beyond the brain capillaries, suggesting the internalization of 
polysorbate 80-coated PBCA nanoparticles by endothelial cells [Reimold et al., 2008]. 
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3.2  Objective 
 
In continuation of the aforementioned investigations by D. Gross [Gross, 2006] the toxicity of 
doxorubicin loaded nanoparticle formulations was evaluated against the human glioblastoma 
cell lines U-87 MG, U-118 MG and U-373 MG. Since these cell lines proved to be p-gp 
(ABCB1) and bcrp (ABCG2) negative [Gross, 2006], ABCB1 overexpressing Kb-V1 cells 
and ABCG2 overexpressing MCF-7/Topo cells [Hubensack, 2005] were used as in vitro 
models to investigate the effect of doxorubicin-loaded nanoparticles on these efflux pumps. 
Furthermore, the chemosensitivity of the corresponding Kb and MCF-7 wildtype cells against 
different doxorubicin formulations was examined.         
 
In a subproject of the present work the toxicity of 2 newly synthesized doxorubicin 
derivatives was investigated on U-87 MG, U-118 MG and U-373 MG cells. In search of new 
compounds for the treatment of glioblastoma, these investigations were arranged as a 
prerequisite since, as mentioned before, the applicability of the parent compound doxorubicin 
in the therapy of malignant brain tumors, is limited due the active efflux by ATP-binding 
cassette transporters expressed at the blood-brain barrier. 
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3.3  Materials and methods 
 
3.3.1  Chemicals and drugs 
 
Doxorubicin was a kind gift from Prof. Kreuter (Institute of Pharmaceutical Technology, 
Johann Wolfgang Goethe Universität, Frankfurt, Germany). The compound was dissolved to 
a 10 mM stock solution in 70 % ethanol. The stocks were stored at -20 °C. Vinblastine sulfate 
(Sigma, Munich, Germany) was dissolved in 70 % ethanol to reach a concentration of 1 mM. 
The stock solutions were stored at 4 °C. Polysorbate 80 (Tween 80) was purchased from 
Merck, Darmstadt, Germany and stored at room temperature. 
 
All polybutylcyanoacrylate (PBCA) nanoparticle (NP) formulations were produced and 
characterized in the workgroup of Prof. Kreuter. The preparation procedure has been 
described previously [Gross, 2006]. For storage, the lyophilized doxorubicin-loaded particles 
containing an equivalent amount of 1 mg doxorubicin hydrochloride were kept in light-
protected glass vials at 4 °C. Investigations on the chemosensitivity of different human cancer 
cells against the nanoparticle formulations were performed by using 1 fresh vial for each 
experiment. Therefore, either a 0.9 % NaCl solution or phosphate buffered saline (PBS) with 
the following ingredients (Merck, Darmstadt, Germany) was prepared: 8.0 g/L NaCl, 1.0 g/L 
Na2HPO4·2 H2O, 0.20 g/L KCl, 0.20 g/L KH2PO4, 0.15 g/L NaH2PO4·H2O. The solution was 
sterile filtered and applied to produce a 1 mM stock suspension (referred to the amount of 
doxorubicin) of the drug-loaded particles. For coating of the NPs, the surfactant polysorbate 
80 was warmed to 37 °C in order to reduce the viscosity. After sterile filtration, Tween 80 
was diluted to a 10 % stock solution in PBS or 0.9 % NaCl, respectively. On the eve of 
experiments, 450 µL of sterile PBS or 0.9 % NaCl and 50 µL of the polysorbate 80 stock 
solution were added to the glass vial. Coating was achieved by stirring of the mixture under 
light-protection for 30 min at 300 rpm.  
 
The doxorubicin derivatives Sb-59 and Sb-63b (Chart 3.1) were provided by Prof. Dr. Rainer 
Schobert, Institute of Organic Chemistry at the University of Bayreuth, Germany. 10 mM 
stock solutions in DMSO (Merck, Darmstadt, Germany) were stored at -20 °C. 
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Chart 3.1: Structures of doxorubicin and its hydrazone derivatives Sb-59 and Sb-63b. 
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3.3.2  Cell culture  
 
Human U-87 MG and U-373 MG glioblastoma cells were grown in Eagle’s Minimum 
Essential Medium (Sigma, Munich, Germany) containing L-glutamine, 2.2 g/L NaHCO3 
(Merck, Darmstadt, Germany) and 0.11 g/L sodium pyruvate (Serva, Heidelberg, Germany) 
supplemented with 5 % fetal calf serum (FCS) (Biochrom AG, Berlin, Germany). U-118 MG 
cells, a further human glioblastoma cell line, were cultured in Dulbecco’s Modified Essential 
Medium (DMEM) from Sigma, Munich, Germany. The medium contained L-glutamine, 3.7 
g/L NaHCO3, 0.11 g/L sodium pyruvate and was supplemented with 5 % FCS.  
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HeLa derived human Kb wildtype cells (Kbwt) were grown in the aforementioned DMEM 
supplemented with 10 % fetal calf serum. The ABCB1 overexpressing subclone Kb-V1 was 
obtained by the addition of increasing amounts of the ABCB1 substrate vinblastine to the 
culture medium. At a final concentration of 300 ng/mL vinblastine, cells showed sufficiently 
increased expression of the efflux transporter to perform ABCB1 inhibition studies 
[Hubensack, 2005].  
 
Human MCF-7 breast adenocarcinoma cells were cultured in EMEM supplemented with 5 % 
FCS. Increasing amounts of the ABCG2 substrate topotecan in the culture medium of MCF-7 
cells yielded the ABCG2 overexpressing subclone MCF-7/Topo. A final concentration of 
0.55 µM topotecan, achieved after a period of approximately 40 days, guarantied sufficient 
expression of the ABCG2 transporter [Hubensack, 2005].  
 
3.3.3  Crystal violet chemosensitivity assay 
 
The assays were performed as described elsewhere [Bernhardt et al., 1992]. Briefly: Having 
reached the appropriate confluency, cells were detached from the surface of the culture flasks 
and seeded into 96-well plates at a density of 8-15 cells per microscopic field (320-fold 
magnification). Cells were allowed to grow for 48-72 h at 37 °C and 5 % CO2. Subsequently, 
supernatant was removed from the cells by suction and replaced by fresh medium containing 
vehicle (growth control), a known toxic compound (positive control) or the test substances at 
increasing concentrations. In general, compounds were added to the medium as 1000-fold 
stock solutions. After various times of incubation at 37 °C / 5 % CO2 the supernatants were 
drained and cells were immediately fixed with glutardialdehyde (Merck, Darmstadt, 
Germany) for at least 20 min. Subsequently, the cells were overlaid with phosphate buffered 
saline and stored at 4 °C until the end of experiment. All microplates were stained 
simultaneously, using an aqueous solution of crystal violet (0.02 %) (SERVA, Heidelberg, 
Germany). After 20 min the dye was removed by draining and excess of crystal violet was 
eliminated by rinsing the microplates with water for another 20 min. Finally, the dye bound 
by cell structures was re-dissolved in ethanol 70 % while shaking the plates for 2-4 h. As an 
indicator of cell mass, the absorbance at 578 nm was determined at a BIOTEK 309 
Autoreader (TECNOMARA, Fernwald, Germany).  
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Effects mediated by the test compounds were expressed as corrected T/C values according to 
the following equation: 
 
100
CC
CT
C/T
0
0
.corr 
 [%]  
 
, where T is the mean absorbance of the treated cells, C the mean absorbance of the controls 
and C0 the mean absorbance of the cells at the time (t=0) when drug was added. The extent of 
cell killing was calculated by the following equation, if the test compounds showed a 
cytocidal effect: 
 
Cytocidal effect [%] = 100
C
TC
0
0   
 
This was the case, when the absorbance of treated cells T was less than that of the culture at 
t=0 (C0.).  
 
 
3.3.4  Modified chemosensitivity assays for determination of the effects of 
short-term drug exposure  
 
For investigations on the effect of short-term drug exposure, the aforementioned crystal violet 
assay was slightly modified. After incubation of the cells with various drug concentrations for 
3 and 6 h, respectively, the media were removed by suction. Subsequently, 200 µL of drug-
free culture medium were added to each well and cells were incubated for various times at 
37 °C / 5 % CO2. Except for this modification, the assay was performed as described above. 
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3.4  Results and discussion 
 
3.4.1 Chemosensitivity of ABCB1 and ABCG2 negative U-87 MG, U-118 
MG and U-373 MG glioblastoma cells against anthracyclines 
 
3.4.1.1  Immunocytochemical detection of ABCB1 and ABCG2 
 
There are controversial reports in the literature on the (over) expression of ABC cassette 
transporters by human glioblastoma cells, responsible for the multi-drug resistance phenotype 
[Kondo et al., 1996; Declèves et al., 2002; Bähr et al., 2003]. As doxorubicin is a substrate of 
ABCB1 / ABCG2  [Alqawi et al., 2004], the human U-87 MG, U-118 MG and U-373 MG 
human glioblastoma cells were investigated with respect to these efflux pumps by confocal 
laser-scanning microscopy experiments (CLSM) [Gross, 2006]. Images of fixed and anti-pgp 
immunostained human glioblastoma cells are presented in Figure 3.1. Kb-V1 cells, the 
ABCB1 overexpressing subclone of human Kbwt cells, served as positive control. In Figure 
3.2 corresponding CLSM investigations with anti-bcrp immunostaining are shown; topotecan 
induced ABCG2-overexpressing MCF-7/Topo were used as positive control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kb-V1 U-87 MG U-118 MG U-373 MG 
Figure 3.1: Expression of ABCB1 in vinblastine induced Kb-V1 cells and the 3 human 
glioblastoma cell lines U-87 MG, U-118 MG and U-373 MG. Cells were fixed with 
paraformaldehyde and incubated with the monoclonal mouse anti-human pgp Ab2 primary 
antibody Clone F4. After removing excess of the primary antibody and washing, the cells 
were incubated with the fluorescein-isothiocyanate (FITC)-conjugated polyclonal rabbit 
anti-mouse IgG secondary antibody. Whereas a high transporter expression was observed 
for the Kb-V1 cells, the human glioblastoma cell lines showed no antibody mediated FITC 
fluorescence demonstrating the absence of the transporter proteins. 
CLSM experiments by Dr. Dietmar Gross.  
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Figure 3.2: Expression of ABCG2 (bcrp). Immunostaining of human glioblastoma U-87 
MG, U-118 MG and U-373 MG cells with anti-bcrp primary antibody and Cy5-conjugated 
secondary antibody revealed lack of ABCG2 expression. MCF-7/Topo cells served as 
positive control for bcrp-overexpression. Anti-bcrp (a), nuclei (b), merge (c).  
CLSM experiments by Dr. Dietmar Gross. 
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3.4.1.2   Chemosensitivity of the glioblastoma cells against anthracyclines 
 
3.4.1.2.1  Chemosensitivity against doxorubicin  
 
With respect to the investigation of newly developed doxorubicin formulations, the 
chemosensitivity of human glioblastoma cell lines against non-modified doxorubicin in 
solution had to be investigated.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Effect of dissolved 
doxorubicin on the proliferation of U-87 
MG (a; 136th passage), U-118 MG (b; 
455th passage) and U-373 MG (c; 188th 
passage) cells.  
Cells were incubated with: vehicle EtOH 
70 % (open stars), 10 nM of vinblastine 
(open diamonds) and various 
concentrations of doxorubicin: 3 nM 
(filled squares), 10 nM (filled circles), 50 
nM (filled triangles), 100 nM (filled 
inverted triangles) or 500 nM (filled 
diamonds). 
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Therefore, the cells were incubated with doxorubicin at increasing concentrations and 
afterwards processed according to the described procedure (see 3.3.3). Results are shown in 
Figure 3.3.  
 
As a positive control for assay correctness, 16 wells of the microtiter plate were incubated 
with 10 nM of vinblastine whereas effects of the solvent were checked by incubation of 
further 16 wells with the equivalent amount of ethanol 70 %.  
 
Doxorubicin at a concentration of 10 nM caused only a slight cytotoxic effect on all 
investigated glioblastoma cells. However, incubation of the cells with 100 nM of doxorubicin 
yielded strong cytotoxic effects on U-87 MG and U-118 MG cells, whereas the same 
concentration resulted in a cytostatic effect on U-373 MG cells. These data are in good 
agreement with results of analogous chemosensitivity assays performed by Dr. Peter 
Altenschöpfer [Altenschöpfer, 1998]. At the highest tested concentration of 500 nM, 
doxorubicin caused a pronounced cytocidal effect on U-87 MG as well as on U-373 MG cells, 
whereas a strong cytostatic effect was observed for U-118 MG cells.  
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3.4.1.2.2  Chemosensitivity against doxorubicin derivatives 
 
2 structural modified doxorubicin derivatives were investigated on their toxicity against U-87 
MG, U-118 MG and U-373 MG cells. Basically, these compounds were synthesized with the 
idea of specifically targeting hormone-dependent breast cancers by addressing the estrogen 
receptor.  
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c Figure 3.4: Effect of doxorubicin (filled 
symbols) and its derivative Sb-59 (open 
symbols) on proliferating U-87 MG (a; 
136th and 174th passage), U-118 MG (b; 
455th and 488th passage) and U-373 MG 
(c; 188th and 223rd passage) cells 
Cells were incubated with the 2 
anthracyclines at concentrations of: 10 
nM (circles), 100 nM (squares) and 500 
nM (triangles). 
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Since these compounds show increased lipophilicity compared to doxorubicin, and this might 
be beneficial to overcome the blood-brain barrier, the derivatives were regarded as promising 
candidates for preliminary toxicity studies on human glioblastoma cell lines. For this purpose, 
U-87 MG, U-118 MG and U-373 MG cells were incubated with 3 concentrations of the 2 
derivatives, Sb-59 and Sb-63b, respectively using doxorubicin as a reference compound 
(Figure 3.4 and Figure 3.5).  
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Figure 3.5: Effect of doxorubicin (filled 
symbols) and Sb-63b on proliferating 
U-87 MG (a; 136th and 180th passage), 
U-118 MG (b; 455th and 495th passage) 
and U-373 MG (c; 188th and 230th 
passage) cells. 
Cells were incubated with the 2 
anthracyclines at concentrations of: 10 
nM (circles), 100 nM (squares) and 500 
nM (triangles). 
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At a concentration of 10 nM, Sb-59 had a weak antiproliferative effect on human U-87 MG 
glioblastoma cells similar to that of 10 nM doxorubicin (Figure 3.4a). However, at 
concentrations as high as 100 and 500 nM, Sb-59 was less potent than doxorubicin. Whereas 
500 nM Sb-59 caused a strong cytostatic effect, the same concentration of doxorubicin was 
cytocidal.  
 
Similar results were obtained for U-118 MG cells in the presence of doxorubicin and Sb-59 
(Figure 3.4b).  
 
Among the 3 human glioblastoma cell types, U-373 MG turned out to be most sensitive 
against doxorubicin and Sb-59 (Figure 3.4c). Even at the lowest tested concentration of 10 
nM, cytotoxic and cytostatic effects were observed. Moreover, incubation of U-373 MG cells 
with 100 and 500 nM of each compound resulted in distinctive cytostatic and cytocidal 
impact. Again, as noticed for U-87 MG and U-118 MG cells, doxorubicin was demonstrated 
to be more potent than its derivative Sb-59. 
 
On U-87 MG cells Sb-63b caused increased antiproliferative activity compared to 
doxorubicin (Figure 3.5a). At a concentration of 10 nM, doxorubicin was ineffective, 
whereas Sb-63b mediated pronounced cytostatic effects. Moreover, at higher concentrations 
(100 and 500 nM), Sb-63b showed increased cytostatic effects compared to doxorubicin, or 
were even elevated to cytocidal impacts.  
 
Contrarily, doxorubicin was more cytotoxic than Sb-63b against U-118 MG cells (Figure 
3.5b), although incubation with 100 and 500 nM of Sb-63b resulted in strong cytostatic and 
cytocidal effects.  
 
Proliferating U-373 MG cells showed comparable susceptibility against Sb-63b and 
doxorubicin (Figure 3.5c). Both compounds were cytotoxic at a concentration as low as 10 
nM. Whereas at a concentration of 100 nM Sb-63b mediated cytocidal outcomes, doxorubicin 
caused strong cytostatic effects. In addition, incubation of U-373 MG cells with 500 nM of 
doxorubicin and Sb-63b, respectively, indicated equi-activity. 
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3.4.1.3  Cytotoxicity of different doxorubicin-loaded NP formulations 
 
For investigations on the chemosensitivity of doxorubicin-loaded nanoparticle formulations, 
the human glioblastoma cells were incubated with the drug-loaded PBCA particles. 
Additionally, doxorubicin-loaded PBCA nanoparticles were coated with polysorbate 80 to 
examine the chemosensitivity of these surface-modified drug-carrier systems.  
 
Figure 3.6 shows the results which were obtained after incubation of U-87 MG, U-118 MG 
and U-373 MG glioblastoma cells with non-coated doxorubicin-loaded nanoparticles. Similar 
to investigations performed with doxorubicin in solution, the incubation with 10 nM of 
doxorubicin-loaded nanoparticles caused only weak cytotoxic effects on both, U-87 MG and 
U-118 MG cells. Furthermore, the incubation of U-373 MG cells with 10 nM of the 2 
different drug formulations (doxorubicin in solution vs. doxorubicin NP, respectively) 
revealed only a slightly enhanced cytotoxicity of the nanoparticle formulation. The highest 
tested concentration of doxorubicin-loaded NP (500 nM) resulted in a pronounced cytocidal 
effect against U-87 MG as well as U-373 MG cells, comparable to outcomes observed for 
doxorubicin in solution. At the latter concentration (500 nM), the doxorubicin-loaded NP 
mediated cytocidal effects to U-118 MG cells, whereas doxorubicin in solution caused only 
cytostatic outcome.  
 
Nevertheless, a drastic increase in toxicity of doxorubicin by loading the drug to PBCA 
nanoparticles was not observed, whether for U-87 MG and U-118 MG nor for U-373 MG 
cells.  
 
Overall, the doxorubicin-loaded PBCA nanoparticles proved to be equipotent with the drug in 
solution. Obviously, the nanoparticle formulation did not enhance the cellular uptake of 
doxorubicin. 
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Effects of polysorbate 80-coated, doxorubicin-loaded nanoparticles on proliferating human 
glioblastoma cells are shown in Figure 3.7. Coating procedure was performed in phosphate 
buffered saline and 0.9 % NaCl solution (data not shown), respectively.  
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c Figure 3.6: Effect of doxorubicin-
loaded nanoparticles on proliferating 
U-87 MG (a; 142th passage), U-118 
MG (b; 460th passage) and U-373 MG 
(c; 194th passage). 
Cells were incubated with 
doxorubicin-loaded NP: 10 nM (filled 
circles), 50 nM (filled triangles), 100 
nM (filled inverted triangles) or 500 
nM (filled diamonds); phosphate 
buffered saline (vehicle, open stars) or 
10 nM vinblastine (open diamonds). 
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At the lowest investigated concentration of 10 nM, the surfactant-coating did not increase the 
toxicity of doxorubicin-loaded nanoparticles. At higher concentrations of 100 and 500 nM, 
the coated doxorubicin-loaded nanoparticles had an enhanced antiproliferative effect on U-
373 MG cells compared to the non-coated, drug-loaded NPs. Nevertheless, 500 nM of 
doxorubicin used as a solution turned out to be equipotent, indicating that coating of the drug-
loaded nanoparticles with polysorbate 80 did not increase the cytotoxicity of doxorubicin. 
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Figure 3.7: Effect of polysorbate 80-
coated, doxorubicin-loaded NPs on 
proliferating U-87 MG (a; 145th 
passage), U-118 MG (b; 463th passage) 
and U-373 MG (c; 197th passage)  
Cells were incubated with: sterile PBS 
(vehicle, open stars), 10 nM vinblastin 
(open diamonds) and different 
concentrations of polysorbate 80-
coated, doxorubicin-loaded 
nanoparticles: 10 nM (filled circles), 
50 nM (filled triangles), 100 nM (filled 
inverted triangles) and 500 nM (filled 
diamonds). 
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In Figure 3.8 the cytotoxicities of doxorubicin-loaded nanoparticles and the polysorbate 80-
coated doxorubicin-loaded nanoparticles against glioblastoma cells are compared at 2 
different concentrations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was no beneficial effect of doxorubicin-loaded nanoparticles at 50 nM against all 
investigated human glioblastoma cell lines. Even surface modification of the particles by 
coating with polysorbate 80 could not enhance the doxorubicin toxicity.  
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c Figure 3.8: Comparison of the effects 
of different doxorubicin formulations 
on proliferating U-87 MG (a), U-118 
MG (b) and U-373 MG (c) cells. 
Cells were incubated with: 
doxorubicin in solution (circles), 
doxorubicin-loaded nanoparticles 
(squares) and polysorbate 80-coated, 
doxorubicin-loaded nanoparticles 
(triangles) at concentrations of 50 nM 
(black symbols) and 500 nM (white 
symbols).  
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An increased antiproliferative effect was only observed on U-118 MG cells, when incubated 
with doxorubicin-loaded nanoparticles at a concentration of 500 nM.  
 
Hence, the loading of doxorubicin to nanoparticles preserved the cytotoxicity of the 
anthracycline, but did not lead to an increased antiproliferative effect against human 
glioblastoma cells.   
 
 
3.4.1.4   Effect of short-term drug exposure on the chemosensitivity of U-373 MG 
cells against different doxorubicin formulations 
 
To investigate putative differences in the toxicity of various doxorubicin formulations during 
short-term drug exposure, the human U-373 MG glioblastoma cells were studied in a 
modified crystal violet assay. For this purpose, exposure of the cells to drug-containing media 
was restricted to 3 and 6 hours, respectively. Subsequently, doxorubicin-containing medium 
was exchanged by fresh drug-free medium. Finally, the cells were allowed to grow for 
different periods of time (Figure 3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As expected, incubation of the cells for 6 hours yielded a stronger cytotoxic effect than 
noticed for a shortened incubation period of 3 hours.  
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100 Figure 3.9: Effect of different doxorubicin 
formulations on proliferating U-373 MG cells. 
The different preparations affected the cells for 
3 (filled symbols) and 6 hours (open symbols), 
respectively. 
The cells were incubated with 50 nM of: 
doxorubicin in solution (circles), doxorubicin-
loaded nanoparticles (squares) and polysorbate 
80-coated, doxorubicin-loaded nanoparticles 
(triangles).  
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This observation was true for all different types of doxorubicin formulation, including the 
ethanolic solution, the non-coated as well as the polysorbate 80-coated nanoparticle 
preparation. There was no enhanced antiproliferative effect of doxorubicin after loading of the 
drug to (surfactant)-coated PBCA nanoparticles and no difference in toxicity depending on 
the incubation period of the doxorubicin formulations. 
 
3.4.1.5  Effect of different doxorubicin formulations on the ATP-binding cassette 
transporters ABCB1 and ABCG2 
 
3.4.1.5.1  Immunocytochemical detection of ABCB1 and ABCG2 
 
Dr. Dietmar Gross confirmed the overexpression of ABCB1 / ABCG2 on Kb-V1 / MCF-
7/Topo cells by confocal laser-scanning micoscropy studies [Gross, 2006]. Figure 3.10 shows 
the corresponding images of immunostained, induced and non-induced Kb- and MCF-7 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Whereas a relatively weak expression of ABCB1 / ABCG2 in the non-induced cells was 
observed (Figure 3.10a, c), the addition of increasing concentrations of the ABCB1 substrate 
vinblastine, and the ABCG2 substrate topotecan respectively, yielded high expression levels 
of the efflux pumps (Figure 3.10b, d).  
Figure 3.10: Immunostaining of 
different cell lines with anti-
pgp/anti-bcrp by Dr. Dietmar 
Gross: non-induced Kb-cells (a) 
and vinblastine induced Kb-V1 
cells (b) stained with anti-pgp; 
non-induced MCF-7 cells (c) and 
topotecan-induced MCF-7/Topo 
cells (d) immunostained with 
anti-bcrp. The expression of the 
ABC-transporters in wildtype 
cells (a,c) can be drastically 
enhanced via the addition of 
increasing amounts of known 
transporter substrates, e.g. 
vinblastine and topotecan to the 
cell culture medium. 
Anti-pgp Anti-pgp
Anti-bcrp Anti-bcrp
a b
c d
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3.4.1.5.2  Cytotoxicity of different doxorubicin-loaded NP formulations 
 
To investigate the effect of different doxorubicin formulations against ABCB1 and ABCG2, 
the ABCB1 overexpressing Kb-V1 and the ABCG2 overexpressing MCF-7/Topo cells were 
incubated with these preparations. For comparison, incubation of the non-induced Kb (Kbwt) 
and MCF-7 cells with the various doxorubicin formulations served as control.  
 
There were no differences in cytotoxic potencies at 100 nM of the different doxorubicin 
formulations on Kbwt cells (Figure 3.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At a concentration of 1 µM, all doxorubicin formulations produced a strong cytostatic effect 
on the non-induced Kbwt cells. Cytotoxicity after incubation of the cells with Tween 80-
coated doxorubicin-loaded nanoparticles was only slightly increased compared to the 
cytotoxicity mediated by doxorubicin in solution and the uncoated doxorubicin-loaded NP.  
 
The experiments using dissolved doxorubicin were in good agreement with previously 
reported data [Gross, 2006] which showed that Kbwt cells recovered after incubation with 
100 nM of the cytostatic. Even a concentration as high as 1 µM, was insufficient to induce a 
cytocidal effect. Due to overexpression of ABCB1, Kb-V1 cells acquire resistance against the 
transporter substrate doxorubicin.  
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Figure 3.11: Effect of different 
doxorubicin formulations on 
proliferating Kbwt cells. 
Cells were incubated with 100 nM 
(black symbols) and 1 µM (white 
symbols) of different doxorubicin 
formulations: doxorubicin in solution 
(circles), doxorubicin-loaded 
nanoparticles (squares) and 
polysorbate 80 coated, doxorubicin-
loaded nanoparticles (triangles) 
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This can be overcome by co-application of the ABCB1 inhibitor valspodar (Figure 3.12). 
Whereas incubation of the cells with 1 µM of dissolved doxorubicin alone resulted in a 
marginal cytotoxic effect, the combination of the cytostatic at non-toxic concentrations (250, 
500 and 750 nM) with valspodar (1 µM) resulted in a strong cytostatic effect due to reversal 
of ABCB1 mediated resistance. Furthermore, incubation of Kb-V1 cells with 1 µM of 
valspodar alone showed no toxicity mediated by the modulator. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For investigations on the effect of different doxorubicin formulations against ABCB1, the Kb-
V1 cells were incubated with 1 µM of the ethanolic solution, the nanoparticle suspension and 
the Tween 80 coated nanoparticles (Figure 3.13), respectively. The coated doxorubicin-
loaded nanoparticles caused the most distinctive antiproliferative effect on Kb-V1 cells.  
 
At higher concentrations - equal to 3 µM doxorubicin - such differential toxic activities on 
Kb-V1 cells were also observed by Dietmar Gross [Gross, 2006], suggesting a more effective 
uptake of doxorubicin into resistant Kb-V1 cells when loaded to overcoated PBCA NP. 
Moreover, control experiments excluded that these effects were caused by the particles or the 
surfactants alone [Gross, 2006].  
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Figure 3.12: Effect of ethanol 70 % 
(open stars), 1 µM of doxorubicin in 
solution (open circles) and 1 µM of 
valspodar alone (open squares) or 
combined with different concentrations 
of doxorubicin: 250 nM (filled circles), 
500 nM (filled squares) and 750 nM 
(filled triangles) on proliferating Kb-V1 
cells. 
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To affirm putative increased cytotoxic effects on ABCB1 by Tween 80-coated PBCA 
nanoparticles, Kb-V1 cells were investigated in additional chemosensitivity assays using the 
aforementioned doxorubicin preparations. The cells were incubated with 250 nM of each 
formulation combined with 1 µM of valspodar to check for synergistic effects of the particles 
and the ABCB1 inhibitor (Figure 3.14).  
 
However, an increased antiproliferative effect of coated doxorubicin-loaded NP combined 
with valspodar was not observed, compared to the other co-incubation experiments. Hence, 
the hypothesized ABCB1 modulating effect of polysorbate 80-coated nanoparticles could not 
be confirmed by these investigations. 
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Figure 3.13: Effect of different doxorubicin 
formulations on proliferating Kb-V1 cells. 
Cells were incubated with 1 µM of different 
doxorubicin formulations: doxorubicin in 
solution (filled circles), doxorubicin-loaded 
nanoparticles (filled squares) and 
polysorbate 80-coated doxorubicin-loaded 
nanoparticles (filled triangles). 
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Figure 3.14: Incubation of ABCB1-
overexpressing Kb-V1 cells with 1 µM of 
valspodar and 250 nM of different 
doxorubicin formulations: doxorubicin in 
solution (filled circles), doxorubicin-loaded 
nanoparticles (filled squares) and polysorbate 
80 coated doxorubicin-loaded nanoparticles 
(filled triangles). 
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By analogy to investigations on the efflux pump ABCB1, the chemosensitivity of ABCG2-
overexpressing MCF-7/Topo cells was studied by treatment with different doxorubicin 
preparations (Figure 3.16).  
 
Additionally, the susceptibility of non-induced MCF-7 cells to these formulations was 
investigated (Figure 3.15) for comparison. This aspect is important not only to interpret the 
data obtained with the MCF-7/Topo cells, but also to identify anthracycline resistence 
resulting from point mutations (e.g. amino acid 482) of ABCG2 [Alqawi et al., 2004].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Differential antiproliferative activities of doxorubicin in solution or loaded to PBCA 
nanoparticles were not observed at a concentration of 10 nM (Figure 3.15). Furthermore, 
coating of the doxorubicin-loaded nanoparticles with the surfactant polysorbate 80 did not 
enhance the antiproliferative effect of the anthracycline. At a concentration of 100 nM, a 
pronounced cytostatic effect was mediated by all preparations of doxorubicin. However, as 
observed at lower concentrations, discrepancies in the cytotoxicity between various 
formulations were not detectable.  
 
Overall, the chemosensitivity of non-induced MCF-7 cells against the different doxorubicin 
formulations was comparable to the susceptibility of the ABCB1 and ABCG2 negative human 
glioblastoma cell lines U-87 MG, U-118 MG and U-373 MG. 
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Figure 3.15: Effect of 10 nM (filled symbols) 
and 100 nM (open symbols) of different 
doxorubicin formulations on proliferating, non-
induced MCF-7 cells. 
Cells were incubated with: doxorubicin in 
solution (circles), doxorubicin-loaded 
nanoparticles (squares) and polysorbate 80- 
coated doxorubicin-loaded nanoparticles 
(triangles). 
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No differences between the cytotoxic effects of various drug applications were observed on 
MCF-7/Topo cells (Figure 3.16). Whereas 10 nM of each formulation did not affect the 
proliferation of ABCG2-overexpressing MCF-7/Topo cells, incubation with 100 nM resulted 
in strong cytostatic effects comparable to those observed on non-induced MCF-7 cells.  
 
Thus, interactions of coated nanoparticles with the efflux pump ABCG2 are implausible, as 
suggested above for ABCB1 in Kb-V1 cells. 
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Figure 3.16: Effect of 10 nM (filled symbols) 
and 100 nM (open symbols) of different 
doxorubicin formulations on proliferating MCF-
7/Topo cells. 
Cells were incubated with: doxorubicin in 
solution (circles), doxorubicin-loaded 
nanoparticles (squares) and polysorbate 80 
coated doxorubicin-loaded nanoparticles 
(triangles). 
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3.5 Summary and conclusions 
 
Doxorubicin formulations (polysorbate 80-coated and uncoated doxorubicin-loaded 
nanoparticles (NP)) and new doxorubicin hydrazone derivatives (Sb-59 and Sb-63b) were 
investigated in chemosensitivity assays on human U-87 MG, U-118 MG and U-373 MG 
glioblastoma cells, using doxorubicin in solution as a reference:  
 
 
Neither doxorubicin-loaded polybutylcyanoacrylate particles nor the polysorbate 80 coated 
drug-loaded NP did show enhanced antiproliferative activity compared to the solution of the 
cytostatic. In addition, short-term drug exposure studies on U-373 MG cells revealed no 
increased cytotoxicity of Tween 80-coated doxorubicin-loaded NP as well. Nevertheless, all 
tested formulations (doxorubicin in solution, doxorubicin-loaded nanoparticles and 
polysorbate 80-coated, doxorubicin-loaded nanoparticles) gave comparable results. Hence, it 
can be concluded the other way around that neither loading to PBCA-nanoparticles nor 
coating of the particles with Tween 80 caused a decrease in toxicity of doxorubicin.  
 
On all investigated glioblastoma cell lines, the derivative Sb-59 proved to be less toxic than 
its parent compound doxorubicin, although the introduction of a highly lipophilic side chain 
into the molecule caused only a moderate decrease in cytotoxicity. This is demonstrated by 
strong cytotoxic / cytostatic effects on all investigated human glioblastoma cell lines at 
concentrations as low as 100 nM. By contrast, the introduction of a steroid moiety into 
doxorubicin yielded an equipotent (U-118 MG and U-373 MG cells) or even more potent (on 
U-87 MG cells) derivative (Sb-63b). Thus, it can be concluded that the structural modification 
of doxorubicin - by introducing a lipophilic side chain or a steroid moiety into the molecule - 
did not significantly decrease the toxicity of the anthracycline, making the derivatives 
interesting for ongoing predictive studies in the chemotherapy of malignant brain tumors.  
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To investigate the effect of doxorubicin-loaded nanoparticle formulations on the efflux pumps 
ABCB1 and ABCG2, the transporter overexpressing subclones Kb-V1 and MCF-7/Topo 
served as an in vitro model. Therefore, by analogy to the performed chemosensitivity studies 
on glioblastoma cell lines, the different doxorubicin formulations were investigated for their 
antiproliferative potential against Kb-V1 and MCF-7/Topo cells. For comparison, the 
corresponding non-induced wild type cells (Kbwt and MCF-7) were incubated with 
doxorubicin in solution, loaded to nanoparticles or loaded to polysorbate 80-coated 
nanoparticles: 
 
 
Differential antiproliferating activities for the various modes of drug application were not 
observed, neither for Kbwt nor for MCF-7 cells. Furthermore, the incubation of ABCG2 
overexpressing MCF-7/Topo cells with increasing concentrations of the different doxorubicin 
preparations revealed no increased toxicity of the cytostatic by application as (polysorbate 80-
coated) nanoparticle formulation. In contrast, Kb-V1 cells showing resistance to doxorubicin 
due to overexpression of ABCB1 were most sensitive to the anthracycline when administered 
as surfactant coated nanoparticles (at a concentration of 1 µM). At concentrations 
corresponding to 3 µM of doxorubicin, similar observations were made by D. Gross [Gross, 
2006]. Hence, high concentrations were necessary to discriminate toxic effects of different 
formulations. Moreover, co-incubation experiments with the ABCB1 inhibitor valspodar did 
not confirm a direct interaction of polysorbate 80-coated nanoparticles on the efflux pump 
ABCB1. Alternatively, it may be speculated that the Tween 80-coated particles act as a kind 
of Trojan horse, protecting a larger amount of doxorubicin from elimination via ABCB1. 
Thus, an increased intracellular concentration of the cytostatic might lead to enhanced 
cytotoxicity. However, in contrast to experiments by Reimold et al. [Reimold et al., 2008] 
penetration of the coated doxorubicin-loaded nanoparticles or uptake via endocytosis could 
not be proven by Gross [Gross, 2006]. Furthermore, it remains unclear whether doxorubicin is 
released after adsorption of the particles to the cell membrane, maintaining a concentration 
gradient counteracting the ABCB1 efflux to a certain extent by saturation of the transporter 
[Gross, 2006]. 
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4.1  Introduction 
 
ATP-binding cassette transporters use the energy of ATP-hydrolysis to transport a broad 
variety of substrates across the cell membrane. Under physiological conditions, these efflux 
pumps, including ABCB1 (p-glycoprotein 170, P-gp), ABCC2 (multidrug resistance related 
protein 2) [Borst et al., 1997; Kuwano et al., 1999] and ABCG2 (ABCP, BCRP, MXR) [Dean 
and Allikmets, 2001; Cervenak et al., 2006], appear to play a protective role in several tissues 
[Robey et al., 2007]. Highly expressed in the gastrointestinal tract, the placenta, the testis and 
the brain endothelium, ABCG2 presumably represents an important part in the protection 
from xenobiotics as well as in the regulation of oral bioavailability [Robey et al., 2009]. In the 
placenta ABCG2 appears to reduce the passage of substrates from the mother to the fetus and, 
as reasoned from mice studies [Staud et al., 2006], decreases the concentration of certain 
substrates in the fetal circulation. The expression of the aforementioned efflux pumps at the 
blood-brain barrier (BBB) is an important limiting factor in the therapy of central nervous 
diseases since numerous pharmacologically active compounds are actively extruded. This is 
also one of the primary causes for the failure of chemotherapy in the treatment of malignant 
brain tumors [Régina et al., 2001], since many anticancer agents are ABCB1 and ABCG2 
substrates.  
 
4.1.1 ABC transporter mediated multi-drug resistance (MDR) 
 
Furthermore, ABC transporters play also an important role in conjunction with multi-drug 
resistance (MDR). According to estimations, multi-drug resistant tumors account for up to 
half of all cancer-related deaths [Leonard et al., 2003; Sheps and Ling, 2007]. Multi-drug 
resistance occurs by the overexpression of efflux pumps such as ABCB1 and ABCG2, located 
in the plasma membrane of cancer cells. The active transport of a vast number of structurally 
unrelated compounds, including many commonly used anticancer drugs, leads to low 
intracellular levels of these substances. Since its discovery in 1998 [Allikmets et al., 1998; 
Doyle et al., 1998], ABCG2 has been the subject of many investigations on its role in MDR. 
The overexpression of the efflux pump is associated with high-level of resistance to a large 
number of cytostatics.  
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4.1.2 ABCG2 as a potential marker of cancer stem cells   
 
In addition, ABCG2 has recently attracted interest with respect to a new concept of tumor 
development and progression, the so-called cancer stem cell hypothesis. By contrast to the 
classical stochastic model (assuming that all cancer cells are involved in tumor initiation and 
progression), the stem cell concept is based on the idea that only a small side-population of 
cancer cells proliferates, analogously to hematopoietic stem cells in the bone marrow. 
Characteristically, members of the side-population cells divide slowly, are capable of long-
term self-renewal and express ABCG2 [Bunting, 2002; Jonker et al., 2005; Sung et al., 2008]. 
In a large number of tumor cell lines and tumor biopsies [Hirschmann-Jax et al., 2004; Kondo 
et al., 2004; Haraguchi et al., 2006], such stem cells, which might be responsible for the long-
term failure of many cancer chemotherapies, have been identified. Due to their slow 
proliferation and the expression of ABCG2 efflux pumps, they are inefficient targets for 
classical cytostatic agents. For this reason, alternative approaches for specifically targeting 
cancer-stem cells might be promising with respect to an eradication of this subpopulation. 
Recently, a drug called salinomycin was identified, which reduced the number of breast 
cancer stem cells in vitro more than 100 times more effectively than paclitaxel [Humphries, 
2009]. Such effective targeting of cancer stem cells could help to avoid recurrence of tumors.  
 
4.1.3 Effects of estrogens on ABCG2 expression 
 
Another interesting aspect of ABCG2 transporters might be the putative involvement of 
estrogens in the regulation of efflux pump expression. Whereas Zhang et al. describe an up-
regulation of ABCG2 mRNA and protein expression in MCF-7 cells under 17β – estradiol 
(E2) treatment [Zhang et al., 2006], the exposure of the aforementioned cells to E2 by Imai et. 
al resulted in a cytotoxic potentiation of the active metabolite of irinotecan SN-38, caused by 
lower levels of the transporter protein ABCG2 [Imai et al., 2005]. 
 
 
Hence, in many respects, the manipulation of the ABCG2 transporter might be a promising 
approach in cancer chemotherapy. Predominantly, inhibition of the efflux pump by potent and 
selective modulators might be a conceivable application to reverse ABCG2-mediated multi-
drug resistance or to specifically target the cancer-stem cells.  
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Long-term survival of these cells, due to resistance against cytostatics, that are ABCG2 
substrates, might be overcome by a specific ABCG2 inhibitor in combination with the 
pharmacologically active compound.  
 
4.1.4 Modulation of ABC transporters expressed at the BBB 
 
The modulation of the physiologically expressed ABCG2 transporters at the blood-brain 
barrier might be an interesting strategy to increase drug levels of ABCG2 substrates in the 
brain [Breedveld et al., 2006]. Such an approach was successful in a proof-of-concept study 
by the combination of the cytostatic paclitaxel, an ABCB1 substrate, and the 2nd generation 
ABCB1 modulator valspodar [Fellner et al., 2002]. The co-application of valspodar yielded 6-
8 fold higher brain levels of paclitaxel as obtained in mice which were treated with paclitaxel 
alone. Furthermore, in an orthotopic human glioblastoma model in nude mice, these increased 
brain levels of paclitaxel yielded a decrease in tumor volume by 90 %. Similarly, the co-
administration of the 3rd generation inhibitors elacridar and tariquidar resulted in higher 
intracerebral levels of paclitaxel [Hubensack et al., 2008]. 
 
4.1.5 Inhibitors of ABCG2 
 
Due to its relatively recent discovery, only a few inhibitors of ABCG2 have been published so 
far [Ahmed-Belkacem et al., 2006; Boumendjel et al., 2007; Han et al., 2008; Jain et al., 2008; 
Liu et al., 2008]. The diketopiperazine fumitremorgin C (FTC, Figure 4.1), isolated from the 
fermentation broth of Aspergillus fumigatus, was reported first [Rabindran et al., 2000]. 
Neurotoxicity of the compound precluded its use in in vivo studies. Novobiocin, a 
coumermycin derivative and inhibitor of the prokaryotic enzyme gyrase was also identified as 
an inhibitor of the efflux transporter ABCG2. However, cytotoxicity and flow cytometric 
assays yielded an overcome of the ABCG2-mediated drug resistance to mitoxantrone, 
topotecan and SN-38, the active metabolite of irinotecan, only at micromolar concentrations 
of novobiocin [Shiozawa et al., 2004]. The original ABCB1 inhibitors elacridar (GF120918, 
Figure 4.1) and tariquidar (XR 9576, Figure 4.1) also act as modulators of ABCG2. It was 
demonstrated that this effect was more pronounced for elacridar [de Bruin et al., 1999] than 
observed for tariquidar [Robey et al., 2004] and their common analog WK-X-34 [Jekerle et 
al., 2006; Jekerle et al., 2007].  
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A very recent study identified the class of botryllamides, obtained by extractions of the 
marine ascidian Botryllus tyreus, as inhibitors of ABCG2 [Henrich et al., 2009]. Nevertheless, 
by means of a fluorescence-based microtiter assay containing the ABCG2 substrate 
pheophorbide a (PhA), these compounds were determined with IC50 values only in the 
micromolar range [Henrich et al., 2009]. The most potent inhibitor of ABCG2, known up to 
the time of our project, was a non-toxic analog of the previously mentioned fumitremorgin C 
[Allen et al., 2002]. The compound, called Ko143 (Figure 4.1), was applied in in vivo studies 
and resulted in an increased bioavailability of orally administered topotecan in mice [Allen et 
al., 2002].  
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Figure 4.1: Structures of the ABCG2 modulators fumitremorgin C (a) and its analog, 
Ko143 (b), the dual ABCB1/ABCG2 inhibitor elacridar (c) and the ABCB1 inhibitor 
tariquidar (d). 
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4.2  Objective 
 
As described above, in many respects, limitations in chemotherapy due to efflux pump-
mediated resistance to cytostatics represent a major problem. Besides the (over) expression of 
these transporters in many tumor types as well as in cancer stem cells, the existence of such 
efflux pumps in healthy tissues, e.g. at the blood-brain barrier, can also cause problems in 
pharmacotherapy (e.g. in the treatment of malignant brain tumors). Increasing drug levels in 
the brain by co-application of an ABC transporter inhibitor with a cytostatic, known to be a 
substrate of the efflux pump, has already been proven with the ABCB1 modulator valspodar 
and the chemotherapeutic paclitaxel in the treatment of glioblastoma [Fellner et al., 2002]. 
Furthermore, such investigations have been performed with the ABCB1 inhibitor tariquidar 
yielding a higher brain / plasma ratio of paclitaxel, but did not result in higher brain levels of 
the cytostatic compared with valspodar [Hubensack et al., 2008]. It has been speculated that 
these relatively low paclitaxel brain level might be due to accumulation of the hydrophobic 
tariquidar in the lipid compartment of the brain. In the search for more hydrophilic tariquidar 
analogs as inhibitors of ABCB1 [Egger et al., 2007; Müller, 2007; Hubensack et al., 2008], 
we found that, interestingly, minimal structural changes at the benzamide core of the parent 
compound tariquidar resulted in potent ABCG2 inhibition. 
 
The objective of this work was to investigate such ABCG2 selective tariquidar analogs in 
more detail. The inhibitory potency of the compounds against ABCG2 was examined in a 
flow cytometric mitoxantrone efflux assay, whereas the selectivity against ABCB1 and 
ABCC2 was investigated by Dr. Christine Müller, Peter Höcherl and Anne Mahringer. The 
results of these studies were published recently [Kühnle et al., 2009]. With regard to ABCG2 
selectivity putative essential structural moieties of the substances were modified, further 
analogs as well as several partial structures and intermediates were synthesized, and the 
compounds were characterized by means of the aforementioned transporter assays. Moreover, 
to fortify the inhibition data of flow cytometric mitoxantrone efflux assays and to circumvent 
these costly as well as time-consuming test systems, 2 fluorescence-based 96-well plate 
assays were developed. For this purpose, the known ABCG2 substrates Hoechst 33342 and 
pheophorbide a were selected for the establishment of such rapid ABCG2 transporter assays.  
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As a prerequisite for planed in vivo studies, the most potent inhibitors were assessed with 
respect to their stability in mouse plasma by means of HPLC-MS analysis. With respect to 
investigations on the mode of ABCG2 inhibition by these tariquidar analogs, a small series of 
fluorescence-labeled tariquidar-like substances was synthesized by Carolin Fischer (Institute 
of Organic Chemistry, University of Regensburg), and IC50 values were determined in the 
newly established Hoechst 33342 assay. In addition, the labeled compounds were applied in 
confocal-laser scanning microscopy (CLSM).  
 
Additionally, the contribution of estrogens to the regulation of ABCG2 protein expression 
should be investigated. Therefore, MCF-7/Topo cells were examined in the crystal violet 
chemosensitivity assays by checking their sensitivity to the cytostatic topotecan in the absence 
or presence of estradiol. 
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4.3 Materials and methods 
 
4.3.1  Drugs and chemicals 
 
A Milli-Q system (Millipore, Eschborn, Germany) was used for the purification of water in 
aqueous drug solutions. All chemicals used were of analytical grade, if not otherwise 
mentioned. Stock solutions of mitoxantrone were performed by diluting Novantron® (Wyeth 
Pharma, Muenster, Germany) in 70 % ethanol to a concentration of 2 mM. Hoechst 33342 
(Invitrogen, Karlsruhe, Germany) was dissolved in sterile water to produce a 1.6 mM working 
solution. Pheophorbide a (PhA) (Frontier Scientific, Logan, UT) was dissolved in DMSO 
(Merck, Darmstadt, Germany) to a concentration of 10 mM. A working solution of 200 µM in 
DMSO was prepared for assay performance. Estradiol (Sigma, Munich, Germany) was 
dissolved in DMSO to a concentration of 10 mM. Estron sulfate was obtained from Sigma, 
Munich, Germany. All stocks were stored at -20 °C. Hycamtin® (GlaxoSmithKline, Munich, 
Germany) was diluted in 70 % ethanol to achieve a topotecan stock solution of 2 mM. 
Precipitates of topotecan were redissolved prior to use by ultrasound and slight heating. For 
cell culture supplementation, a 0.1 mM stock solution of topotecan in ethanol (70 %) was 
prepared. Vinblastine (vinblastine sulfate, Sigma, Munich, Germany) was dissolved in 70 % 
ethanol at a concentration of 1 mM. All topotecan and vinblastin stocks were stored at 4 °C. 
PBS (phosphate buffered saline) was made of 8.0 g/L NaCl, 1.0 g/L Na2HPO4 · 2 H2O, 0.20 
g/L KCl, 0.20 g/L KH2PO4 and 0.15 g/L NaH2PO4· H2O. The pH-value was adjusted to 7.3 -
7.4 by using a 1 M NaOH or HCl solution. Phosphate buffered saline with calcium and 
magnesium was made by dissolving 0.2 g/L KCl, 0.2 g/L KH2PO4, 8.0 g/L NaCl, 1.15 g/L 
Na2HPO4 · 2 H2O in water followed by adding 0.132 g/L of CaCl2 · 2 H2O and 0.10 g/L of 
MgCl2 · 6 H2O. Adjusting the pH-value to 7.3 was performed by the drop-wise addition of a 1 
M NaOH solution. For buffer preparation all chemicals were obtained from Merck, 
Darmstadt, Germany. A solution of 3 % (m/m) of paraformaldeyde (Merck, Darmstadt, 
Germany) in Ca2+/Mg2+ containing PBS was made by stirring 1.5 g of paraformaldehyde per 
50 g total solution while heating on a magnetic stirrer for approximately 30 min. Sodium 
phosphate buffer (0.1 M) was produced with 14.3 g/L of Na2HPO4 · 2 H2O (Merck, 
Darmstadt, Germany) and 11.1 g/L of NaH2PO4 · H2O (Merck, Darmstadt, Germany) and 
adjusting the pH to 7.4. Ortho-nitrophenylbutyrate (Merck, Darmstadt, Germany) was 
dissolved in DMSO to a concentration of 100 mM and stored at 4 °C.  
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4.3.2  Test compounds 
 
The free base of tariquidar was synthesized by Hubensack [Hubensack, 2005]. A 10 mM 
stock solution of tariquidar in DMSO was prepared. Elacridar was a kind gift of 
GlaxoSmithKline, Munich, Germany and dissolved in DMSO. Fumitremorgin C was either 
obtained from Merck, Darmstadt, Germany or a kind gift of Dr. Susan Bates from the NIH 
(Bethesda, MD, USA). The compound was dissolved in DMSO at a concentration of 10 mM 
and stored at -80 °C. The fumitremorgin C analog Ko143 was a kind gift of Dr. A. H. 
Schinkel from the Netherlands Cancer Institute (Amsterdam, NL). All new tariquidar analogs 
were synthesized, characterized and provided by the workgroup of Prof. Dr. Burkhard König, 
Institute of Organic Chemistry (University of Regensburg, Germany). If possible, 10 mM 
stock solutions of the test compounds in DMSO were prepared. Solid substances as well as 
stock solutions of all investigated tariquidar analogs were stored at – 20 °C. Charts 4.1 – 4.5 
give an overview of the different subseries of tariquidar-like compounds. 
 
 
 
 
Chart 4.1: Structures of tariquidar analogs with variations of the heterocyclus. 
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Chart 4.2: Structures of tariquidar-like analogs with quinoline-3-carboxamido function 
and variations of R1 and R2. 
Chart 4.3: Structures of tariquidar analogs with quinoline-2-carboxamido function and 
variations in R1, R2, R3 and R4. 
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Chart 4.4: Chemical structures of 
intermediates of tariquidar-like analogs 
bearing a tetrahydroisoquinolinylethyl-
phenyl moiety. 
Chart 4.5: Chemical structures of 
building blocks with quinoline-2-
carboxamido moiety and methyl 
ester.  
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4.3.3  Cell culture  
 
MCF-7 cells (ATCC HTB-22, a human breast adenocarcinoma cell line), were cultured in 
Eagle’s Minimum Essential Medium containing L-glutamine (Sigma, Munich, Germany), 2.2 
g/L NaHCO3 (Merck, Darmstadt, Germany) and 110 mg/L sodium pyruvate (Serva, 
Heidelberg, Germany) supplemented with 5 % fetal calf serum (FCS) (Biochrom, Berlin, 
Germany). Cells were passaged every 3-7 days after trypsinization using 0.05 % trypsin / 
 0.02 % EDTA (PAA Laboratories, Pasching, Austria).  
 
MCF-7/Estron sulfate cells were obtained by a stepwise increase of the ABCG2 substrate 
estron sulfate in the culture medium of MCF-7 cells, aiming at a final concentration of 1 µM. 
Cells were cultured for approximately 3 months before applying them for the flow cytometric 
assays. 
 
MCF-7/Topo cells, an ABCG2 overexpressing subclone of MCF- cells, were obtained as 
described [Hubensack, 2005]. Briefly: Increasing concentrations of topotecan in Eagle’s 
Minimum Essential Medium (final concentration: 0.55 µM) over approximately 40 days 
yielded sufficient quantities of the ABCG2 transporter.  
 
The ABCB1 overexpressing Kb-V1 cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Sigma, Munich, Germany) supplemented with 10 % FCS and 300 ng/mL 
vinblastine. According to Hubensack [Hubensack, 2005] the cells expressed sufficient 
quantitities of the ABCB1 transporter after 3 passages. 
 
Human epithelial colorectal adenocarcinoma CaCo2 cells were a gift of Prof. Dr. Jörg 
Heilmann, Institute of Pharmaceutical Biology, University of Regensburg. The cells were 
grown in DMEM supplemented with 10 % of fetal calf serum. 
 
ABCC2 overexpressing MDCKII-MRP2 cells transfected with human ABCC2 were a kind 
gift from Prof. Dr. P. Borst (Netherland Cancer Institute, Amsterdam, NL). The cells were 
cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 5 % FCS. 
 
All cells were cultured in a water-saturated atmosphere (95 % air / 5 % CO2) at 37 °C in 25, 
75  and 175-cm2 culture flasks (NUNC, Wiesbaden, Germany; Greiner, Frickenhausen, 
Germany; Sarstedt, Nümbrecht, Germany) respectively. Cell banking was performed 
according to the “seed stock concept” [Hay, 1988]. Mycoplasma contamination was routinely 
monitored by polymerase chain reaction (Venor GeM, Minerva Biolabs GmbH, Berlin, 
Germany), and only mycoplasma free cultures were used for assays. 
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4.3.4  Cell-based assays for the determination of ABCG2 inhibition 
 
4.3.4.1 Flow cytometric mitoxantrone efflux assay 
 
The assay was essentially performed as described elsewhere [Müller, 2007]. Briefly: having 
reached a confluency of approximately 80 % (3 - 7 days after passaging), MCF-7/Topo cells 
were trypsinized and resuspended in Eagle’s Minimum Essential Medium plus 5 % FCS at 
room temperature. After adjusting the cell number to 1.106 per mL with culture medium, 10 
µL of mitoxantrone (2 mM stock solution in 70 % ethanol) were added to the cell suspension 
in order to achieve a final concentration of 20 µM. Subsequently, various concentrations of 
the test compounds, solvent and the known ABCG2 inhibitor fumitremorgin C (final 
concentration 10 µM) were added, respectively. The samples were vortexed and incubated for 
30 min at 37 °C / 5 % CO2 to allow maximal mitoxantrone uptake into the cells. After 1 
washing step with 0.8 mL of ice-cold PBS, the cells of the fumitremorgin C reference were 
resuspended in 0.5 mL phosphate buffered saline and placed on ice in the dark until 
measurement to avoid mitoxantrone efflux (determination of the 100 % mitoxantrone uptake). 
All other samples were incubated with 1 mL of drug-free culture medium for further 60 min 
at 37 °C / 5 % CO2 to reach equilibrium of mitoxantrone between the cytoplasm and the 
surrounding medium. Subsequently, the medium was removed by centrifugation; the cell 
pellets were rinsed once with 0.8 mL of ice-cold PBS and finally resuspended in 0.5 mL of 
the aforementioned buffer for flow cytometry. A FACS caliburTM (Becton Dickinson, 
Heidelberg, Germany) was used to analyze the fluorescence intensity of the cells. 
Mitoxantrone accumulation in the cells was monitored by using an excitation wavelength of 
635 nm, whereas emission was detected at a wavelength of 661 ± 8 nm. A minimum of 
20,000 events was collected per sample. The events were gated according to forward and 
sideward scatter to exclude cell aggregates and debris. Analysis of the raw data was 
performed with the WinMDI 2.8 and WinMDI 2.9 software, respectively. The geometric 
means were calculated from the fluorescence intensity histogram and related to the controls. 
Afterwards, the mean values of different measurements were plotted against the concentration 
of the test compounds. Addition of increasing concentrations of the modulator led to 
sigmoidal concentration-response curves. IC50 values were calculated using SIGMA PLOT 
9.0, Four parameter logistic curve fitting. Errors were expressed as standard error of the mean 
(SEM). 
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4.3.4.2 Hoechst 33342 and pheophorbide a microtiter plate assay 
In order to minimize expenditure of time, material costs and required cell numbers for 
investigations of putative ABCG2 modulators as well as for the screening of large compound 
libraries, two alternative microtiter assays in the 96-well format were established. As 
fluorescent substrates of ABCG2, Hoechst 33342 and pheophorbide a were selected. The 
different spectral properties of these dyes should enable the determination of fluorescence-
labelled compounds as putative ABCG2 modulators in order to investigate the mode of 
transporter inhibition. The assays were performed using a GENios Pro microplate reader 
(TECAN Deutschland GmbH, Crailsheim, Germany). For excitation and emission of the 
Hoechst 33342 dye, the following filter set was used: exc. BP 340/35, em. BP 485/20. 
Pheophorbide a was excited at a wavelength of 380/10 nm, whereas the emission was 
determined at 670/20 nm. In the start-up period of assay development, black microplates with 
clear bottom were used (µclear®, Greiner, Frickenhausen, Germany), which were later on 
replaced with clear, flat-bottomed plates to reduce material costs (sterile, F-Bottom, with lid, 
Cat.-No.655 180, Greiner, Frickenhausen, Germany).   
4.3.5 Assays for the determination of ABCB1 and ABCC2 inhibition 
 
4.3.5.1 Flow cytometric calcein-AM efflux assay for determination of ABCB1 inhibition 
 
The assays were performed as described elsewhere [Müller, 2007]. 
 
4.3.5.2 Calcein-AM microtiter plate assay for determination of ABCB1 inhibition 
 
The assay procedure will be described in detail in the doctoral thesis of Peter Höcherl. In 
brief: ABCB1-overexpressing Kb-V1 cells were seeded into clear 96-well plates at a density 
of 20,000 cells / well and allowed to attach to the surface for 18-24 h. Subsequently, cells 
were simultaneously incubated with 0.5 µM of calcein-AM and the test compounds at 
increasing concentrations. After 10 min of incubation at 37 °C / 5 % CO2, the supernatant was 
removed, and cells were immediately fixed using paraformaldehyde (4 %) in PBS. 
Afterwards, cells were washed three times and finally overlaid with 100 µL of buffer per well. 
Relative fluorescence intensities were determined at the GENios Pro microplate reader. The 
excitation was performed at 485/20 nm, the emission was determined at 535/25 nm. 
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4.3.5.3 CMFDA microtiter plate assay for determination of putative ABCC2 modulation 
 
The assay was performed by Anne Mahringer as described previously [Kühnle et al., 2009]. 
Briefly: ABCC2 overexpressing MDCK-cells were cultured in 24-well plates and incubated 
with 1 µM CMFDA in the absence or presence of the test compounds at increasing 
concentrations. After 90 min of incubation at 37 °C, cells were washed twice and finally lysed 
for 30 min by the use of 1 % Triton X-100. Subsequently, the relative fluorescence intensities 
were measured with a plate reader (Tecan Safire XFLUOR4, Tecan, Crailsheim, Germany) 
using an excitation wavelength of 485 nm, whereas the emission was detected at 516 nm. 
 
4.3.6   Confocal laser-scanning microscopy (CLSM)  
 
After trypsinization, ABCG2-overexpressing MCF-7/Topo cells were resuspended in culture 
medium supplemented with 5 % fetal calf serum and 0.55 µM topotecan. 250 µL of the cell 
suspension were seeded into each well of a sterile 1 µ-slide 8-well ibiTreat™ microscopy 
chamber (ibidi, Martinsried, Germany). Having reached the appropriate confluency of 70 % 
(approximately 48 h later), the medium was removed by suction, and the cells were washed 
with 280 µL of Leibovitz L15 medium containing L-glutamine (Invitrogen, Karlsruhe, 
Germany). Subsequently, the cells were overlaid with 240 µL of Leibovitz´s L15 medium. On 
the eve of the experiment, 40 µL of a 7-fold concentrated stock solution of the test compound 
were pipetted to the cells. Fluorescence imaging was performed with a Carl Zeiss Axiovert 
200M LSM 510 confocal-laser scanning microscope (CLSM) encased by a tempered 
incubation chamber. Instrument settings (excitation wavelengths, beam paths, filter settings) 
for each experiment are given in the corresponding figure legends. For image processing the 
Carl Zeiss LSM Image Examiner and the LSM image Browser software were used.  
 
2 subseries of fluorescence-labeled tariquidar-like compounds were synthesized by Carolin 
Fischer, Institute of Organic Chemistry, University of Regensburg. The structures of these 
substances are shown in Charts 4.6 and 4.7. 
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Chart 4.6: Structures of fluorescence-labeled compounds designed as ABCG2 modulators. 
The pyridinium fluorophore was incorporated in place of the tetrahydroisoquinoline 
moiety in the non-labeled tariquidar analogs. 
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Chart 4.7: Structures of fluorescence-labeled compounds designed as ABCG2 modulators. 
The pyridinium fluorophore was incorporated by linkage of pyrylium dyes to the central 
benzamide moiety of ABCG2 modulators derived from tariquidar. 
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4.3.7  Chemosensitivity assays 
 
The assays were performed as described previously [Bernhardt et al., 1992a]. In brief: 100 
µL/well of a tumor cell suspension, yielding a density of 8-15 cells per microscopic field 
(magnification 320-fold), were seeded into 96-well plates (Greiner, Frickenhausen, Germany). 
Cells were allowed to grow for 2-3 days at 37 °C / 5 % CO2 in a water-saturated atmosphere. 
Subsequently, supernatant was removed by suction and replaced by fresh medium (200 
µL/well) containing varying drug concentrations or vehicle. In general, test compounds were 
added as 1000-fold concentrated feed solutions (16 wells per drug concentration). On every 
plate 16 wells served as growth control (vehicle) and 16 wells were supplied with a reference 
cytostatic as a positive control. Incubation of the cells was stopped after different periods of 
time by removal of medium and fixation with glutardialdehyde (Merck, Darmstadt, 
Germany). All plates were stored at 4 °C until the end of the experiment and afterwards 
simultaneously stained with 100 µL/well of a 0.02 % aqueous crystal violet solution (Serva, 
Heidelberg, Germany) for 20 min. Subsequently, the trays were rinsed with water for further 
20 min in order to remove excess dye. Crystal violet stain bound by the fixed cells was 
redissolved in 70 % ethanol (180 µL/well) while shaking the microplates for 2-4 h. 
Absorbance (a parameter proportional to cell mass) was measured at 578 nm using a BIOTEK 
309 autoreader (TECNOMARA, Fernwald, Germany). Drug effects were expressed as 
corrected T/C-values for each group according to: 
 
100
CC
CT
C/T
0
0
.corr 
 [%]  
 
, where T is the mean absorbance of the treated cells, C the mean absorbance of the controls 
and C0 the mean absorbance of the cells at the time (t=0) when drug was added. When the 
absorbance of treated cells T was less than that of the culture at t=0 (C0), the extent of cell 
killing was calculated as 
 
Cytocidal effect [%] = 100
C
TC
0
0   
 
SigmaPlot analysis software (Systat Software GmbH, Erkrath, Germany) was used for the 
creation of growth curves. 
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4.3.8.  Stability of tariquidar-like ABCG2 inhibitors  
 
4.3.8.1  Preparation of mouse plasma and determination of esterase activity 
 
With respect to future in vivo studies, selected candidates out of a series of potent ABCG2 
modulators developed in collaboration with the group of Prof. Dr. B. König, were 
investigated for stability in plasma. For this purpose, blood of BL6 mice was collected by 
heart puncture in deep anesthesia using heparin-coated syringes. Samples were immediately 
centrifuged for 7 min at 7,000 rpm (Eppendorf centrifuge 5415R, Eppendorf, Hamburg, 
Germany) and the supernatant was carefully removed. After pooling, the plasma was 
fractioned into small aliquots for long-term storage at -80 °C. The enzymatic activity of 
esterases in the plasma samples was measured spectrophotometrically. The colored product o-
nitrophenol, formed by enzymatic cleavage of the chromogenic substrate nitrophenyl butyrate 
was determined as a function of time. Absorbance was plotted against time, the linear slope at 
the beginning of the reaction was determined and used for the calculation of volume activity: 
 
 
VA= 
 
 
The abbreviations of the present equation define the following parameters: 
 
VA = volume activity [U · mL-1] multiplied with 1000 for [U· L-1] 
ΔA = absorbance of o-nitrophenol at 414 nm 
t = time [min] 
V = total volume [mL] 
εo-nitrophenol = 3190 [L · mol-1 · cm-1] 
d = path length [cm] 
v = plasma volume [mL] 
 
 
 
 
vd 
t
VA 
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4.3.8.2  Assay procedure  
 
The test compounds were dissolved in DMSO at a concentration of 1.5 mM. Subsequently, 
test compound stocks, mouse plasma, deproteinated plasma, culture medium and phosphate 
buffered saline were equilibrated on a Wealtec heat plate (Wealtec, Sparks, USA) to 37 °C for 
approximately 15 min. Thereafter, a 1:50 dilution of the substances with the corresponding 
medium was prepared in 1.5-mL polypropylene reaction vessels (Eppendorf, Hamburg, 
Germany). The samples were shortly vortexed and immediately incubated at 37 °C. After 
increasing periods of time, aliquots were taken, and the reaction was stopped by the addition 
of 2 parts of ice-cold acetonitrile. For quantitative precipitation of the denatured proteins, the 
samples were efficiently vortexed and stored at 4 °C for 30 min. Finally, samples were 
centrifuged for 5 min at 17,000 g, using an Eppendorf MiniSpin plus centrifuge, and the 
supernatants were transferred into new plastic cups. For HPLC analysis the samples were 
further diluted (1:2) with acetonitrile and stored at -80 °C until measurement. 
 
4.3.8.3  HPLC and HPLC-MS analysis  
 
4.3.8.3.1 HPLC analysis 
 
HPLC analysis was performed according to the method established by P. Höcherl for the 
investigation of tariquidar-like ABCB1 modulators (part of Peter Höcherl’s PhD project).  
In brief: samples were unfrozen at room temperature and injected into the HPLC system 
(Waters, Eschborn, Germany). Analysis was accomplished by gradient elution with water 
containing TFA (0.05 %) and acetonitrile (0 min, 15 %; 19 min, 60 %; 20 min, 95 %; 24.5 
min, 95 %; 25 min, 15 %; 38 min, 15 %), at a constant flow rate of 0.8 mL/min. The HPLC 
system was equipped with a Luna RP-18 (2), 3 µm, 150 mm x 4.6 mm column. Analysis was 
carried out via UV-detection at a wavelength of 210 nm. 
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4.3.8.3.2 HPLC-MS analysis 
Structure determination of cleavage products was performed by HPLC-MS analysis. For this 
purpose, 2 alternative methods with the following characteristics were established: 
 
HPLC (Agilent 1100, Palo Alto, CA): 
Method 1: A Luna C18, 3 µm, 100 mm x 2 mm column (Phenomenex, Aschaffenburg, 
Germany) was used at 40 °C. Gradient elution with water containing formic acid (0.1 %) and 
acetonitrile (0 min, 20 %; 24 min, 60 %; 25 min, 98 %; 30 min, 98%; 31 min, 20 %; 40 min, 
20 %) was performed at a flow rate of 0.3 mL/min with UV-detection at 220 nm.  
Method 2: The gradient consisted of 0.1 % formic acid and acetonitrile (0 min, 0 %; 1 min, 0 
%; 11 min, 98 %; 12 min, 98 %; 13 min, 0 %; 16 min, 0 %. A Gemini C18 column, 3 µm, 50 
mm x 2 mm (Phenomenex, Aschaffenburg, Germany), was used at 40 °C. Compounds were 
detected at 220 nm. 
 
Mass spectrometry: 
The HPLC was coupled to a Finnigan ThermoQuest TSQ (Triple-Stage-Quadrupol) 7000 ESI 
(Electron-Spray-Ionization) mass spectrometer, capillary temperature: 250 °C, spray voltage: 
4.0 kV, sheath and auxiliary gas: on. 
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4.3.9  In vivo experiments 
 
4.3.9.1  Animals, husbandry and feeding  
 
Tumorigenicity and in vivo growth kinetics of ABCG2-overexpressing MCF-7/Topo cells 
were investigated in NMRI nude mice (nu/nu).  
 
NMRI (nu/nu) mice were randomly bred in the nude mouse laboratory at the University of 
Regensburg under specified pathogen-free (SPF) conditions at 26 °C, 70 % relative humidity 
and a 12 h light/ dark cycle [Spruss et al., 1996].  The animals were kept in type III cages 
from Tecniplast™ (Hohenpeißenberg, Germany), bedded with “3/4 Faser” from ssniff ™ 
(Soest, Germany) and fed ad libitum with combined breeding maintenance diet (Ssniff, Soest, 
Germany) and autoclaved tap water.  
 
4.3.9.2 Tumor cell preparation and inoculation 
For tumor cell implantation into nude mice, MCF-7/Topo cells were harvested by 
trypsinization using a trypsin/EDTA solution. They were washed 2 times with 5 mL serum-
free medium and centrifuged at 1000 rpm for 7 min at room temperature, using a Minifuge T 
centrifuge from Heraeus Instruments GmbH (Hanau, Germany). The resulting cell pellet was 
resuspended in serum-free EMEM and the cell number was adjusted to a density of 1·107 and 
2·107 cells per mL. The cell suspension was homogenized by repeated aspiration with a 
syringe and injected under the thoracic dermis of each mouse (100 µL / animal). Once a week, 
the bodyweight was controlled as a measure for detraction, and the tumor diameters were 
monitored. In order to allocate the measuring data of the mice, animals were labeled with 
tattoos on their pads.  
 
 
Due to known growth retardation of human MCF-7 breast cancer cells in nude mice caused by 
to low estrogen levels compared with human females [Bernhardt et al., 1992b], for studies 
with ABCG2-overexpressing MCF-7/Topo cells, estradiol depots [Bernhardt et al., 1992b] 
were additionally implanted into a subgroup of female nude mice.  
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Mice were anesthetized with a mixture of 3 volumes of ketamine (Ketamin 10 %, WDT-
Wirtschaftsgenossenschaft deutscher Tierärzte eG, Garbsen, Germany) and 1 volume of 
xylazine (Xylazin (2 %) Bernburg 50 mL, Serumwerk Bernburg AG, Bernburg, Germany). 
The intraperitoneal injection of 30-50 µL of this mixture yielded a 20-50 min lasting 
anesthesia for a 30-40 g weighty nude mouse.  
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4.4  Results and discussion 
 
4.4.1  Inhibition of ABCB1, ABCC2 and ABCG2 
 
The potency of new tariquidar-like analogs to modulate the ABCG2 transporter was 
determined in the flow cytometric mitoxantrone efflux assay. In ABCG2-overexpressing 
MCF-7/Topo cells red fluorescent mitoxantrone is not accumulated but extruded by the efflux 
pump. Therefore, ABCG2 inhibitors can easily be recognized by the determination of 
intracellular mitoxantrone levels. Different concentrations of efflux pump inhibitors cause 
changes in the mitoxantrone efflux that can be measured by the relative fluorescence intensity 
of the cells. Similarly, in ABCB1 overexpressing Kb-V1 cells, the accumulation of the 
fluorescent ABCB1 substrate calcein can be quantified by the use of flow cytometric 
techniques or the use of microplate readers. In the presence of ABCB1 inhibitors higher 
intracellular calcein levels lead to increased relative fluorescence intensities of the cells. The 
modulation of ABCC2 was investigated by the use of ABCC2-overexpressing MDCK-cells 
that were incubated with chloromethylfluorescein diacetate (CMFDA) in the presence or 
absence of increasing concentrations of test compounds. After intracellular formation of the 
ABCC2 substrate glutathione methylfluorescein, (GMSF), the extent of intracellular 
fluorescence was monitored with a plate reader in a concentration-dependent manner. Known 
modulators of the 3 efflux pumps were investigated as reference compounds. 
 
Visible precipitations in the culture medium (EMEM / 5 % FCS), used for the mitoxantrone 
efflux assay, occurred at a number of tariquidar analogs at final concentrations above 10 µM. 
Therefore, unless otherwise stated, concentrations higher than 10 µM were not considered in 
the calculation of IC50 values. The data were used for the construction of concentration-
response curves as depicted in Figures 4.2, 4.3, 4.4 and 4.5. For a summary of all data from 
the investigation of test compounds 1-26 and reference substances for inhibition of ABCG2, 
ABCB1 and ABCC2 cf. Table 4.1.  
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Figure 4.2: Concentration-response curves for ABCG2 modulation by the reference 
compounds fumitremorgin C (circles), Ko143 (squares), elacridar (triangles) and tariquidar 
(inverted triangles). 
Figure 4.3: Concentration-response curves for ABCG2 modulation by the new tariquidar 
analogs 1-7. Compound 1 (circles), 2 (squares), 3 (triangles), 4 (inverted triangles), 5 
(diamonds), 6 (stars) and 7 (hexagons). 
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Figure 4.4: Concentration-response curves for ABCG2 modulation by the new tariquidar 
analogs 8-14. Compound 8 (circles), 9 (squares), 10 (triangles), 11 (inverted triangles), 12 
(diamonds), 13 (stars) and 14 (hexagons). 
 
Figure 4.5: Concentration-response curves for ABCG2 modulation by the new tariquidar 
analogs 15-18. Compound 15 (circles), 16 (squares), 17 (triangles), and 18 (inverted 
triangles). 
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Compound ABCG2 
IC50 [nM]a 
ABCG2 
Max. (%)a,b 
ABCB1  
IC50 [nM]c 
ABCC2 
IC50 [nM] 
Fumitremorgin C  > 11 000 100 inactive d inactive e 
Ko143 225 ± 33 82 ± 5 inactive d > 50 000 
Elacridar 250 ± 45 46 ± 2 193 ± 18 inactive e 
Tariquidar 916 ± 197 39 ± 3 223 ± 8 inactive e 
MK571 g n.d. - n.d. > 1000 
LTC4 g n.d. - n.d. < 150 
1  119 ± 22 41 ± 3 (7 µM) 9,450 ± 417 inactive e 
2 60 ± 10 56 ± 6 > 29,000 f > 20,000 
3 183 ± 50 55 ± 3 > 34,000 n.d. 
4 179 ± 35 25 ± 2 inactive d n.d. 
5 552 ± 125 44 ± 2 > 57,000 f > 20,000 
6 632 ± 222 38 ± 3 > 20,000 f > 50,000 
7 1,015 ± 403 47 ± 4 > 14,000 f > 20,000 
8 317 ± 131 63 ± 7 > 6,000 f inactive e 
9 858 ± 210 36 ± 3 > 17,000 inactive e 
10 977 ± 244 43 ± 6 > 15,000 inactive e 
11 1,990 ± 355 52 f > 15,000 f > 50,000 
12 3,414 ± 724 27 f inactive h n.d. 
13 622 ± 152 58 ± 3 95,308 ± 57,364 h n.d. 
14 1,470 ± 420 63 ± 7 103,417 ± 48,140 h n.d. 
15 555 ± 48 56 ± 2 > 50,000 h n.d. 
16 857 ± 122 26 ± 3 > 50,000 h n.d. 
17 297 ± 75 65 ± 2 > 50,000 h n.d. 
18 795 ± 194 39 ± 3 > 50,000 h n.d. 
19 inactive e, f - inactive h n.d. 
20 - 6 ± 3 (50 µM) > 50,000 h n.d. 
21 - 61 ± 2 (50 µM) f, i inactive h n.d. 
22 - 27 ± 1 (50 µM) f, i inactive h n.d. 
23 7,664 ± 1,664 58 ± 6 (100 µM) 10,379 ± 1,018 h  n.d. 
24 inactive e - > 50,000 h n.d. 
25 2,353 ± 251 105 ± 4 (100 µM) > 50,000 h n.d. 
26 1,668 ± 590 64 ± 3 (15 µM) i > 100,000 h n.d. 
Table 4.1: Inhibition of ABCG2, ABCB1 and ABCC2 by compounds 1-26 and reference 
substances. 
a Mean values ± SEM, calculated from 2-3 independent experiments. b Maximal 
inhibitory effects (%) are expressed as inhibition caused by the highest concentration of the 
compound tested (10 µM, if not otherwise stated in parentheses) relative to the inhibitory 
effect caused by 10 µM fumitremorgin C (100% inhibition). c Mean values ± SEM, 
calculated from n=2-5. d No effect up to a concentration of 10 µM; Fumitremorgin C: 0.8 
% inhibition at 10 µM, 22 % inhibition at 100 µM; Ko143: 1.6 % inhibition at 10 µM. e No 
effect up to a concentration of 50 µM; f N= 1. g MK571: 3-(((3-(2-(7-chloroquinoline-2-
yl)ethenyl)phenyl)((3-dimethylamino-3-oxopropyl)thio) methyl) thio) propanoic acid; 
LTC4: leukotriene C4. h Values obtained by the Calcein-AM microtiter assay. i Values 
obtained by Hoechst 33342 assay (see 4.4.2). IC50 values were calculated using SIGMA 
PLOT 9.0, four parameter logistic curve fitting and GraphPad Prism 5.0, respectively. 
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The fumitremorgin C analog Ko143 is a highly potent ABCG2 modulator with a maximal 
inhibitory effect of 82% at a concentration of 10 µM, referred to the control fumitremorgin C. 
The acridone carboxamide derivative elacridar strongly inhibits both transporters without a 
preference, whereas tariquidar was about equipotent with elacridar at ABCB1 but 
approximately 4 times less potent at ABCG2. Transporter inhibition data show that minimal 
structural changes at the benzamide core of tariquidar resulted in a drastic change from 
ABCB1 to ABCG2 modulation. The shift of the quinoline-3-carboxamido substituent from 
position 2 (tariquidar) to position 3 of the benzamide moiety (compound 9) proved to be the 
key to increase the selectivity for ABCG2 over ABCB1: Whereas the moderate inhibition of 
ABCG2 was maintained (9: IC50 858 nM, tariquidar 916 nM), the modulation of ABCB1 
decreased by a factor of >75 (IC50 >17,000 vs. 223 nM for 9 and tariquidar, respectively). 
Furthermore, all compounds with bicyclic hetarylcarboxamides in position 3 and an ester 
group in position 4 (compounds 1-4 and 17) were highly potent and selective ABCG2 
modulators superior to compounds with monocyclic heteroaromatic moieties (5-7). The 2 
most potent inhibitors were obtained with a quinoline-2-carboxamido (compound 2 with an 
IC50 of 60 ± 10 nM) and quinoline-3-carboxamido substituent (compound 1 with an IC50 of 
119 ± 22 nM), respectively. Presumably, the ester group in these compounds contributes 
considerably to the interaction with ABCG2 since structural modifications in position 4 and 5 
of the benzamide core (8-18) resulted in a decrease in potency. For instance, in the series of 
quinoline-2-carboxamides 15-18 the ester 17, an analog of compound 2, lacking the 2 
methoxy groups at the tetrahydroisoquinoline moiety, is only slightly less potent (by a factor 
of 5) than 2 as an ABCG2 modulator, whereas all other structural variations (15, 16 and 18) 
caused a more pronounced decrease in activity. This is specifically true for the amide analogs 
of 2 (16 and 18) in terms of both, potency and maximal response. Additional information on 
structure activity relationships is gained from the data for the substructures and intermediates 
(19-26). With the exception of compound 23, bearing a nitro group in position 3 and the ester 
group in position 4, analogs containing an intact tetrahydroisoquinoline moiety but lacking 
the quinolinecarboxamide substituent (19-23) were almost inactive. In the building blocks 24-
26, both the ester group and the quinoline-2-carboxamide substituent are retained, but the 
characteristic benzamide N-substituent is lacking or truncated. The carboxylic acid 24 turned 
out to be inactive, whereas the benzamides 25, 26, which are not negatively charged at 
physiological pH, showed a moderate inhibition of ABCG2. Thus, ABCG2 modulation 
appears to depend on an intact 3-(acylamino)benzoic amide moiety rather than on the 
substituent at the benzamide N-atom.  
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Only one compound (23) missed selectivity for ABCG2 vs. ABCB1 (ABCB1 transporter 
assays performed by Dr. Christine Müller and Peter Höcherl). The lack of selectivity of 23, a 
moderate inhibitor of ABCG2 and ABCB1, seems to be due to the lack of a “selectivity-
conferring” bulky residue in either position 2 or 3 of the benzamide. Furthermore, a set of 
representative ABCG2 inhibitors (1-11), turned out to be inactive (up to concentrations of 20 
µM or 50 µM, respectively) when studied for modulation of ABCC2 (investigations 
performed by Anne Mahringer), underlining the high transporter selectivity of these 
compounds. 
 
4.4.2  Fluorescence-based microtiter plate assays for the characterization 
of ABCG2 inhibitors  
 
The routinely performed flow cytometric assays for studies on putative transporter inhibitors 
are time-consuming and costly. The throughput is limited to a rather small number of 
compounds. Furthermore, in order to investigate fluorescence-labeled substances as putative 
ABCG2 inhibitors via fluorescence-based assays, the spectral properties of the used 
transporter substrates must not interfere with those of the test compounds. For this reason, the 
2 fluorescent ABCG2 substrates Hoechst 33342 and pheophorbide a were selected to establish 
rapid cell-based assays in the 96-well format. Validation of the elaborated assays was 
arranged on the basis of the published literature [Seigel and Campbell, 2004; Henrich et al., 
2006] with different modifications. The structures of Hoechst 33342 (H33342) and 
pheophorbide a (PhA) are shown in Figure 4.6. 
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4.4.2.1 Validation of Hoechst 33342 and pheophorbide a assay 
 
In order to check the linearity of the dye uptake and the sensitivity of the method, MCF-
7/Topo cells were detached from the culture flask with trypsin/EDTA and resuspended in 
culture medium. Subsequently, cells were seeded into 96-well plates (black with clear, flat 
bottom in case of Hoechst 33342, total clear in case of pheophorbide a) at various densities 
and allowed to attach to the surface for approximately 4 h. Cells were incubated for 90 min 
(Hoechst 33342) or 120 min (pheophorbide a) in the presence of DMSO (vehicle control), 10 
µM of fumitremorgin C (FTC), Hoechst 33342 or pheophorbide a alone and in combination 
with 10 µM of FTC. Afterwards, the supernatant of the Hoechst 33342 preparations was 
removed, cells were washed twice with Ca2+ / Mg2+ containing phosphate buffered saline, and 
the relative fluorescence intensities were measured at the microplate reader. In case of 
incubation with pheophorbide a, the supernatant was removed, cells were fixed with 3 % 
paraformaldehyde solution for 45 min and afterwards washed twice with Ca2+ / Mg2+ 
containing PBS. Subsequently, cells were overlaid with 100 µL of buffer and the fluorescence 
intensities were determined at the microplate reader.  
 
Results of these preliminary experiments are shown in Figure 4.7. 
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Figure 4.6: Chemical structures of the fluorescent ABCG2 substrates Hoechst 33342 (a) 
and pheophorbide a (b).  
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Figure 4.7: Correlation of cell number with fluorescence. Hoechst 33342 experiments (a), 
pheophorbide a studies (b).  
 
Incubation of increasing cell numbers with DMSO (open circles) or fumitremorgin C alone 
(open inverted triangles) had no influence on fluorescence, whereas incubation with 
Hoechst 33342 or pheophorbide a (open squares) yielded a linear uptake of the dyes that 
could be strongly increased when combined with the ABCG2 inhibitor fumitremorgin C 
(open triangles). Furthermore, sensitive measurement of fluorescence intensities was 
feasible on living and fixed cells, and was applicable both, in black microtiter plates with 
clear bottoms and clear polystyrene plates.  
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As a part of the assay validation, incubation times and dye concentrations were systematically 
varied in order to ascertain the optimal conditions for a standard assay protocol. Hoechst 
33342 was investigated at 1 final concentration of 8 µM according to Seigel and Campbell 
[Seigel and Campbell, 2004]. The results of preliminary experiments on pheophorbide a 
assays are shown in Figure 4.8. Whereas 4.8a-4.8c show variations in the incubation time, 
4.8d represents a 2 hour incubation of MCF-7/Topo cells with different concentrations of 
pheophorbide a. 
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Figure 4.8a-4.8c: Incubation of MCF-7/Topo cells with DMSO (open circles), 10 µM of 
fumitremorgin C (open inverted triangles) and 1 µM of pheophorbide a alone (open 
squares) or combined with 10 µM of fumitremorgin C (open triangles) for 2 (a), 4 (b) and 
6 h (c), respectively. Increasing incubation times yielded no improved ratio of unspecific 
vs. transporter-mediated dye uptake.  
 
Figure 4.8d: Cells were incubated with different concentrations of pheophorbide a (black 
symbols 0.5 µM, white symbols 1 µM and gray symbols 5 µM) alone (circles) or in 
combination with 10 µM of fumitremorgin C (triangles). Increasing concentrations of 
pheophorbide a caused higher fluorescence intensities, but showed no improvement on the 
quotient of unspecific and transporter-mediated pheophorbide a uptake. 
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The final standard protocol for the performance of Hoechst 33342 and pheophorbide a assays 
was as follows:  3-5 days after passaging (70-90 % confluency), MCF-7/Topo cells were 
seeded into 96-well plates at a density of 20,000 cells / well (total volume 100 µL). 
Subsequently, the cells were allowed to attach to the surface of the microplates in a water 
saturated atmosphere (95 % air, 5 % carbondioxide) at 37 °C for at least 3 h. In 1.5 mL 
reaction vessels pre-mixtures of the test compounds were prepared by the following 
procedure: 1000 µL of pre-heated (37 °C) EMEM containing L-glutamine, 2.2 g/L of 
NaHCO3 and 0.55 g/L of sodium pyruvate, supplemented with 5 % FCS, were transferred into 
the cups. Subsequently, 10 µL of a 1.6 mM Hoechst 33342 dye solution or 10 µL of a 200 µM 
pheophorbide a solution were added to the samples. Afterwards 10 µL of DMSO, FTC (10 
mM) or the test compounds at increasing concentrations were added to the mixture, 
respectively. The samples were immediately vortexed and transferred into 50 mL polystyrene 
reagent reservoirs™ (BD, Heidelberg, Germany). By means of a multichannel pipette, 100 µL 
of the pre-mixtures were added to each well of the microplate achieving a final concentration 
of 50 µM fumitremorgin C (positive control) and 8 µM of  Hoechst 33342 or 1 µM of 
pheophorbide a, respectively. In order to get homogenous solutions in each well, the 
microplates were slightly shaken horizontally for a couple of times and placed into an 
incubator (37 °C, 5 % carbondioxide) for 120 min. The supernatants were drained, and the 
cells were fixed for 30 min using 100 µL per well of a 3 % paraformaldehyde solution (plates 
were protected from light by covering with aluminium foil). Finally, MCF-7/Topo cells were 
washed twice with 250 µL of calcium and magnesium containing PBS for each well. Thereby, 
the supernatant of the first washing step was immediately removed, whereas the second 
portion of washing buffer allowed in contact with the cells for another 10 min in order to get 
rid of residual dye. Afterwards, cells were overlaid with 100 µL / well of Ca2+ / Mg2+-
containing PBS, and the relative fluorescence intensities were determined on the microplate 
reader.  
 
Instrument settings were as follows:  Measurement mode: fluorescence top; excitation filter 
(Hoechst 33342): 340/35, excitation filter (pheophorbide a): 380/10; emission filter (Hoechst 
33342): 485/20, emission filter (pheophorbide a): 670/25; number of reads: 10; integration 
time: 40 µs; lag time: 0 µs; mirror selection: automatic; plate definition file GRE96ft.pdf or 
GRE96fb.pdf; multiple reads per well (Circle): 4x4; time between move and flash: 50 ms.  
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On each plate, the optimal gain was calculated by determination of the fluorescence intensity 
in the presence of the control substance, fumitremorgin C. After measurements, the microtiter 
plates were stored at 4 °C for the following cell quantification procedures. As a loss of cells 
and unspecific toxic effects of the test compounds during the incubation phase are to be 
considered, the obtained fluorescence values had to be normalized to the cell number of each 
well. Therefore, the microplates were processed with a 0.02 % aqueous crystal violet solution 
(100 µL / well) for 20 min. Excess dye was removed by rinsing the trays with water for 20 
min. Crystal violet bound by the cells was re-dissolved in 70 % ethanol (180 µL / well) while 
shaking the microplates for 2-4 h. Subsequently, the absorbance as a parameter proportional 
to cell mass was measured at the TECAN plate reader. For normalization of the fluorescence 
intensities to the cell mass, detected fluorescence values were divided through the obtained 
absorbance data of each well. All values were corrected to the unspecific uptake of the dye 
(DMSO control value) and the data were referred to the maximal signal caused by 50 µM of 
the reference compound fumitremorgin C. Addition of increasing concentrations of the 
modulators led to sigmoidal concentration response curves. IC50 values were calculated using 
SIGMA PLOT 9.0, Four parameter logistic curve fitting. Errors were expressed as standard 
error of the mean (SEM). The required concentration of 50 µM fumitremorgin C in the final 
assay protocol, as a reference value for maximal transporter inhibition, was determined via the 
performance of the H33342 and pheophorbide a assay according to the standard protocol. 
Corresponding concentration-response curves are shown in Figure 4.9.  
 
 
 
Figure 4.9: Hoechst 33342 (a) and pheophorbide a assay (b) performed with the ABCG2-
modulator fumitremorgin C. Most effective transporter inhibition was observed at a 
concentration of 50 µM in both assays. Calculated IC50 values (H33342 assay: 1,701 nM ± 
287 nM; pheophorbide a assay: 2,607 nM ± 495 nM) are in good agreement with data from 
literature [Henrich et al., 2006] 
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4.4.2.2  ABCG2 inhibition by tariquidar analogs determined in microtiter plate assays 
 
With respect to comparability of data gained from different assays, the known ABCG2 
modulators elacridar, tariquidar and the fumitremorgin C analog Ko143 were characterized in 
the newly developed microtiter assays. Furthermore, selected compounds of the synthesized 
tariquidar analogs were investigated in the Hoechst 33342 and pheophorbide a assay. 
Subsequently, the data were compared to the values obtained flow cytometry (Table 4.2)  
 
 
 
 
 
 
 
 
 
 
Compd. IC50 [nM]a 
Mitox.   
assay 
Max. (%)c 
Mitox.          
assay 
IC50 [nM]b 
H33342     
assay 
Max. (%)c 
H33342         
assay 
IC50 [nM]b 
Ph-a                  
assay 
Max. (%)c 
Ph-a            
assay     
Ko143 225 ± 33 82 ± 5        
(10 µM) 
117 ± 53 103 ± 7        
(25 µM) 
179 ± 12 83 ± 4         
(5 µM) 
Elacridar 250 ± 45 46 ± 2         
(10 µM) 
127 ± 41 63 ± 7         
(5 µM) 
1,136 ± 672 66 ± 8         
(5 µM) 
Tariquidar 916 ± 197 39 ± 3       
(10 µM) 
526 ± 85 69 ± 5        
(15 µM)    
1,756 ± 675 73 ± 13     
(15 µM) 
1 119 ± 22 41 ± 3       
(10 µM) 
104 ± 16 50 ± 1      
(3.5 µM) 
246 ± 58    26 ± 1         
(5 µM) 
2 60 ± 10 56 ± 6       
(10 µM) 
65 ± 8 63 ± 2     
(12.5 µM) 
126 ± 11 54 ± 2     
(12.5 µM) 
3 183 ± 50 55 ± 3       
(10 µM) 
125 ± 28 58 ± 5    
(12.5 µM) 
346 ± 41 49 ± 2         
(5 µM) 
4 179 ± 35 25 ± 2       
(10 µM) 
132 ± 38 50 ±2        
(15 µM) 
1,642 ± 2,380 16 ± 1        
(15 µM) 
5 552 ± 125 44 ± 2       
(10 µM) 
277 ± 57 43 ± 3    
(12.5 µM) 
1,015 ± 317 22 ± 1     
(12.5 µM) 
7 1,015 ± 403 47 ± 4       
(10 µM) 
390 ± 88 53 ± 5     
(12.5 µM) 
2,347 ± 466 37 ± 1     
(12.5 µM) 
8 317 ± 131 63 ± 7       
(10 µM) 
231 ± 103   75 ± 2         
(5 µM) 
722 ± 233 75 ± 4     
(12.5 µM) 
10 977 ± 244 43± 6        
(10 µM) 
359 ± 44 63 ± 3       
(15 µM) 
678 ± 79 53 ± 1        
(15 µM) 
a Mean values ± SEM, calculated from 3 independent experiments. b Mean values ± SEM 
from 2 independent experiments (n=10). c Max. (%) are expressed as inhibition caused by 
the highest concentration of the compound tested (see parentheses), relatively to the 
inhibition caused by FTC. 
Table 4.2: ABCG2 inhibition (IC50 values, maximal effects) by reference compounds and 
selected tariquidar analogs, determined by flow cytometry and the 2 microtiter assays.
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For the reference compound Ko143, results from the flow cytometric and the two microplate  
assays are in agreement with data from literature [Allen et al., 2002]. Furthermore, the new 
tariquidar analogs proved to be highly potent ABCG2 inhibitors in all 3 assays. Among these 
compounds analog 2 was the most potent modulator with a range of IC50 values from 60 – 
126 nM.  
 
All in all, comparing the results from the 3 different experimental protocols, Hoechst 33342 
assays tended to give higher potencies, whereas pheophorbide a assays yielded lowest 
activities for most compounds. For some of the investigated compounds (e.g. compound 4) 
discrepancies between the maximal responses might contribute to these assay-dependent 
differences. As one reason for varying maximal effects a different extent of precipitation of 
the compounds in the course of the experiments should be taken into account. Additionally, 
the tariquidar analogs might act as substrate-like inhibitors. Thus, competition of the 
modulators with the fluorescent compounds could occur and result in different effectiveness 
of dye transport depending on the substrate properties of the individual inhibitor compared to 
that of H33342 or PhA. The concentration-response curves for all compounds investigated in 
the mitoxantrone and the microtiter plate assays are shown in Figures 4.10, 4.11 and 4.12. 
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Figure 4.10: ABCG2 inhibition by the 
reference substances Ko143 (a), elacridar 
(b) and tariquidar (c). Flow cytometric 
mitoxantrone efflux assay: open circles; 
Hoechst 33342 assay: open triangles; 
PhA assay: open squares. 
 
concentration [µM]
0.0001 0.001 0.01 0.1 1 10 100
A
B
C
G
2 
in
hi
bi
tio
n 
[%
]
-20
0
20
40
60
80
100
120
a 
concentration [µM]
0.0001 0.001 0.01 0.1 1 10 100
A
B
C
G
2 
in
hi
bi
tio
n 
[%
]
-20
0
20
40
60
80
100
b 
 Modulation of the efflux pump ABCG2 101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
concentration [µM]
0.0001 0.001 0.01 0.1 1 10 100
A
B
C
G
2 
in
hi
bi
tio
n 
[%
]
-20
0
20
40
60
80
100
a 
concentration [µM]
0.0001 0.001 0.01 0.1 1 10 100
A
B
C
G
2 
in
hi
bi
tio
n 
[%
]
-20
0
20
40
60
80
100
b 
concentration [µM]
0.0001 0.001 0.01 0.1 1 10 100
A
B
C
G
2 
in
hi
bi
tio
n 
[%
]
-20
0
20
40
60
80
100
c 
concentration [µM]
0.0001 0.001 0.01 0.1 1 10 100
A
B
C
G
2 
in
hi
bi
tio
n 
[%
]
-20
0
20
40
60
80
100
d 
Figure 4.11: Concentration-response curves for ABCG2 inhibition by new tariquidar 
analogs. Compound 1 (a), compound 2 (b), compound 3 (c) and compound 4 (d). Flow 
cytometric mitoxantrone efflux assay: open circles; Hoechst 33342 assay: open triangles; 
PhA assay: open squares.  
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Figure 4.12: Concentration-response curves for ABCG2 inhibition caused by new 
tariquidar analogs. Compound 5 (a), compound 7 (b), compound 8 (c) and compound 10 
(d). Flow cytometric mitoxantrone efflux assay: open circles; Hoechst 33342 assay: open 
triangles; PhA assay: open squares.  
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4.4.3 Fluorescent tariquidar analogs  
 
By the performed functional assays, it is impossible to decide, if the tariquidar analogs are 
substrates or inhibitors of the transporter. Since, by analogy to previous projects, fluorescent 
pyridinium compounds turned out to be useful pharmacological tools [Keller, 2008], a small 
series of fluorescence-labeled compounds was produced (27-29 and 30-33) to gain inside into 
the mechanism of action. Therefore, partial structures of the modulator molecules were 
replaced with fluorescent pyridinium moieties by labeling with pyrylium dyes. These 
fluorophores were selected since their spectral properties are regarded suitable for imaging.  
 
The fluorescent substances were investigated for inhibition of ABCG2 in the Hoechst 33342 
assay and applied in confocal laser scanning microscopy. 
  
4.4.3.1 ABCG2 modulation by fluorescence-labeled tariquidar analogs  
 
Since the spectral properties of the labeled compounds led to interference with mitoxantrone 
fluorescence in the flow cytometric assay (data not shown), the substances were investigated 
for ABCG2 modulation in the Hoechst 33342 microtiter plate assay. Additionally, as a 
control, the MCF-7/Topo cells were incubated with high concentrations of the test compounds 
alone. The IC50 values of the fluorescence-labeled tariquidar analogs are summarized in Table 
4.3. 
 
 
 
  
 
 
 
 
 
 
 
 
Compd. IC50 [nM] a          
ABCG2 
Max. (%) b 
27 - 61 ± 4 (50 µM) 
28 4,483 ± 2,517 28 ± 1 (50 µM) 
29 2,086 ± 1,589 37 ± 4 (50 µM) 
30 21,296 ± 9,392 51 ± 2 (90 µM) 
31 - 24 ± 7 (5 µM) c 
32 16,381 ± 13,004 36 ± 1 (50 µM) 
33 - 15 ± 1 (100 µM) 
Table 4.3: IC50 values and maximal inhibition effects (%) for ABCG2 modulation by 
fluorescence-labeled tariquidar analogs, determined in the H33342-assay. 
 
a Mean values ± SEM of 2 independent 
measurements (n=6). b Maximal response 
(%) are expressed as inhibition caused by 
the highest concentration of the 
compound tested (see parentheses), 
relative to the inhibition caused by 50 
µM of FTC. c N=3 from 1 measurement. 
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The introduction of the fluorophores resulted in a drastic decrease in ABCG2 inhibitory 
potency, in particular when the 3-(acylamino)benzoic amide moiety was replaced with a 
pyridinium moiety (30-33), resulting in an additional net charge of the molecule. Introducing 
the fluorophore instead of the tetrahydroisoquinoline residue in the parent compound 2 was 
better tolerated and resulted in the most potent labeled tariquidar analog 29 (IC50: 2,086 ± 
1,589 nM).  
This observation is in good agreement with investigations of partial structures of the non-
labeled inhibitors (19-26). Potent ABCG2 inhibition seems to depend on an intact 3-
(acylamino)benzoic amide moiety rather than on the substituent at the benzamide N-atom. 
With respect to transporter selectivity, the compounds were additionally investigated for 
ABCB1 modulation in the calcein-AM microtiter assay by Peter Höcherl. IC50 values could 
not be calculated (data not shown) due to low activities of these compounds. The most 
pronounced ABCB1 inhibition was achieved with compound 27 (14.7 % maximal response at 
a concentration of 100 µM). Obviously, for this class of compounds, ABCG2 modulation is 
more sensitive to structural modifications than ABCB1 inhibition. 
 
4.4.3.2 Confocal-laser scanning microscopy (CLSM) studies  
ABCG2-overexpressing MCF-7/Topo cells were incubated with different concentrations of 
the labeled compounds for various times. Subsequently, the living cells were imaged on the 
CLSM. 
Instrument settings were as follows: Excitation wavelength: 543 nm (laser intensity 10%), 
emission filter: 650 LP, magnification 400-fold (Apochromat 40 x / NA 1.2W). CLSM 
images for the incubation of MCF-7/Topo cells with the most potent compounds 28 and 29 
and the least active substance 33 are shown in Figures 4.13, 4.14 and 4.15. Due to the weak 
potency of the compounds, concentrations as high as 10 µM were used for each substance.  
All examined compounds entered the cells and accumulated in the cytoplasm. The compounds 
were not detected in the nuclei. Due to the positive charge of the molecules, these 
observations were unexpected and suggest an uptake by carrier mediated processes. A 
selective enrichment within the cell membranes, the localization of ABCG2 transporters, was 
not observed.  
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Figure 4.13: MCF-7/Topo cells, 177th passage, 5 min after incubation with compound 28 
at a concentration of 10 µM. a) Green pseudo-color image, b) rainbow mode with relative 
fluorescence intensities. 
Figure 4.14: MCF-7/Topo cells, 177th passage, 11 min after incubation with compound 29 
at a concentration of 10 µM. a) Green pseudo-color image, b) rainbow mode with relative 
fluorescence intensities. 
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As a control, MCF-7/Topo cells were incubated with a benzylated Py-dye (lab-code CP 157), 
which is considered neither a substrate nor an inhibitor of ABCG2, in order to investigate the 
contribution of the dye moiety. This experiment revealed that the dye component alone was 
also rapidly taken up into the cytoplasm (data not shown). Similar to the experiments with the 
labeled tariquidar analogs, neither a specific enrichment within the cell membrane nor an 
entry into the nuclei of the cells was observed. Presumably, the high concentrations of 
compounds used in the CLSM studies due to the weak potency of labeled tariquidar analogs 
against ABCG2 as well as the structural properties of the pyrylium dyes are responsible for 
the cellular uptake of the substances and the failure of detection of the transporter. Thus it 
remains unclear if the compounds are weak substrates or inhibitors of ABCG2 
 
 
 
 
Figure 4.15: MCF-7/Topo cells, 153th passage, 30 min after incubation with compound 33 
at a concentration of 10 µM. a) Green pseudo-color image, b) rainbow mode with relative 
fluorescence intensities. 
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4.4.5  Effect of estradiol on the chemosensitivity of MCF-7/Topo cells 
against the ABCG2 substrate topotecan 
 
Estrogens are reported to be involved in the regulation of ABCG2 expression [Imai et al., 
2005; Zhang et al., 2006; Robey et al., 2009], although it is controversially discussed if the 
regulation occurs at the transcriptional or post-transcriptional level. According to Imai et al. 
[Imai et al., 2005], estradiol enhanced the cellular uptake of ABCG2 substrates resulting in a 
potentiation of cytotoxicity.  
For this reason, non-induced MCF-7 wildtype and topotecan-resistant MCF-7/Topo cells were 
treated with estradiol and investigated with respect to their chemosensitivity against the 
cytostatic and ABCG2 substrate topotecan. The chemosensitivity assays were performed as 
described previously [Bernhardt et al., 1992a] with slight modifications. As a control, induced 
and non-induced MCF-7 cells were seeded into 96-well plates and allowed to grow for 
approximately 72 h. Subsequently, the supernatant was removed and exchanged by fresh 
medium containing topotecan at various concentrations. To investigate the effect of estradiol 
on ABCG2-mediated drug-resistance, the cells were either pre-incubated with 1 or 10 nM of 
estradiol during the 72 h period, or permanently co-incubated with the estrogen during the 
performance of the cytotoxicity assays. The results of these chemosensitivity assays are 
shown in Figures 4.16, 4.17 and 4.18. 
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Figure 4.16: Effect of topotecan on proliferating, non-induced MCF-7 wildtype cells. a) 
Un-treated cells, b) pre-treated with 1 nM estradiol and c) pre-treated with 10 nM estradiol. 
Growth control (vehicle): filled stars, 10 nM topotecan (open circles), 50 nM topotecan 
(open triangles), 100 nM topotecan (open inverted triangles), 500 nM topotecan (open 
diamonds) and vinblastin 10 nM (filled diamonds, positive control). 
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Regardless of the concentration of the hormon, the chemosensitivity against topotecan 
remained unchanged comparing non-treated and estradiol supplemented MCF-7 wildtype 
cells (Figure 4.16). As expected, there was no resistance against topotecan due to the low 
expression of the ABCG2 efflux transporter in the MCF-7 cells. Already at the lowest 
investigated concentration of 10 nM, topotecan mediated pronounced cytostatic effects on 
both, the controls as well as on estradiol-treated cells.  
 
 
 
 
 
 
 
 
 
 
 
time of incubation [h]
0 50 100 150
-60
-40
-20
0
20
40
60
80
100
120
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
   
   
   
   
  T
-C
0/C
0 [
%
]  
   
   
   
   
 T
/C
co
rr.
 [%
]
ab
so
rb
an
ce
 A
57
8
a 
0 50 100 150
-60
-40
-20
0
20
40
60
80
100
120
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
ab
so
rb
an
ce
 A
57
8
time of incubation [h]
   
   
   
   
   
   
   
T-
C
0/C
0 [
%
]  
   
   
   
   
 T
/C
co
rr
. [
%
]
b 
0 50 100 150
-60
-40
-20
0
20
40
60
80
100
120
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
2.2
ab
so
rb
an
ce
 A
57
8
time of incubation [h]
   
   
   
   
   
   
   
T-
C
0/C
0 [
%
]  
   
   
   
   
 T
/C
co
rr
. [
%
]
c 
Figure 4.17: Effect of topotecan on 
proliferating, ABCG2-overexpressing MCF-
7/Topo cells a) Un-treated cells, b) pre-
treated with 1 nM estradiol and c) pre-
treated with 10 nM estradiol. Growth 
control (vehicle): filled stars, 100 nM 
topotecan (open circles), 500 nM topotecan 
(open triangles), 1 µM topotecan (open 
inverted triangles), 2 µM topotecan (open 
diamonds) and vinblastin 10 nM (filled 
diamonds, positive control). 
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The overexpression of ABCG2 transporters in MCF-7/Topo cells caused resistance to 
topotecan up to concentrations as high as 500 nM in estradiol pre-treated cells as well as in 
the un-treated cells (Figure 4.17). Discrepancies in the chemosensitivity were only observed 
at the highest tested concentration of 2 µM topotecan. In this case, pre-treatment with 1 nM of 
estradiol caused a slightly increased sensitivity against topotecan, but this effect could not be 
enhanced by pre-incubation with 10 nM of estradiol. 
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c Figure 4.18: Effect of topotecan on 
proliferating, ABCG2-overexpressing MCF-
7/Topo cells. a) Un-treated cells, b) co-
incubated with 1 nM estradiol and c) co-
incubated with 10 nM estradiol. Growth 
control (vehicle): filled stars, 100 nM 
topotecan (open circle), 500 nM topotecan 
(open triangles), 1 µM topotecan (open 
inverted triangle), 2 µM topotecan (open 
diamonds) and estradiol 1 nM (b) (filled 
diamonds) or 10 nM (c) (filled diamonds, 
control). 
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The toxicity of topotecan remained unaffected up to concentrations of 1 µM by co-incubation 
of MCF-7/Topo cells with estradiol (Figure 4.18). At a concentration of 2 µM topotecan, the 
co-incubation with estradiol resulted in slightly increased cytotoxicity. This effect was more 
pronounced in the presence of 10 nM of estradiol, however, at such high concentrations a 
cytotoxic effect of estradiol on MCF-7 breast cancer cell has to be taken into account.    
 
4.4.6  Detection of ABCG2 expression in cancer cell lines by flow cytometry 
 
In search for ABCG2-expressing cells other than MCF-7/Topo, 2 cancer cell lines were 
screened by means of a modified flow cytometric mitoxantrone efflux assay. As a control, the 
cells were incubated with mitoxantrone and the vehicle DMSO alone, whereas functional 
activity of ABCG2 was identified by incubation of the cells with mitoxantrone in combination 
with 10 µM of fumitremorgin C (FTC). The samples were treated as described for the 
reference compounds in the mitoxantrone efflux assay. The following cell lines were 
investigated:  
A subclone of MCF-7 wildtype cells resulting from treatment with the ABCG2 substrate 
estron sulfate [Imai et al., 2003], the human epithelial colorectal adenocarcinoma CaCo2 and 
MCF-7 as well as MCF-7/Topo cells as a control. Estron sulfate treatment was performed 
with the idea of an up-regulation of ABCG2 by supplementation of the wildtype cells with a 
known transporter substrate.  
Efflux pump activity was estimated using the following equation: 
 
]DMSO[GeoMean
]FTC[GeoMeanactivity2ABCG                                          
                                               
, where GeoMean [FTC] represents the geometric mean values of cells co-incubated with 
fumitremorgin C, whereas the abbreviation GeoMean [DMSO] defines the geometric means 
of the vehicle controls.  
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The estron sulfate supplemented MCF-7 cells as well as the Caco2 cells showed no enhanced 
functional activity of the ABCG2 transporter compared to the non-induced MCF-7 wildtype 
cells. Co-incubation with 10 µM of fumitremorgin C revealed an increase of fluorescence 
intensity by a factor of approximately 1.5 in all 3 cell types. Contrarily, in the ABCG2-
overexpressing control cell line MCF-7/Topo, the modulator yielded a nearly 14-fold elevated 
geometric mean value compared to the DMSO controls (Figure 4.19) indicating the effective 
blocking of overexpressed efflux pumps in these cells. 
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Figure 4.19: Results of the flow cytometric investigation for expression of functional 
ABCG2. The non-induced MCF-7 wildtype cells as well as the topotecan-treated induced 
MCF-7/Topo cells served as control for the estrone sulfate supplemented MCF-7 cells and 
the human epithelial colorectal adenocarcinoma CaCo2. Quotients are calculated by 8-25 
measured values. Errors are expressed as standard error of the mean (SEM). 
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4.4.7  Attempts to establish a subcutaneous ABCG2 overexpressing tumor 
model  
 
To proof the therapeutic benefit of a combination of an ABCG2 modulator with a cytostatic, 
which is a substrate of this transporter, in vivo, the reversal of ABCG2 mediated 
chemoresistance was investigated in vitro. Furthermore, it is essential that the ABCG2 
transporter status is retained in vivo over a long period of time. 
  
4.4.7.1 In vitro assays to determine stable ABCG2 transporter expression  
For investigations on a stable transporter expression, MCF-7/Topo cells were subdivided into 
2 groups. Whereas the first one was supplemented with topotecan as described (see materials 
and methods), the second group was cultured in the absence of the cytostatic. The cells were 
investigated for expression of functional ABCG2 in the flow cytometric mitoxantrone efflux 
assay over several passages after co-incubation with either DMSO (vehicle control) or 10 µM 
of fumitremorgin C, respectively. As a criterion for stable transporter expression and protein 
functionality, the obtained fluorescence intensities were analyzed according to the following 
equation: 
 
  100
 7/Topo)(MCFGeoMean
7/Topo)-(MCF GeoMean[%]inhibition 2ABCG
suppl. corr.
suppl.-noncorr.                 
                             
, with GeoMeancorr. (MCF-7/Topo)non-suppl. representing the vehicle-corrected geometric means 
of fluorescence intensities for the non-topotecan supplemented MCF-7/Topo cells. The 
corrected GeoMean values obtained for the cells cultured in the presence of topotecan are 
abbreviated as GeoMeancorr. (MCF-7/Topo)suppl.. The results of the flow cytometric assays are 
shown in Figure 4.20. 
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Flow cytometry confirmed a stable expression of the functionally active efflux pump ABCG2 
even in the absence of topotecan. The investigations were arranged over 9 passages 
corresponding to a period of several weeks in which the overexpression of ABCG2 efflux 
pumps was preserved. This is an important result with respect to in vivo studies, as the lack of 
selection pressure due to leaving out topotecan treatment during tumor growth, should not 
affect the transporter levels.  
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Figure 4.20: ABCG2 inhibition [%] by 10 µM of fumitremorgin C of MCF-7/Topo cells 
cultured in the presence of topotecan. Transporter modulation is expressed as the ratio of 
ABCG2 inhibition in non-topotecan supplemented and topotecan-treated MCF-7/Topo 
cells. The cells were analyzed over a period of 9 in vitro passages. 
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4.4.7.2  Overcoming ABCG2-mediated drug-resistance in vitro by co-administration of 
efflux pump inhibitors  
 
The crystal violet chemosensitivity assays were performed as previously described [Bernhardt 
et al., 1992a]. To examine the potential of ABCG2 modulators to reverse the efflux pump-
mediated drug resistance, the assays were arranged as follows:  
2-3 days after seeding, MCF-7/Topo cells were either treated with 100 nM of topotecan alone 
or combined with various concentrations of the known ABCG2 modulator Ko143 (Figure 
4.21). In an additional experiment the cells were incubated with the ABCG2 substrate 
mitoxantrone alone or combined with the new tariquidar analog 2 (Figure 4.22). Moreover, as 
a control, the effect of the transporter modulators alone against the cells was determined in a 
concentration-dependent manner.  
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Figure 4.21: Effect of Ko143 alone (a) and in combination with 100 nM topotecan (b) on 
proliferating MCF-7/Topo cells (passage 138); vehicle (open stars), 100 nM topotecan 
(open circles) and Ko143 at different concentrations: 10 nM (filled squares), 50 nM (filled 
triangles), 100 nM (filled inverted triangles) and 500 nM (filled diamonds). 
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Incubation of MCF-7/Topo breast cancer cells with the ABCG2 inhibitor Ko143 alone caused 
no toxic effects up to concentrations of 500 nM (Figure 4.21a). The combination of 100 nM 
Ko143 with topotecan at a concentration of 100 nM, which was non-toxic in the absence of a 
ABCG2 modulator, resulted in total reversal of the ABCG2-mediated drug-resistance, i.e. a 
remarkable cytostatic effect (Figure 4.21b).  
There was no cytotoxic effect detectable when MCF-7/Topo cells were incubated with the 
new tariquidar analog 2 alone up to a concentration of 500 nM (Figure 4.22a). However, 
compound 2 at a concentration of 10 nM combined with 100 nM mitoxantrone, a per se non-
toxic concentration of the cytostatic in the ABCG2-overexpressing cells, yielded a strong 
antiproliferative effect (Figure 4.22b).  
These in vitro investigations demonstrate that inhibition of the ABCG2 efflux pump is 
effective to reverse the transporter-mediated drug resistance against the cytostatics topotecan 
and mitoxantrone. 
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Figure 4.22: Effect of compound 2 alone (a) and in combination with 100 nM 
mitoxantrone (b) on proliferating MCF-7/Topo cells (passage 193); vehicle (open stars), 
100 nM mitoxantrone (open circles) and compound 2 at different concentrations: 10 nM 
(filled squares), 50 nM (filled triangles), 100 nM (filled inverted triangles) and 500 nM 
(filled diamonds). 
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4.4.7.3 Subcutaneous injection of MCF-7/Topo cells into nude mice 
Stimulated by the promising in vitro results, MCF-7/Topo cells were subcutaneously injected 
into nude mice to establish a subcutaneous tumor model. For this purpose, the human breast 
cancer cells were injected into both, male and female nude mice in order to check sex-
dependent variations in tumor growth. Furthermore, female nude mice were subdivided into 2 
groups:  
One group of animals was left without additional hormone supplementation; in the other 
group estradiol depots were implanted to exclude growth retardations of MCF-7/Topo tumors 
due to estradiol deficiency.  
Figure 4.23 shows the implantation procedure of estradiol depots according to Bernhardt et 
al. [Bernhardt et al., 1992b]. 
 
 
 
 
 
 
 
 
 
 
A total of 22 mice were included in this investigation on the in vivo growth of MCF-7/Topo 
cells. Over a period of more than 3 months, in none group, the subcutaneously injected breast 
cancer cells resulted in tumor growth. Therefore, these attempts to establish a subcutaneous 
model of ABCG2-overexpressing MCF-7/Topo tumors, failed.          
 
Figure 4.23: Implantation procedure of estradiol depots. a) Opening of skin on 
anesthetized female nude mice, b) subcutaneous placement of estradiol depots and c) mice 
with subcutaneous implanted estradiol depots after skin closure by brackets. Tumor cell 
suspensions were subcutaneously injected 7 days after estradiol depot implantation. 
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4.4.8  Stability of selected tariquidar-like ABCG2 modulators 
 
With regard to future in vivo studies, selected candidates of the new ABCG2 modulators were 
subjected to preliminary biopharmaceutical investigations with a focus on stability. For this 
purpose, the compounds were incubated with different media, including PBS, EMEM 
supplemented with 5 % FCS and murine plasma, and the samples were analyzed by HPLC. 
As a degradation of the compounds was detected in murine plasma, HPLC-MS methods were 
established in order to elucidate the structures of the cleavage products.  
Basically, the investigations on plasma stability were performed to substantiate speculations 
about the lack of drug-like properties of ABCG2 inhibitors such as the most potent 
compounds 1 and 2, which contain ester groups prone to enzymatic hydrolysis. The 
corresponding carboxylic acid of 1, compound 12, turned out about 80 times less potent that 
the parent compound in the mitoxantrone assay. However, HPLC-MS analysis revealed an 
enzymatic cleavage pathway as depicted in Figure 4.24. Surprisingly, the ester groups 
remained intact, whereas the benzoic amide was rapidly cleaved.  
To discriminate between hydrolytic instability and enzymatic cleavage, control experiments 
were performed in phosphate buffered saline and deproteinated plasma. In both cases the 
compounds remained stable. Furthermore, there was no indication of degradation when the 
compounds were incubated in cell culture medium containing 5 % FCS (corresponding to the 
conditions of ABCG2 inhibition assays). The results indicate enzymatic cleavage in plasma.  
In order to confirm the HPLC-MS data, all cleavage products (compounds 19, 24 and 34) 
were synthesized for comparison and analyzed by the chromatography method. The mass 
spectra and retention times of the reference compounds were in agreement with the data from 
the investigated plasma samples (Figure 4.25). Whereas compound 1 was almost totally 
degraded after 30 min, the structural isomer 2 turned out to be slightly more stable over the 
same period of incubation: approximately 50 % of the parent compound remained unchanged. 
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Figure 4.24: Enzymatic cleavage of the ABCG2 modulators 1 and 2 in murine plasma. 
Whereas the methyl ester in compounds 1 and 2 remained intact, the benzamide groups in 
both compounds were enzymatically cleaved to give the aniline substructure 19 and the 
carboxylic acids 24 and 34. 
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Figure 4.25: HPLC-MS analysis of compounds 1 and 2 after incubation in mouse plasma 
and reference mixtures. a) Detection of tariquidar analog 1 and the cleavage products 
compound 19 and 34 by HPLC-MS analysis in the plasma of BL6 mice, 15 min after 
incubation at 37 °C. b) HPCL-MS analysis of BL6 mouse plasma incubated for 25 min at 
37 °C with compound 2. The cleavage products 19 and 24 were detected in the samples. c) 
Simultaneous detection of reference compounds 1, 2 and the cleavage products compound 
19 and 24 by HPLC-MS. d) Since up to the time of method development compound 34 had 
not been synthesized yet, the substance was determined later on separately by the same 
HPCL-MS method. Compound 34 elutes at a retention time (RT) of 8.55 min which is in 
agreement with the RT of the degradation product detected in plasma. 
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In order to investigate the inhibitory potency of the cleavage products against the efflux 
transporter ABCG2, the compounds were studied in the flow cytometric mitoxantrone efflux 
assay. Neither compound 19 nor the carboxylic acids 24 and 34 inhibited the ABCG2 
transporter up to the highest tested concentration of 50 µM. These results confirm the 
assumption that the potent and selective inhibition of the efflux pump ABCG2 can only be 
attributed to the intact parent compounds 1 and 2, and not to the cleavage products 19, 24 or 
34. 
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4.5  Summary and conclusions 
In the present study we investigated a series of tariquidar analogs that turned out to be among 
the most potent and selective ABCG2 inhibitors known so far [Kühnle et al., 2009]. 
Compared to tariquidar, in these compounds the hetarylcarboxamid substituent at the benzoic 
amide core was shifted from the ortho to the meta position. The ABCG2 modulators were 
studied in a routinely performed flow cytometric mitoxantrone assay and in 2 newly 
developed microtiter plate assays using the dyes Hoechst 33342 and pheophorbide a as 
fluorescent substrates. Thereby, derivative 2 showed the highest potency against ABCG2 with 
an IC50 value of 60, 65 and 126 nM respectively, determined by means of 3 different assays. 
Investigations on the highly potent ABCG2 inhibitor Ko143 [Allen et al., 2002] yielded IC50 
values of 117, 179 and 225 nM, respectively. Thus, compound 2 was at least equipotent with 
the reference substance. The studies on tariquidar analogs, their corresponding partial 
structures and intermediates showed that the most potent inhibitors were obtained with 
bicyclic hetarylcarboxamides in position 3 and an ester group in position 4 at the benzamide 
core (substances 1-4 and 17). Moreover, inhibition data obtained for the partial structures 19-
23 and 24-26, suggest that ABCG2 inhibition depends rather on an intact 3-
(acylamino)benzoic amide moiety than on the substituent at the benzamide N-atom.  
 
With respect to fluorescence-based cellular investigations including confocal-laser scanning 
microscopy (CLSM), a recently synthesized small series of fluorescence-labeled compounds 
(27-33) was investigated for ABCG2 and ABCB1 inhibition. In these substances, 
substructures of the tariquidar-like ABCG2 inhibitors were replaced with fluorophores 
chemically prepared from pyrylium dyes. Unfortunately, all these substances showed a very 
strong decrease in ABCG2 inhibitory potency: the most effective modulator, compound 29 
achieved only an IC50 value of 2,086 nM corresponding to more than 30-fold lower potency 
compared to ABCG2 inhibitor 2 (IC50 = 65 nM). Surprisingly, CLSM studies revealed an 
accumulation of the labeled positively charged compounds in the cytoplasm of the cells as 
also observed for the dye component alone. If the compounds enter the cells by diffusion as 
ion pairs or by carrier-mediated processes remain a matter of speculation. 
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As estrogens are reported to be involved in the regulation of ABCG2 expression [Imai et al., 
2005; Zhang et al., 2006], non-induced MCF-7 wildtype as well as the topotecan-induced 
MCF-7/Topo cells were investigated in cytotoxicity assays, comparing the influence of pre- or 
co-incubation with estradiol on the chemosensitivity of the cells against topotecan. An 
estradiol-induced reduction in ABCG2 activity was expected [Imai et al., 2005]. However, the 
topotecan-resistance of MCF-7/Topo cells was not reversed or significantly decreased by 
treatment with estradiol at relevant concentrations 
In view of future in vivo studies, to evaluate the combination of cytostatics with ABCG2 
modulators for reversing multidrug resistance, preliminary investigations in vitro and in vivo 
were performed in order to check the suitability of MCF-7/Topo cells to establish a tumor 
model in nude mice. In vitro, the ABCG2 expression remained stable over the duration of 
these experiments (9 passages) although topotecan as an ABCG2-inducing cytostatic was 
omitted. Furthermore, the ABCG2-mediated mitoxantrone resistance was reversed in vitro by 
co-administration of the efflux pump inhibitor 2. Hence, the cells were subcutaneously 
injected into nude mice for the characterization of tumor growth in vivo. Unfortunately, in 
none of the nude mice solid tumor tissues were generated. Thus, due to the lack of 
tumorigenicity the ABCG2-overexpressing MCF-7/Topo cells are not suitable to establish a 
xenograft model.  
Since the most potent ABCG2 inhibitors were considered to be not drug-like due to methyl 
ester groups prone to enzymatic cleavage, biopharmaceutical investigations on the stability of 
compounds 1 and 2 in mouse plasma compared to buffer and cell culture medium were 
performed. Surprisingly, incubation with plasma left the ester groups in 1 and 2 intact but 
resulted in the cleavage of the benzoic amide core to give the amine 19 and the corresponding 
carboxylic acids 24 and 34. Thus, the key structural modification to obtain highly potent and 
selective ABCG2 modulators, i.e. the shift of the hetarylcarboxamido substituent from the 
ortho- to the meta-position of the benzamide core, was also decisive for instability against 
hydrolytic enzymes in plasma. These results suggest the major focus of subsequent projects 
on tariquidar-like ABCG2 modulators to be directed to the design and synthesis of more 
stable, drug-like compounds, for instance, by introduction of bulky groups preventing 
enzymatic attack at the benzamide moiety.  
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5.1  Introduction 
 
5.1.1  Bioluminescence Imaging 
 
5.1.1.1 Bioluminescence 
 
Bioluminescence is a special form of chemoluminescence, i. e. the enzymatic conversion of 
chemical energy into light [Day et al., 2004]. Such reactions frequently occur in the marine 
world from bacteria over dinoflagellates, coelenterates, crustacean to teleosts [Hastings, 
1983]. However, luminous organisms also inhabit the land and are predominantly found 
within the order of  coleopta in the family of the Lamprydiae or closely related beetle families 
[Day et al., 2004]. The most prominent members of these families represent fireflies and 
glow-worms. During the last decades, many different roles of bioluminescence in the various 
organisms have been discussed such as prey attraction [Sivinski, 1998], communication on 
sexual level [Carlson and Copeland, 1985], evasion of predators (aposematism) [Underwood 
et al., 1997; Cock and Matthysen, 1999; De Cock and Matthysen, 2003] or even stimulation 
of DNA-repair processes and detoxification of oxygen radicals [Wegrzyn et al., 2004].  
 
The emission of bioluminescence requires enzymes (luciferases), which act as oxygenases. 
Such luciferases oxidize substrates, namely luciferins or coelenterazines, by utilizing 
molecular oxygen [Hastings, 1996]. Hereby, product molecules are produced in electronically 
excited states, resulting in the emission of light upon relaxation. The terms luciferases and 
luciferins are generic names for different enzymes and substrates. Since there are several 
isozymes and substrates, the emitted light shows different spectral properties [Hastings, 
1996]. For example, fireflies, which are endowed with the wildtype luciferase emit yellow 
and green light of wavelengths between 540-580 nm [Tagami et al., 2009], whereas click 
beetles or railroad worms are known to send out green to red light [Wood, 1995; Hastings, 
1996]. One of the best studied bioluminescent reactions is the enzymatic conversion of 
luciferin by luciferase in the North American firefly Photinus pyralis. In the presence of ATP, 
Mg2+ and oxygen, D-luciferin is decarboxylized over multiple steps under formation of the 
final product oxyluciferin. This reaction is associated with the emission of light, which is 
characterized by a broad spectrum (530-640 nm) and a maximum at 562 nm. An overview of 
the reaction mechanism is shown in Figure 5.1.  
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In the first steps of the reaction, the luciferase-bound luciferin-adenylate is generated, and 
oxygen is added to the complex. Finally, the elimination of carbon dioxide yields 
oxyluciferin, which spontaneously decays to the singlet electronically excited singulet state 
[Day et al., 2004].  
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5.1.1.2 Bioluminescence imaging in preclinical oncological research 
 
Whereas such bioluminescent reactions were originally used for the quantification of 
adenosintriphosphate (ATP) in bioanalytical assay systems, their application in preclinical 
oncological research has become more and more important over the recent years. Thereby, the 
genetic engineering of tumors cells by introduction of luciferase reporter genes proved to be a 
powerful technique for the highly sensitive and non-invasive detection of malignancies in 
vivo.  
Figure 5.1: Reaction of the firefly luciferase with D-luciferin:  (a) generation of luciferase-
bound luciferin adenlylate, (b) abstraction of a proton, (c) addition of oxygen, (d) 
formation of a cyclic peroxide and (e) decarboxylation to the final product oxyluciferin, 
which emits light upon relaxation from the electronically excited singlet level to the 
ground state (f); modified from [Day et al., 2004]. 
a 
b 
c d 
e 
f 
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Several orthotopic tumor models detectable by BLI have been described in literature, 
including breast cancer bone metastasis [Murray et al., 2003], intraperitoneal neoplasms 
[Buchhorn et al., 2007] and bladder carcinoma [Pfost et al., 2009]. 
 
A very attractive target for bioluminescence in vivo imaging in oncology is the investigation 
of orthotopic tumors in the brain. The successful application of BLI in monitoring such brain 
tumors was demonstrated in some reports, indicating the access of D-luciferin to the brain 
across the blood-brain barrier. For example, in 2002, Vooijs et al. [Vooijs et al., 2002] 
described a model, which allowed the non-invasive monitoring of tumor progression in 
pituitary glands of mice by bioluminescence in vivo imaging (BLI). Furthermore, the 
efficiency of doxorubicin in the chemotherapy of the aforementioned tumors was also 
monitored by means of BLI. Moriyama et al. performed BLI studies on orthotopic 
glioblastoma in rats [Moriyama et al., 2004]. For this purpose, 9L rat gliosarcoma cells were 
transfected with the gene encoding luciferase, before implantation into the brain of female 
Fischer rats. After intraperitoneal injection of D-luciferin, the tumor development was 
monitored by BLI, and the efficacy of photodynamic therapy using protoporphyrin IX was 
visualized.  
 
 
 
Thus, there is a broad and permanently growing field of applications of bioluminescence for 
in vivo imaging. Due to the high sensitivity and specificity of signals, BLI is a very useful 
technique in preclinical oncological research.  
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5.1.2  Fluorescence Imaging 
 
5.1.2.1 Fluorescent proteins 
 
Over the recent decades, a great number of various fluorescent proteins has been identified, 
which turned out to be powerful tools for the visualization of dynamic processes in living 
animals. Predominantly in preclinical oncologic research, the use of such fluorescent proteins 
has become indispensable for monitoring cancer dynamics, including inter alia, tumor growth, 
angiogenesis and metastasis [Hoffman, 2009].  
 
The green fluorescent protein (GFP) of the jellyfish Aequorea victoria, a 238 amino acid 
containing polypeptide, which serves as an energy-transfer acceptor, was the first identified 
fluorescent protein [Prasher et al., 1992]. In the course of research in this field several gain-
of-function mutants of wildtype GFP with enhanced brightness and optimized mammalian 
expression were generated [Hoffman, 2009]. Cormack et al. [Cormack et al., 1996] 
constructed a library of GFP mutants in E. coli strains, showing a 100-fold increase in the 
fluorescence intensity detected by flow cytometry. The altered fluorescence properties 
resulted from strongly shifted excitation maxima and improved protein folding of the mutants 
in prokaryotes compared to wt GFP. Intensified GFP fluorescence was also obtained by 
DNA-shuffling methods, which yielded, for instance, mutants with 45-fold higher total cell-
associated  fluorescence intensities than that of the natural protein [Crameri et al., 1996], even 
without changes in the excitation and emission spectrum. Improved GFP expression in 
mammalian cells, mainly in cell types from human origin, was accomplished by multiple base 
substitutions in the coding-sequence leading to efficient codon usage [Zolotukhin et al., 
1996].  
 
In 1999 and 2000, the discoveries of red fluorescent proteins in several reef corals were 
reported [Matz et al., 1999; Fradkov et al., 2000; Gross et al., 2000]. DsRed, a red-fluorescent 
protein from Discosoma sp., is characterized by massive brightness, pH-stability as well as 
resistance against denaturants and photobleaching [Campbell et al., 2002]. Furthermore, by 
mutations an enhanced version of the red fluorescent protein, referred as DsRed2, was 
generated, which is more soluble and faster in fluorophor maturation than the parent protein. 
In search for better red emitting labels, Shaner et al. described a series of new proteins, which 
were also obtained by mutations of DsRed [Shaner et al., 2004].  
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Although emission maxima at wavelengths as long as 649 nm are favorable with respect to 
bioanalytical applications,  these proteins are compromised by low quantum yields, resulting 
in reduced brightness of the fluorescence [Hoffman, 2009].  
 
Quite recently, the isolation of a red fluorescent protein from the sea anemone Entacmaea 
quadricolor allowed the generation of a new bright protein, named Katushka, emitting far-red 
light [Shcherbo et al., 2007]. For this purpose, the natural protein was modified with respect 
to increased velocity of fluorophore maturation, pH-stability and brightness. These 
modifications yielded the red fluorescent protein TurboRFP [Merzlyak et al., 2007], which 
served as a starting point for the generation of Katushka by performing multiple cycles of 
random mutagenesis. Katushka was proven to possess excellent properties for whole body 
imaging with an excitation peak at 588 nm and an emission maximum at 635 nm. 
Furthermore, rapid fluorophor maturation (20 min), an extinction coefficient of 65,000 M-1 
cm-1 and a quantum yield of 0.34 render Katushka the most promising red fluorescent protein 
for fluorescence imaging applications up to now. However, the labeling of cellular proteins by 
Katushka is compromised due to its dimeric structure. For this reason, a monomeric version 
of TurboRFP (called TagRFP) was generated [Merzlyak et al., 2007]. In addition, 
modifications of TagRFP yielded the monomeric version of Katushka, termed mKate 
[Shcherbo et al., 2007].  
 
5.1.2.2 Fluorescent proteins in preclinical oncology 
 
In preclinical oncology, the great number of available fluorescent proteins with different 
properties enables the monitoring of multiple processes during cancer development. Already 
in 1997, Chishima et al. [Chishima et al., 1997] described the visualization of cancer invasion 
and micrometastases in live tissue by using CHO-cells, genetically engineered to stably 
express the green fluorescent protein [Chishima et al., 1997]. The transfectants were 
subcutaneously injected into nude mice, and small pieces of s.c. growing tumors were used 
for the orthotopic implantation into the ovary of nude mice. After 4 weeks, the animals were 
killed, and micrometastases were microscopically detected in different organs due to GFP 
fluorescence. As an advancement, noninvasive imaging of GFP-expressing B16F0 mouse 
melanoma tumors and AC3488 human colon cancer as well as metastases in live mice was 
performed by Yang et al. [Yang et al., 2000].  
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With respect to noninvasive whole-body imaging, the spectral properties of fluorescent 
proteins are the key. Due to the fact that longer excitation wavelengths cause fewer damages 
in cellular proteins as well as in DNA, and that the absorbance of emitted light by tissues, 
containing biomolecules such as hemoglobin, is also less pronounced at longer wavelengths, 
whole-body imaging can be improved by using red fluorescent proteins [Hoffman, 2009]. The 
successful application of DsRed2 for in vivo imaging has been demonstrated in several cases 
[Katz et al., 2004; Bouvet et al., 2005; Jarzyna, 2007]. In contrast, so far, only few reports 
exist on the application of the promising far-red protein Katushka for visualization of cancer 
processes in vivo. 
 
A rather new application of fluorescent proteins in cancer research is the so-called color-
coded fluorescence imaging, which offers the potential of monitoring tumor-host interactions. 
Tumor cells, which express a complementary fluorescent protein are implanted into 
transgenic nude mice , which expresses either a green or red fluorescent protein in all cells or 
specific cell types [Hoffman and Yang, 2006]. Moreover, many other applications, for 
example investigations on tumor angiogenesis [Amoh et al., 2008] or studies on the tumor’s 
microenvironment [Yang et al., 2009], become feasible by color-coded fluorescence imaging. 
 
 
 
Taken together, fluorescent proteins proved to be valuable tools for the visualization of cancer 
dynamics in vivo, including tumor growth, metastasis or angiogenesis. The recent discovery 
of bright red-shifted proteins, in particular Katushka, appears promising for whole-body 
imaging, since limitations of proteins emitting at shorter wavelength, such as the depth of 
tissue penetration and light absorbance by physiologically present molecules, can be 
overcome. 
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5.2  Objective 
 
The objective of this central part of the thesis was to refine an already existing orthotopic 
human glioblastoma model in nude mice with regard to noninvasive monitoring by optical 
imaging. For this purpose, the human glioblastoma cell lines U-87 MG and U-373 MG were 
(co-) transfected with the genes encoding an enhanced version of the firefly luciferase (luc2) 
and the recently discovered far-red emitting protein Katushka, respectively. A prerequisite for 
studies in animals was the in vitro characterization of the transfectants with respect to luc2 / 
Katushka protein expression, growth kinetics and chemosensitivity. The most promising 
transfectants had to be examined in a subcutaneous tumor model in nude mice concerning 
tumorigenicity and the stability of luc2 / Katushka expression. To establish a new orthotopic 
brain tumor model, the transfected malignant human glioblastoma cells U-87 Luc2 / U-87 
Katushka were implanted intracerebrally into nude mice to monitor tumor progression. In 
addition, the advantages and limitations of both techniques, namely BLI and FLI, should be 
comparatively evaluated by orthotopically implanting U-87 Luc2 / Katushka co-transfectants 
into the brain of nude mice. 
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5.3  Materials and methods 
 
5.3.1  Drugs and chemicals 
 
Water, used for the preparation of drug solutions and culture media, was purified by a Milli-Q 
system (Millipore, Eschborn, Germany). The selection antibiotics ampicillin sodium (Sigma, 
Deisenhofen, Germany), puromycin·2HCl (Sigma, Deisenhofen, Germany) and geniticin 
disulfate (G418, Biochrom AG, Berlin, Germany) were dissolved in water to achieve 
concentrations of 100 mg/mL (ampicillin sodium), 1 mg/mL (puromycin·2HCl) and 150 
mg/mL or 300 mg/mL (G418). The stocks were stored at -20 °C. D-luciferin potassium salt 
was purchased from Molecular Imaging Products Company, Ann Arbor, MI, USA and 
SYNCHEM OHG, Felsberg/Altenburg, Germany. For in vivo imaging experiments, 40 mg of 
D-luciferin potassium salt were dissolved in 1 mL of PBS (8.0 g/L NaCl, 1.0 g/L Na2HPO4 · 2 
H2O, 0.20 g/L KCl, 0.20 g/L KH2PO4, 0.15 g/L NaH2PO4· H2O; all chemicals for buffer 
preparation were purchased from Merck, Darmstadt, Germany). The solution was sterile 
filtered and aliquoted into autoclaved Eppendorf reaction vessels (Eppendorf, Hamburg, 
Germany). All preparations of D-luciferin were stored light-protected at -80 °C. 
 
5.3.2  Luria Bertani (LB) media, selective agar plates and SOC media 
For the preparation of LB media, 10 g of bacto tryptone (Difco, Detroit, USA), 5 g of yeast 
extract (Roth, Karlsruhe, Germany) and 5 g of sodium chloride (Merck, Darmstadt, Germany) 
were dissolved in 1000 mL of millipore water. The pH value was adjusted to 7.5 by drop-wise 
addition of 1 M NaOH. Subsequently, the medium was autoclaved at 121 °C / 2 bar for 20 
min. 100 µL of ampicillin stock solution (100 mg/mL) were added to 100 mL of sterile Luria 
Bertani medium. All media were stored at 4 °C and used at most for 2 weeks. Selective agar 
plates were prepared by dissolving 7.5 g of agar (Roth, Karlsruhe, Germany) in 500 mL of 
heated, sterile LB medium under continuous stirring. Subsequently, the solution was 
autoclaved and transferred into a tempered water bath (55 °C) for 30 min. Finally, 100 µL of 
ampicillin stock solution (100 mg/mL) were added to the medium, and agar plates were casted 
under sterile conditions. The plates were stored at 4 °C and used for a maximum of 4 weeks.  
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SOC medium for transformation procedures, derived from Super Optimal Broth (SOB), was 
prepared by dissolving 0.25 g of yeast extract and 1.00 g of bacto tryptone in approximately 
35 mL of millipore water. Subsequently, 1 mL of a 0.5 M NaCl stock solution, 1 mL of a 
0.125 M KCl stock, 1 mL of 0.5 M MgCl2 · 6 H2O solution and 1 mL of a 0.5 M MgSO4 · 7 
H2O stock were appended to the dissolved yeast extract / bacto tryptone, and the resulting 
solution was autoclaved. After cooling down, 1 mL of a sterile-filtered 1 M glucose 
monohydrate stock was added to the medium, and the volume was adjusted to 50 mL by using 
sterile-filtered millipore water. 
 
5.3.3  Cell culture 
The human glioblastoma cell lines U-87 MG and U-373 MG were purchased from the 
American Type Culture Collection (ATTC, Rockville, MD, USA). Wildtype cells were grown 
in Eagle’s Minimum Essential Medium (EMEM, Sigma, Munich, Germany) containing 2.2 
g/L NaHCO3, 110 mg/L sodium pyruvate, L-glutamine and 5 % fetal calf serum (FCS, 
Biochrom AG, Berlin, Germany).  
 
Mono-transfectants, expressing luciferase2, were maintained in the aforementioned medium 
supplemented with puromycin· 2 HCl at a final concentration of 1 µg/mL.  
 
U-87 MG and U-373 MG cells, which were transfected with the genes encoding the red 
fluorescent proteins DsRed2 and Katushka, respectively, were cultured in Eagle’s Minimum 
Essential Medium supplemented with 5 % fetal calf serum and 750 µg/mL of G418.  
 
Luciferase2 and DsRed2 / Katushka co-transfected human glioblastoma cells were grown in 
EMEM supplemented with 5 % FCS. With respect to exertion of selection pressure, 
puromycin·2 HCl (final concentration 1 µg/mL) and G418 (final concentration 750 µg/mL) 
were added to the culture medium.  
 
All cells were cultured in a water-saturated atmosphere of 37 °C / 5 % CO2 and routinely 
screened by PCR for Mycoplasma contamination using the VenorGEM™ detection kit from 
Minerva Biolab, Berlin, Germany. For all in vitro and in vivo investigations, only 
Mycoplasma-free cell cultures were used. 
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5.3.4  Amplification and purification of plasmid DNA 
 
5.3.4.1 The pGL4.20 (luc2/puro), pDsRed2-C1 and pTurboFP635-N vectors (Figure 5.2) 
 
As a shuttle vector, the pGL4.20 plasmid (Promega, Mannheim, Germany) bears the gene 
encoding the codon optimized firefly luciferase2 (from Photinus pyralis) for expression in 
mammalian cells and a gene for a prokaryotic (ampicillin) as well as for a mammalian 
(puromycin) selection marker. According to the providers manual, the pGL4 vectors also 
show a reduced background and risk of expression artifacts by the removal of several cryptic 
DNA regulatory elements as well as transcription factor binding sites [Promega, 2004-2007].  
The purified plasmid DNA of pDsred2-C1 (BD Bioscience Clontech, Heidelberg, Germany) 
was a kind gift from ACGT ProGenomics (Halle a. d. Saale, Germany). The vector contains 
the gene which encodes the enhanced version of the red fluorescent protein DsRed, namely 
DsRed2. Plasmid amplification in prokaryotic cells is enabled by kanamycin selection, 
whereas stable mammalian tranfectants are identified by G418 resistance.                                                
The pTurboFP635-N vector (BioCat, Heidelberg, Germany) is a mammalian expression 
vector bearing the gene encoding for the far-red fluorescent protein Katushka and the DNA 
sequences for G418 and kanamycin resistance [Evrogen].  
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Figure 5.2: Maps of pGL4.20 (luc2/puro), pDsRed2-C1 and pTurboFP635-N vectors 
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5.3.4.2 Transformation of competent E. coli cells 
 
pGL4.20, pDsRed2-C1 and pTurboFP635-N plasmids were amplified via transformation in 
competent E. Coli TOP10 cells. Therefore, frozen competent E. coli cells were thawed and 
immediately transferred on ice. After a period of 10 min, 5 µL of plasmid DNA (2 ng/µL) 
were added to 100 µL of the bacterial cell suspension. Subsequently, the mixture was 
incubated on ice for 30 min and heat shocked to 42 °C for a period of exactly 60 s. The 
suspension was incubated on ice for another 3 min. After the addition of 900 µL of sterile 
SOC medium, the mixture was shaken (200 rpm) at 37 °C for 1 h.  
Finally, 100 µL of the suspension were streaked on ampicillin (100 µg/mL) or kanamycin 
selective (30 µg/mL) agar-plates and incubated at 37 °C overnight. The remaining cell 
suspension was used to concentrate the bacteria for a second preparation. Therefore, the 
bacteria were centrifuged at 3,000 rpm for 5 min and 800 µL of the supernatant were carefully 
removed by suction. Subsequently, the cell pellet was resuspended in the residual medium, 
transferred on the selective agar plates and also incubated at 37 °C overnight. The next day, 
resistant colonies had formed, which were used for large scale preparations of the DNA. 
 
5.3.4.3 Maxi-preparation (Maxi-Prep) of plasmid DNA   
With respect to large scale alkaline lysis for isolation of plasmid DNA, 250 mL of sterile and 
selective LB medium (ampicillin or kanamycin) were transferred into an autoclaved 1000 mL 
Erlenmeyer flask. Subsequently, the medium was inoculated with resistant colonies from the 
selective agar plates and incubated at 37 °C overnight, while shaking the flask at 200 rpm. 
The next day, maxi-preparation was performed using a Qiagen Plasmid Purification Kit 
(Quiagen, Hilden, Germany) according to the manufacturer’s instructions.  
 
In brief: 200 mL of the overnight culture were centrifuged at 4 °C and 6,000 rpm for 15 min. 
The supernatant was carefully removed, and the pellet was efficiently resuspended in 10 mL 
of resuspension buffer P1 (50 mM Tris · Cl, pH 8.0; 10 mM EDTA; 100 µg/mL RNase A, 
LyseBlue reagent (provides visual identification of exhaustive mixture)). 10 mL of lysis 
buffer P2 (200 mM NaOH, 1 % SDS (w/v)) were added to the mixture and the suspension 
was vigorously shaken up to the appearance of a homogenous blue-colored batch.  
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5 min after incubation at room temperature, 10 mL of pre-chilled neutralization buffer P3 (3.0 
M potassium acetate, pH 5.5) were added to the mixture, and the homogenized suspension 
was incubated on ice for 20 min. Thereby, a fluffy white material containing genomic DNA, 
proteins and cell debris, became visible. Afterwards, the lysate was centrifuged at 4 °C and 
11,500 rpm for 30 min. The supernatant, containing the plasmid DNA, was removed and 
centrifuged at 4 °C and 11,500 rpm for another 15 min to eliminate residual lysate. After 
equilibration of the Qiagen-tip by addition of 10 mL of equilibration buffer QBT (750 mM 
NaCl; 50 mM MOPS, pH 7.0; 15 % isopropyl alcohol (v/v); 0.15 % Triton® X-100 (v/v)), the 
plasmid containing supernatant was applied to the tip. Subsequently, the plasmid DNA was 
rinsed twice with washing buffer QC (1.0 M NaCl; 50 mM MOPS, pH 7.0; 15 % isopropyl 
alcohol (v/v)) and finally eluted from the tip by using 15 mL of elution buffer QF (1.25 M 
NaCl; 50 mM Tris · Cl, pH 8.5; 15 % isopropyl alcohol (v/v)). After precipitation of DNA by 
the addition of isopropyl alcohol, the pellet was immediately washed with 70 % ethanol. The 
air-dried DNA pellet was re-dissolved in Millipore water, and the DNA concentrations as well 
as the purity were determined photometrically: a 1:70 dilution of Maxi-Prep DNA was 
prepared, and the absorbance was determined at 260 and 280 nm, respectively. Finally, the 
DNA concentration was calculated using the following equation: 
 
df)A40A70(]mL/µg[ C 280260    
 
, where df is the dilution factor of investigated DNA solution, A260 the absorbance measured 
at 260 nm and A280 the absorbance detected at 280 nm at a path length of 1 cm. Preparations 
with an A260/A280 quotient > 1.3 were considered to have a sufficient purity. The identification 
of plasmid DNA was carried out by sequencing by Entelechon, Regensburg, Germany. 
 
 
5.3.5  Stable transfection of U-87 MG and U-373 MG glioblastoma cells 
 
The transfection of U-87 MG and U-373 MG wildtype cells with pGL4.20 (luc2/puro) as well 
as co-transfection experiments of the aforementioned glioblastoma cells with pGL4.20 and 
pDsRed2-C1 were performed in passage 138 and 193, respectively.  
For experiments using the far-red protein Katushka, U-87 MG and U-373 MG cells were 
transfected with pTurboFP635-N in passage 169 and 223, respectively.  
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The co-transfection of U-87 MG and U-373 MG with the genes encoding luc2 and Katushka 
was performed by transfecting the stably expressing transfectants U-87 Luc2_Clone 3 
(passage 10) and U-373 Luc2_Clone 5 (passage 10) with pTurboFP635-N. All experiments 
were carried out with the transfection reagent FUGENE® HD (Roche Diagnostics GmbH, 
Mannheim, Germany) according to the manufacturer’s instruction.  
In brief: cells (confluency: approximately 80 %) were seeded into 24-well plates in a total 
volume of 500 µL of culture medium (EMEM plus 5 % FCS) for transfection. On the eve of 
experiments, serum-free EMEM was transferred into pyrogen-, DNAase- and RNAase-free 
reaction vessels in order to prepare DNA dilutions with a concentration of 2 µg of DNA / 100 
µL. In case of co-transfection, using pGL4.20 (luc2/puro) and pDsRed2-C1, the total amount 
of plasmid DNA was the same as used in single transfection experiments.  
Subsequently, 3, 6 and 9 µL of FUGENE® HD were added per 100 µL of the DNA solution, 
respectively. The mixtures were homogenized and incubated for 15 min at room temperature. 
Afterwards, 25 µL of the transfection complex were added drop-wise to each well, and the 
plates were carefully shaken to ensure a homogenous distribution. 3 wells for each FUGENE® 
HD / DNA ratio were incubated with the transfection mixture. After 48 h of incubation at 37 
°C / 5 % CO2, the supernatant was removed by suction, and cells were detached from the 
surface by short trypsinization. The triplicates of equivalent FUGENE® HD transfection 
reagent/DNA ratios were pooled and transferred into 12.5-cm² culture flasks (BD, Heidelberg, 
Germany) containing EMEM, supplemented with 5 % FCS and the respective selection 
antibiotic (puromycin·2HCl, G418 or a combination of both compounds). As a control, U-87 
MG and U-373 MG wildtype cells were cultured in the presence of equal concentrations of 
the antibiotics to verify the selection of transfected cells by resistance against puromycin and 
G418, respectively. The selective culture media were removed every 3-7 days by suction and 
replaced by fresh one. Over a period of 2-4 weeks, several resistant colonies of transfected 
cells had grown, whereas wildtype cells were killed by the antibiotics. After short 
trypsinization, parts of several colonies were picked and transferred into 1 well of a 24-well 
plate, which contained EMEM plus 5 % FCS, supplemented with the appropriate selection 
antibiotic. Having reached adequate confluency, the cells were expanded by up-scaling in 75-
cm² flasks. Thereafter, the cells were aliquotted, cryopreserved and stored in liquid nitrogen 
for further characterization.  
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5.3.6   Crystal violet assays 
5.3.6.1  Chemosensitivity assays 
Crystal violet chemosensitivity assays [Bernhardt et al., 1992] were performed as described 
elsewhere (chapters 3 and 4).   
5.3.6.2  Growth kinetic assays 
For the characterization of in vitro growth kinetics of different cell lines, including several 
transfectants, the aforementioned crystal violet chemosensitivity assay was slightly modified. 
For this purpose, the tumor cell suspensions were seeded into 96-well plates at a total volume 
of 200 µL/well and stored in the incubator (37 °C / 5 % CO2) for various times. Afterwards 
the cells were treated according to the protocol [Bernhardt et al., 1992] and the absorbance 
was determined at 580 nm on a Tecan GENios Pro microplate reader. Finally, the obtained 
absorbance values were plotted against the period of cell growth. 
 
5.3.7   Characterization of luciferase2 expression in vitro 
5.3.7.1  Assay procedure using cell lysates 
Tumor cells were detached from the culture flasks, resuspended in the appropriate culture 
medium and finally seeded into 24-well plates in a total volume of 500 µL for each well. 
Afterwards, the cells were allowed to grow at 37 °C / 5 % CO2 for approximately 48 h to 
reach a confluency of 80-100 %. Subsequently, the supernatant was removed by suction, and 
cells were washed with phosphate buffered saline in order to get rid of phenol red from the 
culture medium. Depending on the cell density, 60-200 µL of lysis buffer (25 mM TricineTM 
(N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; pH 7.8; Sigma); 10 % (v/v) glycerol 
(Merck, Darmstadt, Germany); 2 mM ethyleneglycoltetraacetic acid (EGTA) (Merck, 
Darmstadt, Germany); 1 % (v/v) TritonTM X-100 (Serva, Heidelberg, Germany); 5 mM 
MgSO4·7 H2O (Merck, Darmstadt, Germany), 1 mM dithiotreitol (DTT; Sigma, Munich, 
Germany)) were added to each well and incubated for 20 min, while slightly shaking the 
microtiter plates. 30 µL of the lysate were transferred into polystyrene tubes (Sarstedt, 
Nümbrecht, Germany).  
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The tube was placed into a Lumat LB 9501 luminometer (Berthold, Bad Wildbad, Germany) 
and 100 µL of a 0.2 mg/mL D-luciferin solution in assay buffer (25 mM TricineTM (pH 7.8); 5 
mM MgSO4·7H2O; 2 mM EGTA; 2 mM ATP (Boehringer, Mannheim, Germany); 50 μM or 
100 μM coenzyme A were added (CoA; Sigma, Munich, Germany), when indicated) were 
automatically injected into the solution. D-luciferin was stored as stocks at -80 °C with a 
concentration of 10 mg/mL in 25 mM tricine buffer (pH 7.8), supplemented with 10 mM 
DTT. Over a period of 10 s the photon counts of the bioluminescent reaction were integrated 
and values were expressed as RLU (relative light units).  
5.3.7.2  Normalization of luminescence to protein concentration (Bradford)  
The RLUs of each sample were normalized to the total protein content, which was determined 
according to the method of Bradford [Bradford, 1976]. Therefore, 5 µL of the cell lysate were 
added to 95 µL of lysis buffer and incubated with 1000 µL of Bradford´s dye reagent (Bio 
Rad Laboratories, Munich, Germany) for 10 min. Afterwards, the absorption at 595 nm was 
determined with an Uvikon 930 spectrophotometer (Kontron, Düsseldorf, Germany). The 
corresponding protein contents were calculated from a standard calibration curve using human 
serum albumin (HSA; Behringwerke, Marburg, Germany), which was dissolved in lysis 
buffer to compensate for matrix effects. The corrected RLU values were expressed as relative 
light units per µg of protein (RLU/µgProtein). 
5.3.7.3  Determination of luciferase2 activity in living cells in microtiter plates 
For the evaluation of luciferase2 activity in living cells, a microtiter plate-based assay, was 
established according to the following procedure: cells were detached from the culture flask 
by short trypsinization and resuspended in culture medium. The tumor cell suspensions were 
transferred into 10-mL Falcon™ tubes (BD, Heidelberg, Germany) and centrifuged at 1200 
rpm for 3 min using a Minifuge T centrifuge from Heraeus Instruments GmbH (Hanau, 
Germany). Subsequently, the supernatant was discarded, and cells were washed with 
phenolred- and serum-free EMEM (Biochrom AG, Berlin, Germany) to minimize interference 
with the luminescence measurements. To investigate the correlation between the cell number 
and the photon count, a dilution series of the tumor cells was prepared in phenolred- and FCS-
free medium. Afterwards, 150 µL of the cell suspensions were pipetted into each well of a 
totally black Nunclon™ 96-well plate (Nunc, Langenselbold, Germany), and the cells were 
allowed to attach to the surface of the plates at 37 °C / 5 % CO2 for at least 1 h.  
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On the eve of experiments, 50 µL of a D-luciferin solution in PBS (prepared by the dilution of 
100 µL D-luciferin stock solution (40 mg/mL in PBS) with 5900 µL of phosphate buffered 
saline) were added to each well of the microtiter plates. After 5 min of incubation, the 
microtiter plates were imaged with the Andor EMCCD camera DV887 ECS-BV (cooled 
down to -89 °C). The instrument and camera settings (stage height, exposure time, electron 
multiplying gain etc.) are described in the legends of the corresponding figures. 
  
5.3.8  Determination of DsRed2 and Katushka fluorescence in vitro 
 
5.3.8.1 Fluorescence microscopy  
Fluorescence detection in living human glioblastoma cells, genetically modified to express the 
DsRed2 or the Katushka protein, was performed on a Leica DM-IRB microscope (Texas Red 
filter cube; exc. 560/40 nm, em. 645/75 nm) and a Carl Zeiss Cell Observer (Zeiss, Munich, 
Germany; Zeiss filter set No. 43 (excitation wavelength 545/25 nm; FT 570; emission 
wavelength 605/70 nm)), respectively.  
 
5.3.8.2  Fluorescence detection by the means of a microtiter plate reader and the 
Maestro™ imaging system 
 
For quantification of fluoresecence emitted by Katushka-expressing cells, a microtiter assay 
was established according to the following protocol: after trypsinization, the cells were 
resuspended in culture medium and immediately centrifuged at 20 °C and 1500 rpm for 5 
min, using a Minifuge T centrifuge from Heraeus Instruments GmbH (Hanau, Germany). The 
supernatant was removed, and cells were washed twice with phenolred- and serum-free 
culture medium.  
Subsequently, the cell number was adjusted by resuspension of the cell pellet in an 
appropriate volume of EMEM, without phenolred and FCS. 150 µL of the tumor cell 
suspension were transferred into each well of a flat-bottomed polystyrene 96-well plate 
(sterile, F-Bottom, with lid, Cat.-No.655 180, Greiner, Frickenhausen, Germany). Afterwards, 
the plates were stored at 37 °C and 5 % CO2 for approximately 2 h allowing the cells to 
adhere to the surface.  
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The relative fluorescence intensities were recorded with a Tecan GENios Pro microtiter plate 
reader (settings: measurement mode: fluorescence top; excitation wavelength: 580/10 nm; 
emission wavelength: 670/20 nm; number of reads: 5; integration time: 40 µs; lag-time: 0 µs; 
mirror selection: automatic; plate definition file: GRE96ft.pdf; multiple-reads per well 
(circle): 4 x 4; time between move and flash: 50 ms).  
To explore the sensitivity of the Maestro™ in vivo imaging system, the same procedure as 
described for the plate reader was pursued. However, instead of clear 96-well plates, the cells 
were seeded into black microtiter plates with clear and flat bottoms (µclear®; Greiner, 
Frickenhausen, Germany). The filter settings for the fluorescence of DsRed2 and Katushka-
expressing cells were as follows: excitation 503-555 nm; emission 580 nm cut off; for further 
instrument settings (stage height, exposure time etc.) see legends to the respective figures. 
 
5.3.9  Installation of a laboratory for in vivo imaging and in vivo 
experiments 
 
5.3.9.1 Laboratory for in vivo imaging 
Fluorescence in vivo imaging (FLI) studies were performed with a Maestro™ (500 FL 
system, wavelength range from 500-950 nm) according to the instructions of the user manual 
(Cambridge Research and Instrumentation, Inc., Maestro™, Revision 1.2.6). Bioluminescence 
in vivo imaging (BLI) studies were carried out by adaptation of the commercial Maestro™  
system, i.e. exchanging the liquid crystal tunable filter camera from CRI™ with an Andor™ 
DV887 ECS-BV EMCCD camera. All devices are explained in detail in the doctoral thesis of 
Peter Jarzyna [Jarzyna, 2007].  
This highly sensitive back-illuminated camera uses electron multiplying technology and is 
cooled down to -89 °C. The extremely high sensitivity of EMCCD cameras makes the 
detection of specific photon emission prone to any kind of stray light from external sources (e. 
g. daylight, illuminants such as LED’s etc.). For this reason, the Maestro™ system was 
further modified, to exclude extraneous light (Figure 5.4) and placed in a specially devised 
dark room (Figure 5.3) 
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a b 
a 
d
cb 
Figure 5.3: In vivo imaging laboratory. a) Dark room equipped with the tailor-made 
Maestro™ system (black arrow) suited for macroscopic fluorescence / bioluminescence 
imaging, the fluorescence camera system for microscopy studies (red arrow), the EMCCD 
camera Andor™ DV887 ECS-BV (green arrow) and a circulation thermostat  to cool the 
Peltier element of the EMCCD (blue arrow); b) Blinds for laboratory door to prevent 
incident light. 
Figure 5.4: Dark box to shield the imaging device 
from extraneous light. Front view of the closed (a) 
and opened (b) dark box, detail showing 
overlapping edges (c) and top view of the 
integrated Maestro™ system, equipped with the 
Andor™ EMCCD camera (d). 
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5.3.9.2  Implantation of human glioblastoma cells into nude mice 
 
5.3.9.2.1  Subcutaneous tumors 
The procedure was performed according to the method described in chapter 4 (“Animals, 
husbandry and feeding”). 
  
5.3.9.2.2  Intracerebral tumors 
To investigate the growth characteristics of human glioblastoma transfectants in the brain of 
nude mice, genetically modified U-87 cells cells were prepared in vitro as described above. 
After washing twice with FCS-free EMEM, the cell pellet was resuspended in serum-free 
culture medium, and the cell number was adjusted to 5·104 per 10 µL. For the orthotopic 
implantation, the animals were anesthetized as described in Chapter 4. The parietal bone was 
drilled through with a 1-mm diameter bit, 3 mm on the right-hand side of the sagittal suture 
and 3 mm rostral of the coronal suture. Tumor cell suspensions were carefully homogenized 
and 10 μL containing 50,000 cells were injected 3 mm deep into the brain tissue by using a 
Hamilton syringe with a blunt tip. Finally, a surgical clamp was used to close the skin wound 
and the pads of the mice were labeled by tattooing.  
Figure 5.5 shows the various steps of the orthotopic transplantation procedure. 
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Figure 5.5: Orthotopic implantation of human glioblastoma cells into the brain of nude 
mice. Mice were placed on a heated stage to prevent a decline of body temperature during 
anesthesia. Skin incision and position of the drill (a); diamante drill for parietal bone 
perforation  (b); injection of tumor cell suspension via a Hamilton syringe (c); wound 
closure with surgical clamps (d). 
a 
c 
b
d
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5.3.9.2.3  Bioluminescence imaging (BLI) of subcutaneous and orthotopic 
glioblastoma in nude mice 
 
Prior to each bioluminescence imaging (BLI) experiment, the specimen stage was heated to 
39.5 °C in order to achieve a desired temperature of 37 °C on the surface of the table. The 
mice were anesthetized by intraperitoneal injection of 30-50 µL of the aforementioned 
mixture containing ketamine and xylazine. According to the body weight (25-40 g) of the 
nude mice anesthesia persisted for 20-50 min.  
 
For imaging of subcutaneous tumors, 100 µL of freshly thawed D-luciferin solution (40 
mg/mL in sterile PBS) were injected intraperitoneally. For BLI measurements of orthotopic 
human glioblastoma, surgical clamps were removed from the animals, and 200 µL of the D-
luciferin solution, containing 8 mg of D-luciferin, were injected i.p.. After a period of 5 min, 
the mice were positioned on the heated stage and emitted photon counts were integrated 
(instrument settings are given in the figure legends).  Analysis of the data was performed with 
the “Andor Solis imaging software 4.3”. 
 
 
5.3.9.2.4  Fluorescence imaging (FLI) of subcutaneous and orthotopic glioblastoma 
 
The specimen stage was heated to 39.5 C, and mice were anesthetized (see 5.3.9.2.3). 
Subsequently, the animals were placed on the table and fluorescence imaging was performed 
with the Maestro™ device (500 FL system with a wavelength range of 500-950 nm). Used 
filters as well as further instrument settings (stage height, exposure time etc.) are given the 
respective paragraphs. Data analysis was carried out with the “Maestro Software 2.6.0B”. 
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5.3.10 Histology 
Histological paraffin sections of tumor tissues and organs were prepared according to the 
procedure by Walter et al. [Walter et al., 2000] with various modifications. Animals were 
killed by cervical dislocation, and tissue were excised and dissected. For a period of at least 3 
days, the tumors and / or organ samples were fixed at room temperature in Bouin’s solution 
containing picric acid, formaldehyde and acetic acid. After washing with phosphate buffered 
saline, tissues were dehydrated by using a Histokinette Shandon Processor 2LE (Frankfurt am 
Main, Germany). Dehydration was performed by an ascending isopropyl alcohol series at 
room temperature. Thereafter, the specimen were placed in paraffin Paraplast X-tra® 
(Sherwood Medical, Roth GmbH, Karlsruhe, Germany) and left at 50-54 °C for 4 h (4 times). 
Finally, the tissues were embedded in Paraplast®, cut into 6 µm-thick sections by using a 
Leica Microtome RM2255 (Leica, Bensheim, Germany) and transferred on poly-L-lysine 
(Sigma)-coated glass slides. For staining, the sections were deparaffinized with xylene and 
rehydrated by means of descending alcohol series. Haematoxylin-Eosin (HE) staining was 
performed according to the procedure by Romeis [Romeis, 1989]. Alternatively, the samples 
were stained by the method of Masson-Goldner 
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5.4. Results  
5.4.1  Determination of the required concentrations of selection antibiotics 
G418, hygromycin and puromycin 
 
As a prerequisite for the identification of human U-87 MG and U-373 MG glioblastoma cells, 
transfected with the pGL4.20, pDsRed2-C1 and pTurboFP635-N vectors, the 
chemosensitivity against eukaryotic selection markers G418, puromycin and hygromycin was 
investigated in the crystal violet chemosensitivity assay.  
 
 
 
 
 
 
As becomes obvious from Figure 5.6, G418 showed comparable cytotoxicity at the highest 
concentrations tested (750 and 1500 µg/mL) against both glioblastoma variants. 
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Figure 5.6: Effect of G418 on proliferating U-87 MG wildtype cells (a), 137th passage, and 
U-373 MG wiltype cells (b), 250th passage. 
Cells were incubated with G418 at concentrations of: 50 µg/mL (filled circles), 250 µg/mL 
(filled squares), 750 µg/mL (filled triangles) and 1500 µg/mL (filled inverted triangles). As 
a control, both cell lines were incubated with the vehicle water (open stars) and 10 nM of 
vinblastin (open diamonds). 
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The same holds for puromycin ·2HCl at concentrations of 0.75 µg/mL and 1.5 µg/mL (Figure 
5.7). 
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Figure 5.7: Effect of puromycin·2HCl on proliferating U-87 MG wildtype cells (a), 137th 
passage, and U-373 MG wildtype cells (b), 250th passage. 
Cells were incubated with puromycin·2HCl at concentrations of: 0.05 µg/mL (filled 
circles), 0.25 µg/mL (filled squares), 0.75 µg/mL (filled triangles) and 1.5 µg/mL (filled 
inverted triangles). As a control, both cell lines were incubated with the vehicle water 
(open stars) and 10 nM of vinblastin (open diamonds). 
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Hygromicin at a concentration of 800 µg/mL caused comparable cytocidal effects on both, U-
87 MG wildtype and U-373 MG wildtype cells (Figure 5.8). 
 
 
 
 
 
 
Summing up, puromycin proved to be the most potent selectable marker of all investigated 
antibiotics. A quite low concentration of 750 ng/mL sufficed to mediate massive cytocidal 
effects on both human glioblastoma cell lines. To achieve similar effects by incubation of the 
cells with G418 and hygromycin, approximately 1000-fold higher concentrations (750 µg/mL 
and 800 µg/mL, respectively) were necessary on U-87 MG cells as well as on U-373 MG 
wildtype cells. Therefore, 750 µg/mL of G418 and 1.0 µg/mL of puromycin·2HCl were 
considered as sufficient concentrations for the selection of stable transfected U-87 and U-373 
MG cells with the pGL4.20 (luc2/puro), pDsRed2-C1 and pTurboFP635-N vectors, 
respectively. 
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Figure 5.8: Effect of hygromycin on proliferating U-87 MG wildtype cells (a), 137th 
passage, and U-373 MG wildtype cells (b), 250th passage. 
Cells were incubated with hygromycin at concentrations of: 10 µg/mL (filled circles), 100 
µg/mL (filled squares), 400 µg/mL (filled triangles) and 800 µg/mL (filled inverted 
triangles). As controls, both cell lines were incubated with the vehicle water (open stars) 
and 10 nM of vinblastin (open diamonds). 
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5.4.2   In vivo imaging using bioluminescent glioblastoma cell lines 
5.4.2.1  Luciferase2 activity in cell lysates 
To investigate the luciferase2 activity of the puromycin-resistant transfectants, different 
clones of U-87 and U-373 cells were seeded into 24-well plates and lysed after having 
reached appropriate confluency. Bioluminescence of the lysates, incubated with D-luciferin, 
was measured over a period of 10 s. U-87 MG and U-373 MG wildtype cells served as 
negative controls.  
8 resistant U-87 clones were obtained by 2 different transfection procedures. On the one hand, 
a ratio of 3 parts FUGENE HD transfection reagent and 2 parts of plasmid DNA (3:2) was 
used, whereas the second preparation was performed with 9 parts of FUGENE HD and 2 parts 
of DNA (9:2). The 4 colonies which were obtained from the 3:2 preparations were termed 
Clone 1-4, whereas picked clones from the 9:2 transfection procedures were numbered from 
5-8. The residual colonies were pooled and designated U-87 Luc2 (3:2) and U-87 Luc2 (9:2). 
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Figure 5.9: Specific luciferase2 activity determined in lysates of U-87 cells transfected 
with pGL4.20 (luc2/puro). U-87 MG wildtype cells served as negative control (mean 
values ± SEM, n=3). 
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As shown in Figure 5.9, clones 2, 3 and 5 of U-87 transfectants showed by far the highest 
enzyme activity. Clones 2 and 3 were generated from the 3:2 preparations whereas clone 5 
was obtained by picking a resistant colony from the transfection sample which contained 9 
parts of FUGENE HD and 2 parts of plasmid DNA. Comparing clones 2 and clone 3 with the 
U-87 MG wildtype cells, reveals approximately 800-fold higher RLU values (14 vs. 10,781 
for clone 3 and 11,223 for clone 2). Hence, for further investigations U-87 Luc2_Clone 2, 3 
and 5 cells were used.  
In case of U-373 cells (Figure 5.10), 12 resistant colonies were obtained. By analogy with the 
U-87 transfectants, the clones were termed: Clones 1-4 (3:2, FUGENE HD:DNA ratio), 
clones 5-8 (6:2, FUGENE HD:DNA ratio) and clones 9-12 (9:2, FUGENE HD:DNA ratio). 
Residual colonies were also pooled. 
 
 
 
U-373 Luc2_Clone 5 showed paramount luciferase2 activity (Figure 5.10). However, clone 7 
and clone 9 were also included into the subsequent studies. 
Figure 5.10: Specific luciferase2 activity in the lysates of U-373 cells transfected with the 
pGL4.20 (luc2/puro) plasmid. U-373 MG wildtype cells served as negative control (mean 
values ± SEM, n=3). 
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5.4.2.2 Luciferase2 activity in living cells 
To explore the sensitivity of the imaging device on live cells, serial dilutions of the 
transfectants were investigated in microtiter plates. Low-expressing subcultures or wildtype 
cells served as controls.  
Figure 5.11 shows exemplary results obtained with U-87 Luc2_Clone 1, 3 and 5. 
Clone 1, which was identified as a very weakly-expressing clone (cf. Figure 5.9), gave no 
signal up to 300,000 cells / well. By contrast, in case of U-87 Luc2_Clone 3 and 5 (cf. Figure 
5.9) the limit of detection was 18,750 and 37,500 cells / well, respectively. In addition, the 
photon counts and cell numbers of U-87 Luc2_Clone 3 correlated directly over a range of 2 
orders of magnitude with r² = 0.983. In view of the signal to noise ratio, 50,000 cells were 
considered appropriate for orthotopic implantations into the brain of nude mice.  
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To investigate, if the luc2 expression is retained over a long period of time, the transfectants 
were imaged in different passages (Figure 5.12 and Figure 5.13).  
U-87 Luc2_Clone 2 cells (Figure 5.12) showed stable luciferase2 expression for at least 6 
months. Similar results were obtained with the U-373 clones, namely Clone 5, 7 and 9 over 
17 passages (Figure 5.13). 
Figure 5.11: Specific luciferase2 activity of the clones U-87 Luc2_Clone 1, 3 and 5, 5th 
passage, detected in living cells by means of the in vivo imaging system. Bright field 
image and corresponding light signals (a) and correlation of photon count (determined in 
the “Regions of interest” (ROI, red marked squares)) vs. cell number of U-87 Luc2_Clone 
3 cells (b). Cell suspensions were serially diluted 1:2 starting from 300,000 to 293 cells per 
well (decreasing cell numbers from left to right).  
Instrument settings: stage height h2a, exposure time 1800 s, no binning, EM gain 255, 
readout rate 1 MHz. at 16 bit. 
a 
U-87 Luc2_Clone 1 
bright field bioluminescence 
U-87 Luc2_Clone 3 
U-87 Luc2_Clone 5 
b 
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However, in case of U-87 Luc2_Clone 3 cells, bioluminescence in passage 14 (detection limit 
~ 18,750 cells / well) was slightly lower compared to passage 25 (detection limit ~ 37,500 
cells / well) (Figure 5.12b).  
With respect to the relative luciferase2 expression by the different glioblastoma transfectants, 
the results obtained in cell lysates and live cells are in good agreement (cf. Figure 5.9, 5.10 
and Figure 5.12, 5.13) 
 
 
 
 
 
 
 
 
 
Figure 5.12: Long-term expression of luc2 activity in genetically engineered human 
glioblastoma cells (U-87 Luc2_Clone 2 (a) and clone 3 (b)) in vitro. The cells were 
investigated in passages 6, 14 and 25 at densities from 300,000 - 293 cells per well (1:2 
dilution steps, decreasing cell numbers from left to right.)  
Instrument settings: stage height h2a, exposure time 1800 s, no binning, EM gain 255, 
readout rate 1 MHz. at 16 bit.  
Figure 5.13: Long-term expression of luc2 activity in genetically engineered human 
glioblastoma cells (U-373 Luc2_Clone 5, 7 and 9) in vitro. The cells were investigated in 
passages 5 (a) and 17 (b) at densities from 300,000 – 293 cells per well (1:2 dilution 
steps, decreasing cell numbers from left to right), respectively.  
Instrument settings: stage height h2a, exposure time 1800 s, no binning, EM gain 255, 
readout rate 1 MHz. at 16 bit.  
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5.4.2.3  Proliferation and chemosensitivity of U-87 and U-373 transfectants  
As cancer cell lines are usually polyclonal and genetically extremely variable, which becomes 
obvious e.g. by karyotyping [Altenschöpfer, 1998], it must be kept in mind, that transfectants 
represent only a small subpopulation of the parent cells. Therefore, the transfectants were 
compared to the respective wildtype cells concerning growth kinetics and chemosensitivity.  
5.4.2.3.1  Growth kinetics 
U-87 Luc2_Clone 2 and U-87 Luc2_Clone 3 cells showed comparable in vitro growth 
kinetics (Figure 5.14a) compared to the U-87 MG wildtype cells.  
There were also no significant differences between the genetically engineered U-373 Luc 
transfectants and the U-373 MG wildtype cells (Figure 5.14b). All investigated transfectants 
of U-373 cells proved to be comparable to the wild type cells according to their in vitro 
growth kinetics, indicating that obviously, the introduction of the gene encoding for the 
luciferase2 enzyme did not alter the cell proliferation. 
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Figure 5.14: In vitro growth kinetics of different U-87 cell lines (a): U-87 MG (filled stars, 
159th passage), U-87 Luc2_Clone 2 (filled squares, 13th passage) and U-87 Luc2_Clone 3 
(filled triangles, 13th passage), and various U-373 cells (b): U-373 MG (filled stars, 213th 
passage and open stars, 217th passage), U-373 Luc2_Clone 5 (filled squares, 7th passage), 
U-373 Luc2_Clone 7 (filled triangles, 7th passage) and U-373 Luc2_Clone 9 (filled 
inverted triangles, 7th passage). 
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5.4.2.3.2  Chemosensitivity of transfectants against mitoxantrone and topotecan 
In view of the co-administration of cytostatics, which are substrates of the ABCG2 
transporter, with inhibitors of this efflux pump (see Chapter 4), the chemosensitivity of the 
transfectants against mitoxantrone and topotecan was investigated.  
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Figure 5.15: Effect of the cytostatic and ABCG2 substrate mitoxantrone on proliferating 
U-87 MG cells (filled circles; 161th passage), U-87 Luc2_Clone 2 cells (filled squares; 15th 
passage) and U-87 Luc2_Clone 3 cells (filled triangles; 15th passage) 
Cells were incubated with mitoxantrone at concentrations of: 10 nM (a), 50 nM (b), 100 
nM (c) and 500 nM (d). 
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Within the range of experimental errors, there were neither statistically significant differences 
in case of U-87 MG wildtype cells and transfectants (Figure 5.15, Figure 5.17) nor between 
the different U-373 glioblastoma variants (Figure 5.16, Figure 5.18). 
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Figure 5.16: Effect of the cytostatic and ABCG2 substrate mitoxantrone on proliferating 
U-373 MG cells (filled circles; 216th passage), U-373 Luc2_Clone 5 cells (filled squares; 
8th passage) and U-373 Luc2_Clone 9 cells (filled triangles; 8th passage). 
Cells were incubated with mitoxantrone at concentrations of: 10 nM (a), 50 nM (b), 100 
nM (c) and 500 nM (d). 
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Figure 5.17: Effect of the cytostatic and ABCG2 substrate topotecan on proliferating U-87 
MG cells (filled circles; 161th passage), U-87 Luc2_Clone 2 cells (filled squares; 15th 
passage) and U-87 Luc2_Clone 3 cells (filled triangles; 15th passage) 
Cells were incubated with topotecan at concentrations of: 5 nM (a), 25 nM (b), 100 nM (c) 
and 500 nM (d). 
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Figure 5.18: Effect of the cytostatic and ABCG2 substrate topotecan on proliferating U-
373 MG cells (filled circles; 216th passage), U-373 Luc2_Clone 5 cells (filled squares; 8th 
passage) and U-373 Luc2_Clone 9 cells (filled triangles; 8th passage)  
Cells were incubated with topotecan at concentrations of: 5 nM (a), 25 nM (b), 100 nM (c) 
and 500 nM (d). 
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5.4.2.4  Tumorigenicity and growth kinetics of transfectants in subcutaneous tumor 
models 
 
Figure 5.19 shows the in vivo growth kinetics of U-87 Luc2_Clone 2 xenografts compared to 
the control U-87 MG. The maintenance of solid U-87 Luc2_Clone 2 tumors could only be 
sustained up to the 1st in vivo passage.  
 
 
 
 
 
 
All investigated glioblastoma variants were highly tumorigenic (Tables 5.1 and 5.2) and 
showed reproducible growth, both, when injected as cell suspension or implanted as solid 
tumor pieces. Within the variability of xenograft progression, typically associated with errors 
up to 50 %, the growth kinetics were similar when comparing genetically engineered with 
wildtype cells (Figures 5.19 and 5.20).  
This fact was further substantiated by long-term investigations on subcutaneous U-87 
Luc2_Clone 3 tumors over a period of several months (10 serial passages) (Figure 5.21). The 
take rates of this human glioblastoma variant are summarized in Table 5.3. 
Cell line Passage Take rate  
(%) 
U-87 MG 0 80 
 1 100 
U-87 Luc2_Clone 2 0 100 
 1 100 
Table 5.1: Take rates of subcutaneous U-
87 MG and U-87 Luc2_Clone 2 tumors
days after subcutaneous injection / piece implantation
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Figure 5.19: In vivo growth kinetics of 
subcutaneous U-87 MG (filled symbols) and U-
87 Luc2_Clone 2 tumors (open symbols) in nude 
mice: In vivo passage 0 (circles) and 1st in vivo 
passage (squares); (mean values ± SEM).  
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Cell line Passage Take rate  
(%) 
U-87 MG 0 80 
 1 100 
 2 100 
U-87 Luc2_Clone 3 0 100 
 1 100 
 2 100 
Passage Take rate  
(%) 
0 100 
1 100 
2 100 
3 100 
4 70 
5 82 
6 100 
7 86 
8 83 
9 50 
10 100 
days after subcutaneous injection /  piece implantation
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Passage 0
Passage 1
Passage 2
Passage 3 
Passage 4
Passage 5
Passage 6
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Passage 9
Passage 10
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Table 5.2: Take rates of subcutaneous U-
87 MG and U-87 Luc2_Clone 3 tumors 
shown for in vivo passages 0, 1 and 2. 
Figure 5.20: In vivo growth kinetics of 
subcutaneous U-87 MG (filled symbols) and 
U-87 Luc2_Clone 3 tumors (open symbols) in 
nude mice: In vivo passage 0 (circles), 1st 
passage (squares) and 2nd passage (triangles); 
(mean values ± SEM).  
Figure 5.21: In vivo growth kinetics of subcutaneous U-87 
Luc2_Clone 3 tumors monitored over 10 in vivo passages 
(mean values ± SEM). 
Table 5.3: Take rates 
of subcutaneous U-87 
Luc2_Clone 3 tumors 
in nude mice. The 
studies revealed an 
average take rate of 88 
± 5 % (mean value ± 
SEM) 
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Unfortunately, efforts to establish an analogous in vivo model using U-373 cell lines, 
including MG wild type cells, U-373 Luc2_Clone 5 and clone 9 transfectants, failed. In 
contrast to U-87 glioblastomas, the tumorigenicity of the former variants was extremely low 
and tumor growth usually ceased at 1-2 mm³. Figure 5.22 presents the growth and histology 
of 1 U-373 Luc2_Clone 5 reaching an area of 20 mm². However, the subsequent piece 
implants of this tumor did not form solid subcutaneous xenografts. 
 
 
 
 
 
 
 
The observed difficulties to maintain U-373 tumors growing in nude mice are in agreement 
with investigations performed by Dr. Peter Altenschöpfer [Altenschöpfer, 1998], who 
described an irregular growth behavior of U-373 MG cells in vivo, i.e. either tumorigenicity 
was extremely low or tumor progression was only stable over a few passages [Altenschöpfer, 
1998].  
 
5.4.2.5  Bioluminescence in vivo imaging (BLI) of subcutaneous, U-87 MG derived 
glioblastoma in nude mice 
 
Due to selection pressure in vitro, mediated by the antibiotic puromycin, the subcutaneous U-
87 Luc2 glioblastoma tumors had to be studied on their ability to stably express the 
luciferase2 enzyme under in vivo conditions. Therefore, the substrate D-luciferin was 
intraperitoneally injected into nude mice bearing subcutaneous U-87 Luc2_Clone 2 / U-87 
Luc2_Clone 3 tumors, respectively, and the emitted light signals were recorded via the in vivo 
imaging system equipped with the Andor™ EMCCD camera as shown in Figure 5.23. 
Figure 5.22: a) In vivo growth of a single subcutaneous U-373 Luc2_Clone 5 xenograft 
(passage 0) and b) corresponding histological proof of tumor tissue (Masson-Goldner 
staining). 
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Figure 5.23: Bioluminescence in vivo imaging of subcutaneous U-87 Luc2_Clone 2 (a) 
and clone 3 (b) xenografts; 1st in vivo passage; 8, 16 and 22 days after tumor piece 
implantation. Specific light signals emitted from tumor tissues (red arrows in bright field 
images) were obtained 300 s after i.p. injection of 4 mg D-luciferin into each mouse. 
Instrument settings: stage height h2a, exposure time 360 s, EM gain 1, no binning, readout 
rate 1 MHz. at 16 bit. 
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Figure 5.23 shows tumor progression in 2 randomly selected nude mice within a period of 
approximately 3 weeks.  
Bioluminescence signals of subcutaneous U-87 Luc2_Clone 2 and Clone 3 xenografts were 
directly proportional to the tumor area, measured in parallel using an electronic caliper. Thus, 
the expression of luciferase2 in U-87 Luc2 cells turned out to be stable under in vivo 
conditions and resulted in sufficient enzyme activity for the detection of light signals by the 
optical imaging devices. It is noteworthy, that the required exposure times, at a relatively 
insensitive EM gain to resolve the resulting bioluminescence, were very short. This suggested 
that also small intracerebral tumors could be imaged in the orthotopic tumor model.  
Figures 5.24 and 5.25 demonstrate, that for specific tumor-associated bioluminescence 
signals not only the tumor tissue has to be vital, but also that D-luciferin has to be provided to 
the tumor cells via an intact blood circulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.24: In vivo imaging of a control mouse without tumor: bright field image (a) and 
corresponding bioluminescence after the intraperitoneal injection of 4 mg D-luciferin (b).  
Instrument settings: stage height h2a, exposure time 360 s (300 s after D-luciferin 
injection), EM gain 1, no binning, readout rate 1 MHz. at 16 bit. 
a b
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Figure 5.25: Effect of the blood supply and vitality of the tumor tissue on 
bioluminescence.  
a, b):  Optical imaging of a dead nude mouse bearing a subcutaneous U-87 Luc2 _Clone 3 
tumor. 
Instrument settings: stage height h2a, exposure time 360 s (300 s after D-luciferin 
injection), EM gain 1, no binning, read out rate 1 MHz. at 16 bit).  
 
c-f): Although a massive tumor is visible in the bright field image (c), a high gain is 
required (f) to detect specific signals, since bioluminescence is only emitted by vital 
tumor tissue. Necrotic areas in the tumor appear dark using an EM gain of 1 (d).  
e, f): EM gain 255 (maximum value) (stage height h2a, exposure time 360 s (900 s after 
injection of D-luciferin), no binning, readout rate 1 MHz. at 16 bit). 
a b
c d e f
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5.4.2.6  Long-term expression of luciferase2 in vivo 
To investigate the in vivo stability of luc2 expression over a period of several months, the 
serially passaged subcutaneous tumors were controlled by bioluminescence in vivo imaging 
studies (Figures 5.26 and 5.27). These investigations were performed with subcutaneous U-
87 Luc2_Clone 3 tumors. 
As depicted in the corresponding figures, luc2 was expressed by the tumors at a constant level 
over a period of approximately 9 months. This is surprising, as no puromycin was 
administered to exert a selection pressure in vivo  
 
 
 
 
 
 
 
 
 
 
Figure 5.26: Long-term expression on luciferase2 by U-87 Luc2_Clone 3 xenografts (red 
arrows). Bright field (left) and corresponding bioluminescence (right) images of 
subcutaneous tumors, recorded for passages 0-2. 
Instrument settings: stage height h2a, exposure time 360 s (300 s after injection of D-
luciferin), EM gain 1, no binning, readout rate 1 MHz. at 16 bit. 
Passage 0 Passage 1 Passage 2 
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Figure 5.27: Long-term expression on luciferase2 by U-87 Luc2_Clone 3 xenografts (red 
arrows). Bright field (left) and corresponding bioluminescence (right) images of 
subcutaneous tumors, recorded for passages 3-10.  
Instrument settings: stage height h2a, exposure time 360 s (300 s after injection of D-
luciferin), EM gain 1, no binning, readout rate 1 MHz. at 16 bit. 
Passage 3 Passage 4 Passage 5 Passage 6
Passage 8 Passage 9 Passage 10Passage 7 
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5.4.2.7  Histopathology of subcutaneous luminescent glioblastoma xenografts 
 
The histology shows the morphology of a high grade, cell rich and fast dividing glioma, 
comprising pleomorphic nuclei with prominent nucleoli. The U-373 MG tumors contained 
more stroma (data not shown) than the U-87 variants depicted in Figure 5.28.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.28: Masson-Goldner staining of subcutaneous U-87 Luc2_Clone 2 (a, b) and U-
87 Luc2_Clone 3 (c, d) tumors. Objective 20 x (a, c), objective 40 x (b, d). 
c 
50 µM 
d
50 µM
a b
50 µM 50 µM
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5.4.2.8  Bioluminescence in vivo imaging (BLI) of intracerebral, U-87 MG derived 
glioblastoma  
 
Encouraged by the subcutaneous results, U-87 Luc2_Clone 2 and U-87 Luc2_Clone 3 cells 
were implanted into the brain of nude mice. Subsequently, the intracerebral tumor growth was 
monitored over a period of 4-5 weeks by means of noninvasive bioluminescence imaging. 
Prior to measurements, 8 mg of D-luciferin were intraperitoneally injected into each mouse, 
and the photon counts were integrated for 15 min at an EM gain of 255. 
Due to these extremely sensitive instrument settings, control experiments prior to each BLI 
were required to investigate the effects on the detection of noise. For this reason, every mouse 
was imaged in the absence of D-luciferin using the identical instrument settings as applied for 
the subsequent investigations after substrate application. This procedure is exemplarily shown 
in Figure 5.29. 
 
 
 
 
 
 
 
 
 
 
For validation of the model, U-87 Luc2_Clone 2 and clone 3 cells were implanted into the 
brain of nude mice (4 and 6 female nude mice, respectively). Subsequently, all animals were 
imaged over a maximal period of 33 days (Figures 5.30 and 5.31).  
 
Figure 5.29: Detection of intracerebral glioblastoma xenografts by BLI.  
Determination of background: bright field image (a), bioluminescence (b) image.  
Optical imaging of the intracerebral tumor: bright field (c) and bioluminescence (d) image.  
Instrument settings: stage height h2c, exposure time 900 s, EM gain 255, no binning, 
readout rate 1 MHz. at 16 bit.  
Light signals (d) were obtained after i.p injection of 8 mg D-luciferin. 
a b d c 
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Figure 5.30: Optical in vivo imaging of orthotopic U-87 Luc2_Clone 2 tumors in the brain 
of nude mice over a period of 26 and 33 days, respectively. Due to massive detraction by 
tumor growth, mouse 1 was killed after 26 days. Specific light signals were obtained after 
i.p. injection of 8 mg D-luciferin.  
Instrument settings were as follows: stage height h2c, exposure time 900 s (300 s after 
substrate application), EM gain 255, no binning, readout rate 1 MHz. at 16 bit. 
Mouse 1 
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13 days  
after 
 orthotopic 
implantation 
26 days  
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33 days  
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Figure 5.31: Optical in vivo imaging of orthotopic U-87 Luc2_Clone 3 tumors in the brain 
of nude mice over a period of 33 days. Bioluminescence signals were obtained after i.p. 
injection of 8 mg D-luciferin.  
Instrument settings were as follows: stage height h2c, exposure time 900 s (300 s after 
substrate application), EM gain 255, no binning, readout rate 1 MHz. at 16 bit. 
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Figure 5.30 shows the optical imaging of 2 selected mice bearing orthotopic U-87 
Luc2_Clone 2 tumors. 13 days after tumor cell implantation a specific light signal was 
noticed in the head region of mouse 1, whereas no bioluminescence was determined in mouse 
2. Within in the next 13 days, the intracerebral tumor growth proceeded in both animals, 
according to increasing signals in BLI. The measurements showed a pronounced light signal 
expanded over the whole head of mouse 1 indicating the existence of a massive intracerebral 
tumor, supported by the marked decrease in body weight. According to the guidelines of the 
animal’s welfare, mouse 1 was killed by cervical dislocation and the brain tissue was 
dissected for histopathology. Since bioluminescence signals emitted from mouse 2 were less 
pronounced, and the body weight retained constant, the animal was imaged once again at day 
33, showing an increased signal due to the progression of the intracerebral tumor.  
The semi-quantitative evaluation of intracerebral U-87 Luc2_Clone 3 tumor progression is 
exemplarily demonstrated for 2 selected mice in Figure 5.31. Already 13 days after 
implantation, specific bioluminescence was recorded in both animals. Mouse 1 showed a 
significant stronger light signal than mouse 2, suggesting a faster tumor progression. These 
data were supported by the optical imaging 26 and 33 days after tumor cell implantation. The 
signals recorded from mouse 1 had a higher intensity suggesting a higher tumor load 
compared to that of mouse 2.  
These investigations clearly demonstrate the semi-quantitative monitoring of the progression 
of orthotopic human brain tumors in nude mice by BLI. Only 6 days after tumor cell 
implantation, specific light signals were determined in 2 out of 10 mice. Another 5 animals 
had BLI detectable tumors at the end of the study. 
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5.4.2.9  Confirmation of orthotopic brain tumors by histopathology  
To confirm the results of BLI investigations on orthotopic glioblastoma in nude mice, the 
animals were killed and dissected brain tissues were examined by histology. Table 5.4 gives 
an overview of bioluminescence data and corresponding histology for each mouse of the 
experiment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
In 7 out of 10 cases, the histological examinations were in agreement with data obtained from 
optical imaging studies. 
In the group of nude mice bearing U-87 Luc2_Clone 2 tumors, mouse 3 showed high specific 
bioluminescence, indicating the existence of a massive tumor, but which could not detected 
by histological examination of brain sections. Presumably by the implantation procedure, an 
extracranial tumor was induced (Figure 5.32a).   
 
  Tumor detection 
by 
bioluminescence 
signal 
Histological 
detection of 
orthotopic tumor 
growth 
U-87 Luc2_Clone 2   
Mouse 1 + + 
Mouse 2 + + 
Mouse 3  + - 
Mouse 4 - - 
U-87 Luc2_Clone 3   
Mouse 1 + + 
Mouse 2 + + 
Mouse 3 + + 
Mouse 4 - - 
Mouse 5 +/- - 
Mouse 6 -/+ - 
Figure 5.32: Mouse 3 of 
U-87 Luc2_Clone 2 group 
with an extracranial tumor 
(a) and bioluminescence 
imaging (b) of mouse 5 
(right) and mouse 6 (left) 
from the U-87 Luc2_clone 
3 group. 
Table 5.4: Optical imaging results and histopathology data 
of intracerebral U-87 Luc2_Clone 2 / Clone 3 tumors 
a 
b 
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Due to significant loss of body weight, mouse 5 and mouse 6 had to be killed already after 18 
days. At day 18, only very weak bioluminescence signals were detected (Figure 5.32b). The 
discrepancy of bioluminescence and histopathology of such very small tumors might result 
from the procedure used to prepare the serial sections of the brain.   
 
Figure 5.33 and 5.34 show exemplarily the histology of intracerebral U-87 Luc2_Clone 2 and 
clone 3 tumors as well as their corresponding BLI images. The histology images represent 
details, localized at the demarcation of the intracerebral tumor (marked by a red arrow) from 
the normal brain tissue (marked by a blue arrow).  
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
b
Figure 5.33: Histology 
of an intracerebral U-87 
Luc2_Clone 2 xenograft 
in mouse 1 (a) and 
corresponding BLI image 
(b), performed on day 26. 
Figure 5.34: Histology 
of an intracerebral U-87 
Luc2_Clone 3 xenograft 
in mouse 1 (a) and 
corresponding BLI image 
(b), performed on day 33. 
a 
b
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5.4.3 In vivo imaging using red fluorescent glioblastoma cells 
By analogy with the generation of bioluminescent brain tumors, the human U-87 MG and U-
373 MG glioblastoma cells were transfected with the gene encoding the far-red protein 
Katushka. These investigations were performed as an alternative approach to overcome the 
high technical complexity of bioluminescence in vivo imaging and to reduce limitations 
inherent in the method: the long exposure times and the need for application of the costly D-
luciferin are disadvantages. Since the EM gain had to be elevated to its maximum for the 
determination of the extremely low signals emitted from orthotopic brain tumors, control 
experiments for every animal were indispensable to exclude any interference during the 
measurements. Furthermore, the injection of the substrate was not only associated with stress, 
but also with the necessity of an intact blood circulation.  
The individual U-87 Katushka and U-373 Katushka clones were designated by analogy to 
those expressing luc2 (see 5.4.2.1). 
 
5.4.3.1 Fluorescence microscopy 
 
To determine the transfection efficiency the Katushka fluorescence was checked via 
fluorescence microscopy. Those clones which showed the highest fluorescence were selected 
for further investigations. 
 
 
 
 
 
 
 
Figure 5.35: Microscopic phase contrast (a), epifluorescence (b) and merged (c) images of 
U-87 Katushka_Clone 3 cells.  
Images were taken on the Carl Zeiss Cell Observer (Zeiss, Munich, Germany) using the 
Zeiss filter set No. 43 (excitation wavelength 545/25 nm; FT 570; emission wavelength 
605/70 nm) 
a c b 
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5.4.3.2  Fluorescence detection by the means of a microtiter plate reader and the 
Maestro™ imaging system 
 
5.4.3.2.1  Microtiter plate reader assays 
Increasing numbers of Katushka expressing cells yielded an increase in fluorescence intensity. 
The fluorescence signals and cell numbers correlated in a linear manner (Figure 5.36). By 
contrast, the fluorescence intensity of wildtype cells stayed constant, independent of the cell 
number.  
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Figure 5.36: Comparison of relative fluorescence intensities determined for 
U-87 MG wildtype cells (filled circles; 165th passage) and U-87 
Katushka_Clone 3 cells (open circles; 11th passage).  
The excitation wavelength was 580 nm, whereas the emission was detected at 
670 nm. 
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5.4.3.2.2 Katushka activity in living U-87 and U-373 cells 
 
Excitation was performed using a bandpass filter with a range of 503-555 nm. For analysis, an 
image cube was generated by overlaying 23 single images in 10 nm steps, ranging from 580-
800 nm. With respect to interfering spectra, a reference library containing the Katushka 
spectrum as well as autofluorescence spectra was recorded and applied in the unmixing 
procedure.                   
 
 
 
 
 
 
 
 
 
Taken together, most of the U-87 clones, transfected with pTurboFP635-N, showed higher 
expression levels of the red fluorescent protein than U-373 Katushka transfectants (data not 
shown). Whereas at least 37,500 cells of U-87 Katushka_Clone 3, 4, 10 and 17 were resolved 
by the Maestro™ system, clone 2 proved to be a low-expressing cell line, requiring at least 
300,000 cells for detection. According to the signal to noise ratio, 50,000 cells were 
considered appropriate for orthotopic implantations into the brain of nude mice. 
In case of different U-373 Katushka transfectants, only 2 subcultures, namely clone 10 and 
clone 18 proved to express Katushka at levels allowing the determination of at least 75,000-
150,000 cells.  
Clone 2 
Clone 3 
Clone 4 
Clone 10 
Clone 17 
Figure 5.37: Specific Katushka 
fluorescence in several U-87 Katushka 
transfectants. The Katushka fluorescence is 
displayed as red pseudo-color. Cell 
suspensions were serially diluted 1:2 
starting from 300,000 to 293 cells per well 
(decreasing cell numbers from left to 
right). The images show the unmixed 
overlay of 23 single pictures, exposed 
every 10 nm in the range from 580-800 
nm.  
Instrument settings: stage height h1c, 
exposure times 4,660 ms (Clone 3) and 
5,000 ms (all other subcultures) for each 
single 10 nm step. 
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5.4.3.3   Proliferation and chemosensitivity of U-87 and U-373 transfectants against 
the ABCG2 substrates topotecan and mitoxantrone 
 
5.4.3.3.1 Growth kinetics 
 
Figure 5.38 shows comparative growth curves of U-87 MG wildtype and U-87 Katushka 
clones as well as U-373 MG wildtype cells and the transfectant U-373 Katushka_Clone 10. 
 
 
 
 
 
 
 
 
 
 
 
The transfectant U-87 Katushka_Clone 3 showed comparable in vitro growth kinetics as the 
U-87 MG wildtype cells, whereas clone 10 was characterized by a slightly retarded in vitro 
growth (Figure 5.38a). The reason for this slower proliferation is caused by a lower initial 
cell density.  
Similar results were obtained in case of U-373 cell variants (Figure 5.38b). 
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Figure 5.38: In vitro growth kinetics of different U-87 cell lines (a): U-87 MG wildtype 
cells (open stars 171st passage, filled stars 173rd passage), U-87 Katushka_Clone 3 cells 
(filled squares, 4th passage) and U-87 Katushka_Clone 10 cells (filled circles, 10th 
passage); and U-373 cell lines (b): U-373 MG wildtype cells (open stars, 192nd passage) 
and U-373 Katushka Clone 10 cells (filled circles, 3rd passage).
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5.4.3.3.2  Chemosensitivity of U-87 Katushka transfectants vs. U-87 MG wildtype 
cells against mitoxantrone and topotecan 
 
Due to lower expression of Katushka and the lack of in vivo tumorigenicity, U-373 
transfectants were not considered for the toxicity studies. 
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Figure 5.39: Effect of the cytostatic and ABCG2 substrate mitoxantrone on proliferating 
U-87 MG cells (filled circles; 160th passage), U-87 Katushka_Clone 3 cells (filled squares; 
5th passage) and U-87 Katushka_Clone 10 cells (filled triangles; 4th passage)  
Cells were incubated with mitoxantrone at concentrations of: 10 nM (a), 50 nM (b), 100 
nM (c) and 500 nM (d). 
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When compared with the respective wildtypes, the sensitivities of all investigated U-87 
transfectants against mitoxantrone and topotecan, respectively, were almost identical (Figure 
5.39, Figure 5.40).  
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Figure 5.40: Effect of the cytostatic and ABCG2 substrate topotecan on proliferating U-87 
MG cells (filled circles; 160th passage), U-87 Katushka_Clone 3 cells (filled squares; 5th 
passage) and U-87 Katushka_Clone 10 cells (filled triangles; 4th passage).  
Cells were incubated with topotecan at concentrations of: 5 nM (a), 25 nM (b), 100 nM (c) 
and 500 nM (d). 
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5.4.3.4 Tumorigenicity and in vivo growth kinetics of subcutaneous Katushka-
transfected glioblastoma 
 
According to performed in vitro investigations on Katushka expression, growth kinetics and 
chemosensitivity, the transfectant U-87 Katushka_Clone 3 proved to be suitable for first in 
vivo studies in nude mice.  
For this purpose, the cells were subcutaneously injected into several animals, and the 
tumorigenicity was recorded via the measurement of tumor diameters once a week. U-87 MG 
wildtype cells, which were subcutaneously implanted into mice, served as control for 
classification of the obtained data. 
 
 
 
 
 
 
 
 
Whereas in passage 0 and 1 U-87 Katuhska_Clone 3 cells showed a delayed in vivo growth 
compared to the wildtype cells, this behavior was inverted in the second passage resulting in a 
faster growth rate of U-87 Katushka_Clone 3 tumors than observed for U-87 MG 
malignancies (Figure 5.41).  
Cell line Passage Take rate  
(%) 
U-87 MG 0 80 
 1 100 
 2 100 
U-87 Katushka 0 100 
_Clone 3 1 100 
 2 100 
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Figure 5.41: In vivo growth kinetics of 
subcutaneous U-87 MG (filled symbols) 
and U-87 Katushka_Clone 3 tumors (open 
symbols) in nude mice: In vivo passage 0 
(circles), 1st passage (squares) and 2nd 
passage (triangles); (mean values ± SEM).  
Table 5.5: Take rates of subcutaneous U-
87 MG and U-87 Katushka_Clone 3 
tumors shown for in vivo passages 0, 1 
and 2.
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Nevertheless, the injection of transfected U-87 cells proved to cause persistent subcutaneous 
tumors with maximal take rates of 100 % in the first 3 in vivo passages.  
 
These observations were confirmed by long-term investigations on the tumorigenicity of 
subcutaneous U-87 Katushka_Clone 3 tumors (Figure 5.42). 
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Figure 5.42: In vivo growth kinetics of subcutaneous U-87 Katushka_Clone 
3 tumors monitored over 7 in vivo passages (mean values ± SEM). 
 Optical imaging of orthotopic human glioblastoma in nude mice  189 
 
Over a period of several months, the serially passaged tumor pieces caused a reproducible 
growth of subcutaneous U-87 Katushka_Clone 3 xenografts (Figure 5.42). The growth rates 
allowed an averaged observation period of approximately 40 days. Furthermore, the 
investigations proved highest possible take rates of 100 % for all 7 in vivo passages indicating 
the vitality and high malignancy of U-87 Katushka_Clone 3 tumors. 
U-373 Katushka_Clone 10 cells, when subcutaneously implanted into nude mice, did not 
cause tumor formation for at least 3 months. As mentioned previously (5.4.2.4), attempts to 
establish subcutaneous U-373 MG wildtype tumors failed also. The same situation was 
observed for U-373 Katushka transfectants. 
 
 
5.4.3.5  Fluorescence in vivo imaging (FLI) of subcutaneous U-87 Katushka_Clone 3 
tumors 
 
The luciferase2 expression of U-87 Luc2 tumors remained stable under in vivo conditions, 
even in the absence of puromycin, allowing semi-quantitative monitoring of tumor 
progression by noninvasive in vivo imaging (see 5.4.2.5 and 5.4.2.6).  
By analogy with these investigations, mice bearing solid U-87 Katushka_Clone 3 tumors 
were anesthetized and Katushka fluorescence was controlled on the Maestro™ fluorescence 
in vivo imaging system (Figure 5.43). 
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The studies revealed high stable Katushka expression in subcutaneous U-87 Katushka_Clone 
3 neoplasms for the determination of specific fluorescence signals emitted by the tumor 
tissue. Despite of the short exposure times, fluorescence signals were extremely extensive 
although there was no selection pressure due to lack of the antibiotic G418 under in vivo 
conditions. 
21 days after injection 
of tumor cells 
21 days after injection 
of tumor cells 
34 days after injection 
of tumor cells
34 days after injection 
of tumor cells
41 days after injection 
of tumor cells 
41 days after injection 
of tumor cells 
a 
b 
c 
Figure 5.43: Fluorescence in vivo imaging of a subcutaneous U-87 Katushka_Clone 3 
tumor. Monitoring over a period of 41 days: bright field images (a), Katushka fluorescence 
(b) (red pseudo-color; after unmixing procedure) and merge (c).  
Instrument settings: excitation 503-555 nm, emission 580 nm cut off, stage height h1c. 
Images represent an overlay of 23 pictures in 10 nm steps ranging from 580-800 nm 
(Maestro™ image Cube). Exposure times for fluorescence detection were as follows: 450 
ms (studies on day 21), 125 ms (studies on day 34) and 80 ms (studies on day 41). 
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Figure 5.44 shows an example of the “unmixing procedure” using the Maestro™ software. 
For analysis of specific fluorescence, the correct spectrum of the fluorophor in the 
corresponding environment (tissue) has to be determined. Autofluorescence and specific 
spectra of the transfectants, recorded in vitro, are the basis of a spectral library to be measured 
for the in vivo situation in various organs and tissues.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.44: Unmixing procedure for fluorescence in vivo imaging demonstrated by 
means of a small subcutaneous U-87 Katushka_Clone 3 tumor. The autofluorescence in the 
unmixed overlay picture (black spectrum curve) can be eliminated from the specific 
Katushka signal (red spectrum curve) by computational analysis. 
autofluorescence 
„Katushka“
overlay (cube) unmixed 
bright field image 
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5.4.3.6  Long-term expression of Katushka in vivo 
 
In order to investigate the growth as well as the Katushka expression of serially passaged 
subcutaneous tumors, randomly selected mice of each in vivo passage were imaged on the 
Maestro™ system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The subcutaneous U-87 Katushka_Clone 3 tumors proved to be tissues with stable expression 
of the red fluorescent protein Katushka. Specific fluorescence signals of the tumors were 
detected in all investigated in vivo passages, demonstrating preservation of the Katushka 
encoding gene in these genetically modified tumor cells. 
Figure 5.45: Fluorescence in vivo imaging of subcutaneous U-87 Katushka_Clone 3 
tumors (marked by blue arrows in bright field images). The studies were performed over 
a period of 7 in vivo passages (representing several months).  
Instrument settings: excitation 503-555 nm, emission 580 nm cut off, stage height h1c. 
Fluorescence images represent the unmixed overlay of 23 pictures in 10 nm steps 
ranging from 580-800 nm (Maestro™ image Cube). Exposure times for fluorescence 
detection were set to the calculated autoexposure values of the software. 
Passage 0 
Passage 1 
Passage 2 
Passage 3 
Passage 4 
Passage 5 
Passage 6 
Passage 7 
 Optical imaging of orthotopic human glioblastoma in nude mice  193 
 
5.4.3.7  Histology of subcutaneous U-87 Katushka tumors 
 
The subcutaneous U-87 Katushka tumors were subjected to histopathological examinations.  
As observed for U-87 Luc2 tumors, high malignancy is reflected by numerous mitoses and 
the incidence of pleomorphic nuclei (Figure 5.46).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.46: Masson-Goldner stains of a subcutaneous U-87 Katushka_Clone 3 tumor: 
low magnification (a) and high magnification (b). 
a b
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5.4.3.8 Fluorescence in vivo imaging (FLI) of intracerebral U-87 Katushka_Clone 3 
tumors in nude mice 
 
The U-87 Katushka_Clone 3 transfectant was regarded as suitable for the intracerebral 
implantation into nude mice. 50,000 cells of U-87 Katuhska_Clone 3 were implanted into the 
brains of 13 female nude mice. 
10 days after the implantation procedure, 2 of the 13 mice developed orthotopic human 
glioblastomas that could be detected by their fluorescence. After additional 10 days, 
orthotopic brain tumors were visualized by FLI in 7 out of 12 investigated animals. 1 mouse 
had to be killed earlier due to loss of body weight > 10 %. The final studies, performed on day 
27, proved the existence of intracerebral brain tumors in 11 of 13 nude mice, demonstrating a 
high take rate of 85 %. 
Figure 5.47 shows representative fluorescence images of 2 selected mice bearing 
intracerebral U-87 Katushka_Clone 3 tumors. The animals were investigated by FLI for a 
total of 27 days. Whereas the whole body of mouse 1 was imaged, the FLI pictures of mouse 
2 represent details of the animal’s head region. These examples demonstrate the suitability of 
FLI as a semi-quantitative method to monitor intracerebral tumor progression. 
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Figure 5.47: Fluorescence in vivo imaging of nude mice bearing intracerebral U-87 
Katushka_Clone 3 xenografts. The studies were performed 10, 20 and 27 days after tumor 
cell implantation. Left images show the “raw” image cubes (580-800 nm, 10 nm steps) 
containing unspecific signals such as autofluorescence, whereas right images represent 
corresponding unmixed pictures.  
Instrument settings: excitation filter 503-555 nm, emission filter 580 nm cut off, stage 
height h2 (mouse 1) and h3 (mouse 2). Exposure times were set to the calculated 
autoexposure values of the software. 
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5.4.3.9  Comparison of FLI data and histopathology of orthotopic U-87 
Katushka_Clone 3 tumors 
 
 
Table 5.6 summarizes both, the FLI data and the histology, displayed for each individual 
mouse. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Tumor 
detection by 
Fluorescence 
signal 
Histological 
detection of 
orthotopic tumor 
growth 
Mouse 1 + + 
Mouse 2 + + 
Mouse 3  + + 
Mouse 4 + + 
Mouse 5 + + 
Mouse 6 + + 
Mouse 7 + + 
Mouse 8 + + 
Mouse 9 + + 
Mouse 10 + + 
Mouse 11 +/- - 
Mouse 12 + + 
Mouse 13 - + 
Table 5.6: Overview of results obtained from FLI 
studies and histopathological examinations on 
orthotopic human glioblastoma (U-87 
Katushka_Clone 3) in nude mice. 
Figures 5.48: FLI of mouse 11 and 
mouse 13: bright field (a), overlay (b) 
and unmixed cube (c). Unmixing 
procedure for mouse 13 was not 
performed due to missing specific 
Katushka fluorescence. The blue 
arrow in the overlay of mouse 11 
marks a weak fluorescence signal 
which could be confirmed by the 
unmixing procedure. 
b
c 
a
Mouse 11 
b
a
Mouse 13 
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The histopathological investigations confirmed 11 intracerebral U-87 Katushka_Clone 3 
tumors. Hence, in 11 of totally 13 cases, the FLI data were in agreement with histopathology. 
Even signals as low as of mouse 11 could be detected via FLI (left part of Figure 5.48).  
A possible reason for a false-negative result of the histopathological examination has been 
discussed under 5.4.2.9. Inversely, a false-negative result of FLI (see mouse 13; right part of 
Figure 5.48) can be explained either by a very deep localization of a small tumor, or factors 
affecting fluorescence e.g. pH, oxygen partial pressure as well as physical properties of the 
environment such as lipophilicity. It is well known that the microenvironment of tumor cells 
in different areas of the neoplasm is very heterogeneous. 
The reproducibility of the established orthotopic glioblastoma model was checked in a second 
independent experiment using 5 male nude mice. The implantation procedure was performed 
as described for the first study, and mice were investigated by FLI after 10, 16, 22 and 29 
days. At the end, intracerebral U-87 Katushka_Clone 3 tumors were detected in all animals by 
FLI and confirmed by histopathological investigation (for an example, cf. Figure 5.49) in 4 
out of 5 brains. 
Taken together, the FLI of orthotopic U-87 Katushka_Clone 3 tumors and the successive 
histological examinations of dissected brain tissues were in very good agreement. In 83 % of 
all investigated mice, orthotopic human glioblastoma were detected by both, noninvasive 
fluorescence in vivo imaging and histopathology.  
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The morphology of intracerebral U-87 Katushka_Clone 3 tumors appeared similar to that of 
orthotopic U-87 Luc2 tumors.  
 
 
 
 
Figure 5.49: Bright field 
image of mouse 1 (a), and 
corresponding fluorescence 
image with a high intensity 
specific fluorescence signal 
localized in the brain of 
mouse 1 (b).  
Histopathology of a human 
glioblastoma, orthotopically 
grown in nude mouse 1 (c): 
Masson-Goldner staining; the 
normal, non-malignant brain 
tissue (blue arrow) and the 
intracerebral high grade 
glioblastoma (red arrow). 
a b 
c 
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5.4.4  In vivo imaging using co-transfected human glioblastoma cells 
bearing bioluminescent and fluorescent reporter genes 
 
In order to directly compare the advantages and limitations of BLI and FLI in one and the 
same specimen, U-87 and U-373 cells were co-transfected with the genes encoding the luc2 
enzyme and the red fluorescent proteins Katushka or DsRed2, respectively. For this purpose, 
U-87 MG and U-373 MG cells were simultaneously transfected with the pGL4.20 vector and 
the pDsRed2-C1 vector, whereas stably expressing U-87 Luc2 and U-373 Luc2 cells were 
used for co-transfection studies with the pTurboFP635-N vector. As described for the mono-
transfectants, the co-transfectants were characterized in vitro with respect to protein 
expression, growth kinetics and chemosensitivity. Furthermore, the tumorigenicities of the 
cell lines and the applicability of reporter gene expression for BLI and FLI were studied in 
subcutaneous tumor models. Finally, suitable co-transfectants were implanted into the brain 
of nude mice, and the tumor progression was noninvasively monitored by means of both 
optical imaging devices. 
Approximately 4 weeks after transfection, several resistant colonies were picked for 
cultivation (designated according to the nomenclature of the mono-transfectants). Residual 
cells were pooled and termed U-87 and U-373 Luc2/DsRed2 3:2, 6:2 and 9:2 (according to 
the nomenclature of the mono-transfectants). 
 
 
5.4.4.1  Luciferase2 and DsRed2 expression in co-transfected U-87 and U-373 cell lines 
 
The determination of luc2 activity in cell lysates as well as epifluorescence microscopy 
revealed that all U-87 Luc2/DsRed2 co-transfectants lost at least 1 of the 2 reporter genes 
immediately after transfection. Hence, further investigations on U-87 Luc2/DsRed2 cells 
could not be performed. However, the in vitro investigations of U-373 co-transfectants were 
successful.  
1 promising clone, namely U-373 Luc2/DsRed2_Clone 2, was identified by both, luciferase2 
expression (luc2 activity in cell lysates) and DsRed2 fluorescence (Figure 5.50).  
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5.4.4.2 Effect of cell number on luc2 expression and Katushka fluorescence  
 
A dilution series of U-373 Luc2/DsRed2_Clone 2 cells was prepared in EMEM without 
phenol red. Subsequently, the cells were seeded into 2 separate 96-well plates at various 
densities. For the determination of luc2 activity on living cells, the transfectants were 
incubated with D-luciferin, and the emitted photons were integrated over a period of 30 min. 
In parallel, the DsRed2 fluorescence of U-373 Luc2/DsRed2_Clone 2 cells was measured 
using the Maestro™ in vivo imaging system. The minimal cell number per well which could 
be detected by both methods was about 75,000 (Figure 5.51). The limit of detection was low 
enough with respect to the intended cell number for the implantation into the brain of nude 
mice. 
 
 
 
 
 
b 
Figure 5.51: BLI and FLI of U-373 Luc2/DsRed2_Clone 2 cells, seeded into 96-well 
plates (300,000 – 293 cells / well; 1:2 dilution steps; decreasing cell numbers from left to 
right).  
Instrument setting for BLI: stage height h2a, EM gain 255, exposure time 1800 s (300 s 
after D-luciferin application, no binning, readout rate 1 MHz. at 16 bit; instrument settings 
for FLI: stage height h1, exc. 503-555 nm, em. 580 nm cut of, exposure time 5000 ms for 
each 10 nm step (range: 580-800 nm (cube)).  
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Figure 5.50: Specific luciferase2 activity 
(detected in cell lysates) of several U-373 
Luc2/DsRed2 clones (a; mean values ± 
SEM from 3 measurements) and DsRed2 
fluorescence of U-373 Luc2/DsRed2_Clone 
2 cells (b; Leica DM-IRB microscope 
(Texas Red filter cube), exc. 560/40 nm, 
em. 645/75 nm).
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5.4.4.3  Proliferation and chemosensitivity of U-373 Luc2/DsRed2_Clone 2 cells against 
the ABCG2 substrates topotecan and mitoxantrone 
 
The investigation on U-373 Luc2/DsRed2_Clone 2 cells revealed comparable growth kinetics 
of the co-transfectants and the corresponding U-373 MG wildtype cells (Figure 5.52), and 
there was no difference in the chemosensitivity against mitoxantrone (Figure 5.53) and 
topotecan (Figure 5.54) respectively, between the co-transfectants and the wildtype cells. 
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Figure 5.52: In vitro growth kinetics of U-373 MG wildtype cells (filled circles; 
213th passage) and U-373 Luc2/DsRed2_Clone 2 cells (open circles; 12th passage). 
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Figure 5.53: Effect of the cytostatic and ABCG2 substrate mitoxantrone on proliferating 
U-373 MG wildtype cells (a; 216th passage) and U-373 Luc2/DsRed2_Clone 2 cells (b; 
14th passage) 
Cells were incubated with ethanol 70 % (open stars; vehicle control) and increasing 
concentrations of mitoxantrone: 10 nM (filled circles), 50 nM (filled squares), 100 nM 
(filled triangles) and 500 nM (filled inverted triangles). 
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5.4.4.4  Tumorigenicity of U-373 Luc2/DsRed2_Clone 2 cells after subcutaneous 
injection into nude mice 
 
After subcutaneous injection of U-373 Luc2/DsRed2_Clone 2 cells into thymus aplastic mice, 
1 animal developed a solid tumor after a period of approximately 2 months. The respective 
mouse was killed and the tumor was dissected for tumor propagation in vivo. Furthermore, to 
confirm malignancy of the tissue, several tumor pieces were fixed with Bouin’s fixative for 
histopathology. Figure 5.55 shows the growth kinetics and the histology of the subcutaneous 
U-373 Luc2/DsRed2_Clone 2 xenograft. 
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Figure 5.54: Effect of the cytostatic and ABCG2 substrate topotecan on proliferating U-
373 MG wildtype cells (a; 216th passage) and U-373 Luc2/DsRed2_Clone 2 cells (b; 14th 
passage).  
Cells were incubated with ethanol 70 % (filled stars; vehicle control) and increasing 
concentrations of topotecan: 5 nM (open circles), 50 nM (open squares), 100 nM (open 
triangles) and 500 nM (open inverted triangles). 
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The histology confirmed high-grade malignancy of the generated subcutaneous tumor. 
Numerous mitoses were detected. As described for U-373 MG wildtype tumors by Dr. Peter 
Altenschöpfer [Altenschöpfer, 1998], the subcutaneous U-373 Luc2/DsRed2_Clone 2 tumor 
was characterized by extreme pleomorphology and higher extents of connective tissue 
(Figure 5.55b, marked by an blue arrow) than observed for U-87 tumors. 
The subcutaneous passaging of small tumor pieces (1st in vivo passage) resulted in faster 
tumor formation and higher take rates than observed for the injection of suspended cells (data 
not shown). However, this effect was already inverted in the 2nd in vivo passage yielding 
again only a few solid tumors (data not shown). These observations underline the described 
problems associated with U-373 xenografts. 
 
 
 
 
 
 
Figure 5.55: In vivo growth kinetics of the single U-373 Luc2/DsRed2_Clone 2 tumor (a) 
and its corresponding microscopy image of the histopathology (b). 
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5.4.4.5  Optical imaging of subcutaneous U-373 Luc2/DsRed_Clone 2 tumors using 
bioluminescence in vivo imaging (BLI) and fluorescence in vivo imaging (FLI) 
 
To detect the expression levels of luc2 and DsRed2 in vivo, 2 mice bearing subcutaneous U-
373 Luc2/DsRed2_Clone 2 tumors were studied by BLI and FLI (Figure 5.56). The animals 
were anesthetized and light signals were recorded after application of D-luciferin. 
Subsequently, the DsRed2 fluorescence intensity of these tumors was investigated by means 
of FLI.  
However, although the subcutaneous tumors were visible, both BLI and FLI failed to detect 
the malignancies, indicating absence or dysfunction of luc2 and DsRed2. Obviously, the 
tumor tissue which was used for serial passaging (from passage 0 to passage 1) had already 
lost the transfected genes. Hence, the studies on luc2 and DsRed2 co-transfected glioblastoma 
cells were discontinued.  
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Figure 5.56: BLI (a) of subcutaneous U-373 Luc2/DsRed2_Clone 2 tumors (marked by 
blue arrows in bright field images) and corresponding FLI (b) experiments. Specific tumor 
signals could not be detected, neither by bioluminescence nor by fluorescence.  
Instrument settings of BLI: stage height h2a, EM gain 255, exposure time 600 s (600 s 
after D-luciferin application), no binning, readout rate 1 MHz. at 16 bit.  
Instrument settings of FLI: stage height h2, exposure times were set to the calculated 
autoexposure values of the software, excitation filter 503-555 nm, and emission filter 580 
nm cut off; fluorescence images represent a cube of 23 single exposures in the range from 
580-800 nm. 
a 
Mouse 1 
Mouse 2 after injection of D-luciferin 
b 
Mouse 2
Mouse 1
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5.4.4.6  Luciferase2 activity and Katushka fluorescence in live U-87 and U-373 co-
transfectants 
 
Several subcultures of U-87 Luc2 and U-373 Luc2 cells, which had been additionally 
transfected with the gene encoding the Katushka protein, showed fluorescence (conventional 
fluorescence microscopy; data not shown). For this reason, the sensitivity of both, FLI and 
BLI, was detected for these promising co-transfected clones.  
 
 
 
 
 
 
 
 
 
 
The investigations on U-87 Luc2 / Katushka co-transfectants revealed stable expression of 
luciferase2 and Katushka in several clones. Depending on the clone and the used imaging 
method (BLI or FLI), the measurements allowed the detection of at least 38,500 – 75,000 
cells (Figure 5.57). The U-373 co-transfectants showed high activity of luciferase2 in all 
investigated clones allowing determination of at least 9,375 cells by bioluminescence, 
whereas the Katushka associated fluorescence proved to be sufficient to detect a minimum of 
37,500 cells (Figure 5.57).  
Thus, the lowest detectable cell numbers of co-transfected human glioblastoma cells were at 
least in the same range as the amount of cells (50,000 cells in a total volume of 10 µL) used 
for the implantation into the brain of nude mice.  
Figure 5.57: BLI and FLI of 
different U-87 Luc2/Katushka and 
U-373 Luc2/Katushka clones. 
Instrument settings of BLI: stage 
height h2a, EM gain 255, exposure 
time 1800 s (300 s after incubation 
with D-luciferin), no binning, 
readout rate 1 MHz. at 16 bit.  
Instrument settings of FLI: stage 
height h1c, exposure time 5000 ms 
for each single image of the cube 
(overlay of 23 pictures ranged 
from 580-800 nm), exc. 503-555 
nm, emission 580 nm cut off. 
Bioluminescence Fluorescence
U-87 Luc2/Kat. cells
U-373 Luc2/Kat. cells
Clone 3
Clone 15
Clone 18
Clone 1
Clone 12
Clone 16
Cell number 
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5.4.4.7  Proliferation and chemosensitivity of U-87 and U-373 co-transfectants against 
the ABCG2 substrates topotecan and mitoxantrone 
 
 
  
 
 
 
 
 
 
 
 
 
 
Whereas U-87 Luc2/Katushka_Clone 15 and clone 18 cells showed comparable growth 
kinetics as the wildtype cells (Figure 5.58a), clone 16 of U-373 co-transfectants was growing 
more slowly and less dense than U-373 MG cells (Figure 5.58b). However, this effect is most 
probably due to the seeding at a lower density.  
With respect to the chemosensitivity there was no difference against mitoxantron (Figure 
5.60) and topotecan (Figure 5.59) respectively, between the co-transfectants and the wildtype 
cells. 
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Figure 5.58: In vitro growth kinetics of U-87 cells (a): U-87 MG (171st passage open stars, 
173rd passage filled stars), U-87 Luc2/Katushka_Clone 15 (filled circles, 5th passage) and 
U-87 Luc2/Katushka_Clone 18 (filled squares, 5th passage); and U-373 cells (b): U-373 
MG (open stars, 192nd passage) and U-373 Luc2/Katushka_Clone 16 cells (3rd passage 
filled circles, 5th passage open circles); mean values ± SEM. 
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Figure 5.59: Effect of the cytostatic and ABCG2 substrate topotecan on proliferating U-87 
MG cells (filled circles; 160th passage), U-87 Luc2/Katushka_Clone 15 cells (filled 
squares; 4th passage) and U-87 Luc2/Katushka_Clone 18 cells (filled triangles; 4th 
passage). 
Cells were incubated with topotecan at concentrations of: 5 nM (a), 25 nM (b), 100 nM (c) 
and 500 nM (d). 
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Figure 5.60: Effect of the cytostatic and ABCG2 substrate mitoxantrone on proliferating 
U-87 MG cells (filled circles; 160th passage), U-87 Luc2/Katushka_Clone 15 cells (filled 
squares; 4th passage) and U-87 Luc2/Katushka_Clone 18 cells (filled triangles; 4th 
passage). 
Cells were incubated with mitoxantrone at concentrations of: 10 nM (a), 50 nM (b), 100 
nM (c) and 500 nM (d). 
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5.4.4.8 Tumorigenicity of subcutaneously injected co-transfectants in nude mice 
 
U-87 Luc2 / Katushka_Clone 15 and clone 18 co-transfectants were subcutaneously injected 
into nude mice.  
 
 
 
 
Tumors originating from these co-transfectants showed similar growth rates as the U-87 MG 
controls (Figure 5.61). Indeed, in several in vivo passages discrepancies between the growth 
rates of transfectants and wildtype tumors were observed, but there was no clear tendency 
towards a reduced velocity in tumor formation depending on the number of in vivo passages.  
In total, the transfectants proved to be comparably tumorigenic as the U-87 MG wildtype 
cells. This observation was further substantiated by the high take rates of U-87 
Luc2/Katushka tumors (Table 5.7). 
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Figure 5.61: In vivo growth kinetics of subcutaneous U-87 MG tumors (open symbols) 
compared to U-87 Luc2/Katushka_Clone 15 (a) and U-87 Luc2/Katushka_Clone 18 (b) 
tumors (filled symbols) recorded for the 0th (circles), 1st (squares) and 2nd (triangles) in vivo 
passage. 
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Cell line Passage Take rate  
(%) 
U-87 MG 0 80 
 1 100 
 2 100 
U-87 Luc2/Kat. 0 80 
_Clone 15 1 100 
 2 100 
U-87 Luc2/Kat. 0 75 
_Clone 18 1 100 
 2 100 
Table 5.7: Overview of take rates for 
subcutaneous U-87 MG, U-87 
Luc2/Kat_Clone 15 and U-87 
Luc2/Kat_Clone 18 tumors presented 
for the first 3 in vivo passages. 
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5.4.4.9  Optical imaging of subcutaneous U-87 Luc2/Katushka co-transfectant 
xenografts using BLI and FLI 
 
The subcutaneous tumors were investigated by both, BLI and FLI, in order to investigate luc2 
activity and Katushka fluorescence. For this purpose, mice were imaged first by means of 1 of 
the 2 in vivo imaging methods, followed by the second investigation on the next day.  
BLI and FLI experiments demonstrated the ability to specifically determine bioluminescence 
and fluorescence signals arising from the genetically modified tumors. As observed in vitro, 
the luciferase2 activity of U-87 Luc2/Katushka_Clone 15 cells turned out to be lower than 
that of clone 18 cells (Figure 5.62). However, by increasing the electron multiplying gain of 
the EMCCD camera to the maximum value, the bioluminescence of the U-87 
Luc2/Katushka_Clone 15 tumors was easily detectable. By contrast, the Katushka 
fluorescence was significantly lower in subcutaneous tumors formed after injection of clone 
18 cells than in U-87 Luc2/Katushka_Clone 15 neoplasms (Figure 5.62).  
Obviously, the expression of 1 reporter gene was suppressed when the second protein was 
efficiently expressed simultaneously.  
This assumption was supported by long-term investigations (data not shown) which showed a 
total loss of Katushka fluorescence in U-87 Luc2/Katushka_Clone 18 tumors during the first 
3 in vivo passages, whereas the luciferase2 enzyme retained active in the aforementioned 
tumors.  
Comparing the luc2 and Katushka expression in U-87 Luc2/Katushka_Clone 15 xenografts 
over several passages, the imaging studies demonstrated that the red fluorescent protein was 
stably expressed. Furthermore, the activity of luc2 remained sufficient to detect specific 
tumor-associated signals although the EM gain of the EMCCD camera had to be set to its 
maximum. 
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Figure 5.62: BLI and FLI of 
subcutaneous U-87 
Luc2/Katushka_Clone 15 and 
clone 18 tumors (0th passage). 
Whereas the subcutaneous U-87 
Luc2/Katushka_Clone 15 tumor 
shows high fluorescence due to 
Katushka expression, the 
determination of light signals 
after D-luciferin application 
was possible as recently as the 
multiplier gain was set to its 
maximum. Contrarily, the U-87 
Luc2/Katushka_Clone 18 tumor 
showed high expression of 
luciferase2 allowing the 
determination of specific light 
signals even without increased 
EM gains, but instead proved to 
express the red fluorescent 
protein Katushka only in low 
amounts. Furthermore, due to 
the weak fluorescence signals, 
the unmixing procedure turned 
out to be useful only in 
particular for the analysis of 
specific Katushka fluorescence. 
Instrument settings of FLI: exc. 
503-555 nm, em. 580 nm cut 
off, cube range 580-800 nm (10 
nm steps), autoexposure time. 
Fluorescence 
imaging (22 days 
after cell injection) 
Bioluminescence 
imaging (21 days 
after cell injection) 
„Clone 15“ „Clone 15“
„Clone 18“
„Clone 18“ 
Overlay (cube) 
Overlay (cube) 
„unmixed“ 
„unmixed“ EM gain 1, exposure 
time 360 s 
EM gain 255, exposure 
time 360 s
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5.4.4.10  Histology of subcutaneous U-87 Luc2/Katushka_Clone 15 / 18 tumors 
 
The morphology of subcutaneous U-87 Luc2/Katushka_Clone 15 and clone 18 tumors 
(Figure 5.63) turned out to be comparable to the morphology of subcutaneous U-87 Luc2 and 
U-87 Katushka tumors.  
 
 
 
 
5.4.4.11  Optical imaging of orthotopic human glioblastoma in nude mice by means 
of BLI and FLI 
Since luc2 expression retained stable over multiple in vivo passages, and the Katushka 
fluorescence proved to suffice the specific monitoring of tumor signals, U-87 
Luc2/Katushka_Clone 15 cells were orthotopically implanted into the brain of nude mice. For 
the subsequent imaging studies, mice were investigated by both, BLI and FLI, within a period 
of 24 h. 
BLI experiments, which were performed 9 days after cell implantation procedure, showed no 
intracerebral growth of glioblastoma in all 8 investigated animals. This observation was in 
good agreement with FLI studies 24 h later, which failed also to detect brain tumors. On day 
21 and 22 intracerebral tumors were detected in 5 mice by means of BLI but only in 2 mice by 
fluorescence imaging caused by the different sensitivities of the 2 different techniques 
(Figures 5.64 and 5.65). Finally, fluorescence imaging studies on day 28 confirmed 4 of the 5 
brain tumors detected by BLI. Unfortunately, the 5th tumor could not be confirmed by FLI due 
to premature dead of the respective animal. The strong increase in volume of intracerebral 
brain tumors in 3 animals inevitably caused massive detractions of the mice, so that the 
experiments had to be discontinued prior to the final BLI studies. All remaining mice of the 
test group were examined once more by BLI, confirming the absence of glioblastoma in 3 
animals, but detecting a brain tumor in mouse 8. The semi-quantitative monitoring of tumor 
progression in the brain of mouse 8 is demonstrated in Figure 5.66. 
Taken together, the orthotopic implantation of U-87 Luc2/Katushka_Clone 15 cells enabled 
semi-quantitative monitoring of tumor progression by both, BLI and FLI.  
Figure 5.63: Masson-Goldner stain 
sections of subcutaneous U-87 
Luc2/Katushka_Clone 15 (a) and U-
87 Luc2/Katushka_Clone 18 (b) 
tumors (0th in vivo passage). b a
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As expected, the bioluminescence was more sensitive than fluorescence imaging; 
intracerebral tumors could be detected in an earlier phase of the experiment by means of BLI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mouse 2 
Mouse 3 Mouse 4 
Mouse 1 
Bio. 
Bio.  Bio. 
Bio.  Fluo. Fluo. 
Fluo.  Fluo. 
Figure 5.64: Optical imaging of orthotopic U-87 Luc2/Katushka_Clone 15 glioblastoma in 
nude mice (mouse 1 – mouse 4) via bioluminescence and fluorescence in vivo imaging. 
Experiments were performed 21 (bioluminescence) and 22 (fluorescence) days after tumor 
cell implantation into the brain. Blue arrows mark the signals derived from orthotopic 
glioblastoma.  
Instrument setting of BLI: stage height h2c, EM gain 255, exposure time 900 s (300 s after 
intraperitoneal injection of 8 mg D-luciferin), no binning, readout rate 1 MHz. at 16 bit. 
Instrument setting of FLI: stage height h3, exc. filter 503-555 nm, em. filter 580 nm cut 
off, autoexposure time; fluorescence images represent an overlay of 23 pictures (image 
cube with 10 nm steps from 580-800 nm).  
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Figure 5.65: Optical imaging of orthotopic U-87 Luc2/Katushka_Clone 15 glioblastoma in 
nude mice (mouse 5 – mouse 8) via bioluminescence and fluorescence in vivo imaging. 
Experiments were performed 21 (bioluminescence) and 22 (fluorescence) days after tumor 
cell implantation into the brain. Blue arrows mark the signals derived from orthotopic 
glioblastoma. 
Instrument setting of BLI: stage height h2c, EM gain 255, exposure time 900 s (300 s after 
intraperitoneal injection of 8 mg D-luciferin), no binning, readout rate 1 MHz. at 16 bit. 
Instrument setting of FLI: stage height h3, exc. filter 503-555 nm, em. filter 580 nm cut 
off, autoexposure time; fluorescence images represent an overlay of 23 pictures (image 
cube with 10 nm steps from 580-800 nm).  
Mouse 6 
Mouse 7 Mouse 8 
Mouse 5 
Bio. 
Bio.  Bio. 
Bio.  Fluo. Fluo. 
Fluo.  Fluo. 
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Figure 5.66: Optical imaging of an orthotopic U-87 Luc2/Katushka_Clone 15 
glioblastoma in mouse 8 via bioluminescence and fluorescence measurements. Blue arrows 
mark the signals derived from orthotopic glioblastoma. 
Instrument setting of bioluminescence imaging studies: stage height h2c, EM gain 255, 
exposure time 900 s (300 s after intraperitoneal injection of 8 mg D-luciferin), no binning, 
readout rate 1 MHz. at 16 bit.  
Instrument setting of fluorescence measurements: stage height h3, exc. filter 503-555 nm, 
em. filter 580 nm cut off, autoexposure time; fluorescence images represent an overlay of 
23 pictures (image cube with 10 nm steps from 580-800 nm).
21 / 22 days after tumor cell 
implantation 
28 / 29 days after tumor cell 
implantation 
Bio. Bio. Fluo. Fluo. 
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5.4.4.12  Correlation of histology with optical imaging of orthotopic co-transfectants 
 
Table 5.8 summarizes BLI and FLI data from individual animals as well as the corresponding 
results of histopathological studies.  
The overall agreement of imaging results and histopathology was 63 %. Intracerebral U-87 
glioblastomas were detected in 3 mice (mouse 1, mouse 7 and mouse 8) by BLI, FLI and 
histopathology. Histopathological investigation of the brain of mouse 2 proved the existence 
of an orthotopic glioblastoma, however, this malignancy could not be detected by optical 
imaging, neither by BLI nor by FLI. Probably, this tumor was too small and presumably 
located to deeply to be detected by the noninvasive imaging techniques. Reasons for false-
negative and false-positive results have been discussed above.  
The morphology of orthotopic U-87 Luc2/Katushka_Clone 15 tumors proved to be 
comparable to subcutaneous malignancies (data not shown).  
 
  
 
 
 
 
 
 
 
 
 
 
   
Tumor detection by 
Bioluminescence 
signal 
Tumor detection 
by Fluorescence 
signal 
Histological 
detection of 
orthotopic tumor 
growth 
Mouse 1 + + + 
Mouse 2 - - + 
Mouse 3  + + - 
Mouse 4 + + no histology 
Mouse 5 - - - 
Mouse 6 - - - 
Mouse 7 + + + 
Mouse 8 + + + 
Table 5.8: Overview of results obtained from BLI, FLI and 
histopathological examinations on orthotopic human glioblastoma (U-87 
Luc2/Katushka_Clone 15) in nude mice. 
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5.5 Summary and discussion 
For the refinement of an existing orthotopic brain tumor model in nude mice, the human U-87 
MG and U-373 MG glioblastoma cells were transfected with the genes encoding an enhanced 
version of the firefly luciferase (luc2) and the recently discovered far-red emitting protein 
Katushka. These genetic modifications were performed with the aim of establishing 
noninvasive methods for optical imaging of intracerebral tumor progression, predominantly 
during the performance of neuro-oncologic studies.  
Over the last decades, an increasing amount for applications of bioluminescence and 
fluorescence in vivo imaging has been reported in the field of preclinical neuro-oncology. For 
example Murray et al. [Murray et al., 2003] developed an in vivo breast cancer bone 
metastasis model, which enabled the control of tumor growth by bioluminescence imaging. 
Moreover, the therapeutic efficacy of the receptor tyrosine kinase inhibitor SU11248 against 
tumor growth and tumor-induced osteolysis was evaluated in this model [Murray et al., 2003]. 
By analogy, the progression and treatment efficacy of radioimmunotherapy against 
intraperitoneal tumors [Buchhorn et al., 2007] as well as orthotopic human bladder carcinoma 
[Pfost et al., 2009] in mice was reported to be efficiently visualized by BLI. In parallel, the 
development of far-red light emitting fluorescent proteins during the last years offered an 
interesting starting point for the noninvasive monitoring of cancer processes in vivo by means 
of FLI. For example, the red fluorescent protein DsRed2 was demonstrated  to be a powerful 
tool for optical tumor imaging in an orthotopic model of human pancreatic cancer [Katz et al., 
2004] and in an orthotopic human colon carcinoma model [Jarzyna, 2007]. Furthermore, the 
investigations by Katz et al. [Katz et al., 2004] proved the potential of fluorescence in vivo 
imaging to evaluate the efficacy of new antitumor agents. In addition, fluorescence in vivo 
imaging (FLI) of orthotopic pancreatic cancers genetically engineered to express DsRed2, 
revealed high resolution of FLI and turned out to highly correlate with tumor volume and size, 
simultaneously imaged by MRI [Bouvet et al., 2005]. However, so far, there are only few 
applications using the exceedingly interesting far-red protein Katushka for fluorescence in 
vivo imaging in the field of preclinical oncology. 
Encouraged by the successful applications of BLI and FLI reported in the literature, the idea 
of this project was, that the stable expression of luc2 in transfected human glioblastoma cells 
should provide the opportunity to specifically detect light signals from intracerebral tumors 
after application of the substrate D-luciferin.  
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On the other hand, the stable transfection of the glioblastoma cells with the gene encoding the 
Katushka protein was regarded as an alternative method for the noninvasive confirmation of 
intracerebral brain tumors by using fluorescence in vivo imaging devices. Therefore, the red 
emitted light of Katushka expressing tumors should be exploited for the monitoring of 
orthotopic tumor progression. Furthermore, to directly compare advantages and limitations of 
both techniques within the same model, the human brain tumor cells were co-transfected with 
reporter genes, namely luciferase2 and 1 of the 2 red fluorescent proteins, either DsRed2 or 
Katushka, enabling both optical imaging methods.  
Preliminary in vitro studies on luc2 activity and Katushka fluorescence confirmed high 
protein expression in several genetically engineered glioblastoma cells. Moreover, the 
transfectants showed growth kinetics and chemosensitivity against cytostatics (the ABCG2 
substrates mitoxantrone and topotecan) comparable with the corresponding wildtype cells. 
Since the detection limits of transfectants on the in vivo imaging devices turned out to be in 
the same range as the amount of cells which are used for intracerebral implantation, several 
clones were selected for preliminary in vivo studies. For this purpose, the cells were 
subcutaneously injected into nude mice in order to assess tumorigenicity and the suitability of 
luc2 and Kathushka expression for the monitoring of tumor progression in vivo. These 
investigations revealed high take rates in the case of transfected U-87 cells, whereas the 
attempts to establish a subcutaneous U-373 glioblastoma model failed due to lack of 
tumorigenicity. Furthermore, solid U-87 Luc2 and U-87 Katushka tumors proved to express 
luciferase2 and Katushka at high levels, allowing the imaging of tumor progression by 
noninvasive optical methods. Additionally, it was shown, that even in the absence of 
antibiotics (lack of selection pressure) in vivo, both proteins, namely luciferase2 and 
Katushka, were stably expressed over a period of several months. 
Since studies on subcutaneous U-87 Luc2 and U-87 Katushka tumors demonstrated  
tumorigenicity comparable with that of the wildtype cells, as well as expression of luciferase2 
and Katushka remained high in vivo, the aforementioned tumor cells were intracerebrally 
implanted into nude mice. Aiming at monitoring the intracerebral tumor growth, the animals 
were investigated by means of the in vivo imaging devices over several weeks. Thereby, the 
expression of luciferase2 and Katushka in the genetically modified U-87 cells enabled semi-
quantitative determination of the intracerebral tumor growth.  
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Hence, in case of BLI, it could be proven, that the substrate D-luciferin sufficiently crosses 
the blood-brain barrier to visualize intracerebral human glioblastoma progression in nude 
mice. These results are of great value since only few reports in the literature describe the 
monitoring of orthotopic malignant brain tumors, especially xenografts, by means of BLI. 
However, two studies by Szentirmai et al. [Szentirmai et al., 2006] and Dinca et al. [Dinca et 
al., 2007] demonstrated similar efficiency of BLI to monitor the intracranial progression of U-
87 MG xenografts in nude mice. In case of FLI, it was shown, that the noninvasive imaging of 
orthotopic brain tumors by means of the far-red light emitting protein Katushka is a powerful 
tool to monitor intracerebral tumor progression. Moreover, both optical imaging studies, 
namely BLI and FLI, were in good agreement with subsequent histopathological 
examinations. 
 
 
The co-transfection of glioblastoma cells with the genes encoding luciferase2 and Katushka, 
revealed several clones with high functionality of both proteins. In agreement with the mono-
transfectants, only the genetically modified U-87 cell clones showed reproducible in vivo 
tumorigenicity as well as stable expression of luciferase2 and Katushka. The implantation of 
such stably expressing U-87 Luc2/Katushka co-transfectants into the brain of nude mice 
allowed the monitoring of tumor progression by both, BLI and FLI. Thereby, intracerebral 
tumor growth was detectable earlier, when BLI was used instead of FLI. Thus, as expected, 
bioluminescence in vivo imaging offers higher sensitivity compared to the FLI method.   
              
A disadvantage of bioluminescence compared to FLI is the considerably higher complexity of 
such experiments (D-luciferin application, background measurements, exclusion of any 
external light etc.). Moreover, BLI requires an intact blood supply as the substrate, D-
luciferin, has to be transported to the tumor across the blood-brain barrier. Contrarily, the 
detection of fluorescence signals by the tumor is even possible after the death of the animals, 
as long as the protein remains functionally active, provided that the light (excitation and 
emission) is able to penetrate surrounding tissues.   In spite of the aforementioned limitations 
of BLI and FLI, both techniques represent an explicit refinement of the available 
methodology in the preclinical investigation of the therapy of glioblastomas. Predominantly, 
the ability to guarantee the existence of intracerebral tumors at the beginning of neuro-
oncologic studies, and the option to evaluate differences in tumor sizes, represent major 
improvements with respect to future in vivo studies.  
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In conclusion, the semi-quantitative monitoring of tumor progression by such noninvasive 
optical imaging methods in live animals should be a powerful tool to study new approaches in 
the chemo-/radiotherapy of malignant brain tumors including strategies to overcome the 
blood-brain barrier. 
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The treatment of malignant brain tumors, especially of high-grade gliomas, poses one of the 
major challenges in cancer therapy. Despite seminal advancements in imaging techniques for 
the early diagnosis of CNS neoplasms as well as amendments in surgery and radiooncology, 
the prognosis of patients with glioma is very poor. The administration of temozolomide 
adjuvant to irradiation after resection of the tumor - the current “gold standard” in the 
treatment of glioblastoma - has only marginally improved median survival by ca. 3 months. 
Hence, there is an urgent need for novel approaches to the treatment of malignant brain 
tumors. To investigate the efficiency of such regimens in vivo, predictive preclinical animal 
models are indispensible.  
 
In this thesis, three subject areas were dealt with:  
- evaluation of doxorubicin-loaded poly(butylcyanoacrylate) (PBCA) nanoparticle (NP) 
formulations as drug-carriers,  
- modulation of the ATP-binding cassette transporter ABCG2, which is expressed in brain 
capillaries, by newly synthesized inhibitors, as a strategy to overcome the blood-brain barrier 
(BBB) with chemotherapeutics, which are substrates of this efflux pump, and  
- refinement of orthotopic glioblastoma models in nude mice to allow noninvasive optical 
imaging of intracerebral tumors. 
 
 
Human glioblastoma cells U-87 MG, U-118 MG and U-373 MG were incubated with free 
doxorubicin and doxorubicin loaded onto PBCA NPs. As the glioblastoma cells do neither 
express ABCB1 nor ABCG2, Kb-V1 and MCF-7/Topo cells were included, to study effects 
on both efflux pumps. In the crystal-violet chemosensitivity assay, cytotoxicities of the 
doxorubicin-loaded NPs and of the dissolved cytostatic were similar against all glioblastoma 
cells. By contrast, a higher efficacy of the NP formulations was observed on ABCB1-
overexpressing Kb-V1, but not on ABCG2-expressing MCF-7/Topo cells, indicating an 
interaction of the NPs with the ABCB1 efflux pump. Therefore, increased drug concentrations 
in the brain after administration of such drug-loaded NPs to animals, as reported in literature, 
might be due interactions of the NPs with ABCB1 at the BBB. 
 
The modulation of ABC transporters at the BBB represents an attractive strategy to increase 
intracerebral levels of drugs, which are known to be substrates of such efflux pumps.  
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For this reason, the identification of potent efflux pump inhibitors is a promising approach to 
improve the chemotherapy of brain tumors. A series of analogs, derived from the original 
ABCB1 inhibitor tariquidar, was investigated for potency against ABCG2 and selectivity vs. 
ABCB1. To expand methodology and to by-pass problems associated with the flow 
cytometric (FACS) mitoxantrone-efflux assay, two 96-well plate assays, using the fluorescent 
ABCG2 substrates Hoechst 33342 and pheophorbide a, were developed. Interestingly, slight 
structural modifications of tariquidar analogs yielded potent and selective inhibitors of 
ABCG2. The most potent modulator showed an IC50 value of 60 nM in the FACS assay and 
65 and 126 nM in the microtiter plate assays. In view of future in vivo studies, the most potent 
inhibitors were investigated for stability in plasma by the means of HPLC-MS analysis. 
Unfortunately, these compounds are prone to rapid enzymatic cleavage at the central 
benzamide moiety. Therefore, compounds with improved drug-like properties are required. 
Since a regulation of ABCG2 by estrogens is discussed in literature, MCF-7/Topo cells were 
treated with estradiol and subjected to treatment with topotecan. No differences in the 
antiproliferative effect between estradiol-treated and non-treated controls were observed, 
indicating, at best, a therapeutically irrelevant regulation of the ABCG2-level by estradiol. 
 
To investigate the therapeutic value of new concepts, e.g. the combined administration of 
selective inhibitors of ABC-transporters with appropriate cytostatics, the main focus of this 
work was the refinement of in vivo xenograft models. Indeed, orthotopic brain tumor models, 
allowing the monitoring of tumor progression by noninvasive optical imaging, were 
established in nude mice. For this purpose, human U-87 MG glioblastoma cells were 
transfected with the genes encoding luciferase2 (Luc2) and the recently discovered far-red 
fluorescent protein Katushka (Kat), respectively. Numerous clones were characterized in vitro 
with respect to bioluminescence / fluorescence, growth kinetics and chemosensitivity. As the 
transfectants were tumorigenic subcutaneously (s.c.), and Luc2 as well as Kat expression 
persisted in the s.c. model, the human glioblastoma variants were injected into the brains of 
nude mice, where reproducibly growing tumors developed. Most important is the fact that 
these intracerebral xenografts were accessible to both, bioluminescence and fluorescence 
imaging. Moreover, there was a direct correlation between the optical signals and the tumor 
load, confirmed by histology.  
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A Introduction 
 
The cryopreservation of microorganisms and mammalian cells (e.g. spermatozoa, hybridoma, 
and tumor cells) is common practice for long-term storage of these biological materials in cell 
banks [Royere et al., 1996; Oktay, 2001]. By contrast, the cryopreservation of solid tissues, in 
particular human tumors, is of great importance with respect to oncological research on tumor 
biology and experimental pharmacology. Viable small pieces should offer advantages over 
cell suspensions from in vitro culture, especially in case of slowly proliferating cells. In 
addition, cryopreservation of solid tissues will reduce the number of animals required to 
establish and maintain in vivo tumor models. Furthermore, specimen banks gain importance 
with respect to the identification,  characterization and expression analysis of human genes  as 
well as in proteomics [Loken and Demetrick, 2005].  
 
Since tumor tissue is very inhomogeneous containing different cell types, i.e. tumor cells and 
many stromal constituents such as fibroblasts and endothelial cells, cryopreservation is 
associated with various problems [Ehrhart et al., 2009]. Therefore, only very few freezing 
protocols, claiming the successful cryopreservation of human tumor tissues, are available 
[Ehrhart et al., 2009].  A multitude of parameters such as osmotic tolerance of the cells, 
nucleation and growth of ice crystals, recrystallization and vitrification are known to influence 
the effective freezing of individual cell material [Meryman, 2007]. For example, the presence 
of blood vessels and large proteins of the extracellular matrix, such as collagen, can disturb 
the freezing process or interfere with cryoprotectants [Ehrhart et al., 2009]. Due to the fact 
that intracellular ice nuclei are usually not formed in living cells [Meryman, 2007], ice almost 
always develops extracellularly, and the growth of ice detracts water from the extracellular 
solution [Meryman, 2007]. This mechanism leads to concentration of the medium, resulting in 
an increase in osmotic pressure and a concomitant dehydratation of cellular components 
[Meryman, 2007]. Since ice formations inside the cells can damage intracellular structures 
mechanically, intracellular vitrification, instead of freezing, seems a prerequisite for  
successful cryopreservation [Meryman, 2007].  Therefore, in a number of freezing procedures 
the addition of cryoprotectants, such as glycerol or DMSO, is recommended, as these 
compounds enter the cells and thereby counteract the loss of water yielding an effective 
vitrification [Meryman, 2007].   
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B Objective 
With respect to long-term cryopreservation, various tissue preparations of subcutaneous, 
human cancer xenografts were used to establish a standardized freezing method in 
collaboration with Peter Höcherl. The work focused on the validation of the automated 
freezing procedure by studying the tumorigenicity of frozen and re-thawed tumor tissues in 
nude mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
236 Appendix  
 
C Materials and methods 
 
 
 
Chemicals and culture media 
 
DMSO was purchased from Merck, Darmstadt, Germany in analytical quality. Eagle’s 
Minimum Essential Medium (Sigma, Deisenhofen, Germany) was supplemented with 2.2 g/L 
NaHCO3 (Merck, Darmstadt, Germany) and 110 mg/L sodium pyruvate (Serva, Heidelberg, 
Germany). DMEM (Dulbecco’s Modified Eagle’s Medium) was obtained from Sigma, 
Deisenhofen, Germany and supplemented with 3.7 g/L NaHCO3 and 110 mg/L sodium 
pyruvate. 
 
 
Computer controlled rate freezer IceCube 14S  
To devise an automated freezing procedure, a computer controlled rate freezer IceCube 14S 
(SYLAB Geräte GmbH, Neupurkersdorf, Austria) was used. By means of a pressurized liquid 
cylinder, nitrogen is injected into the freezing chamber towards a turbine wheel [SYLAB 
Geräte GmbH, 2004]. Scripting of the freezing programs is carried out on an external personal 
computer, which is connected to the internal process controller within the freezing chamber. 
These internal controlling elements guarantee that, even in case of malfunction of the external 
computer, the IceCube freezer continues working until the end of the program [SYLAB 
Geräte GmbH, 2004]. The operating program of IceCube allows the set-up of freezing 
protocols with a number of variations, such as diverse start temperatures, freezing rates and 
additional features, e.g. the controlled start of crystallization by “autoseeding”. Furthermore, 
the software displays the operating parameters such as the liquid nitrogen uptake as well as 
chamber and probe temperatures, which are registered by numerous Pt-thermometers 
[SYLAB Geräte GmbH, 2004].  
Figure 1 shows an overview of the freezing device, containing the liquid nitrogen container, 
the IceCube freezing chamber and the external personal computer for controlling. 
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Freezing procedure  
For cryopreservation of tumor tissues, culture medium was modified as follows: Eagle’s 
Minimum Essential Medium or DMEM (Sigma, Munich, Germany) were supplemented with 
DMSO (Merck, Darmstadt, Germany) to reach a final concentration of the cryoprotectant of 
10 %. Subsequently, the mixture was sterile filtered and transferred into 2-mL CRYO.S™ 
reservoirs from Greiner Bio-One (Frickenhausen, Germany) under laminar air flow.  
Differently seized tumors (mean area: 70-200 mm²) were selected, and the animals were 
killed by cervical dislocation. The tumors were resected and carefully washed with sterile 
PBS (for preparation see Chapters 3, 4 and 5). For cryopreservation, the neoplasms were cut 
into small pieces of approximately 2 · 2 mm and immediately transferred into the cryo-tubes.  
These tubes, containing a total of 6-10 tumor pieces, were stored on ice until the time of 
computer controlled rate freezing by means of the IceCube 14S freezer according to the 
following standard protocol: 
Figure 1: Technical assembly of the liquid nitrogen reservoir container (black arrow) and 
the corresponding computer-controlled (red arrow) rate freezer IceCube 14S (blue arrow). 
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Samples were taken from ice and allowed to stand at room temperature for approximately 10 
min. Storage times on ice up to 2 h were well tolerated by the tissues. Subsequently, the 
samples were transferred into the freezing chamber of IceCube 14S, and the fully automated 
cryopreservation procedure was started according to the programmed parameters. The 
samples were linearly cooled down from the starting temperature at 20 °C to 0 °C within a 
period of 10 min, and the temperature was held at 0 °C for another 5 min, allowing the 
specimen to equilibrate. Thereafter, the freezing chamber was cooled down to approximately 
 -15 °C, a temperature close to the experimentally determined crystallization point of the 
samples, within 15 min. In order to counteract tissue damage, mediated by the release of heat 
of crystallization, the chamber temperature was rapidly (within 56 seconds) decreased to 
-70 °C by massive influx of nitrogen (held for 30 s, supported by “autoseeding”). Having 
overcome this critical phase, the samples were linearly cooled down to -27 °C (within 2.15 
min) and finally to -22 °C within another 2.50 min. The freezing protocol ended with cooling 
of the samples from -22 °C to -40 °C over a period of 18 min and from - 40 °C to -140 °C 
within another 50 min.  
When the fully automated freezing process was finished, the cryo-tubes were immediately 
transferred into special plastic boxes and stored in Dewar containers over liquid nitrogen in 
the gas phase.  
 
Figure 2 shows a detail of the temperature profile during automated freezing, measured by 
sensors in the sample and the freezing chamber. The starting point of crystallization is 
indicated by the black arrow in the graph. Abrupt, extensive cooling rapidly compensates the 
released heat, becoming manifest in a short overshoot of temperature.  
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Thawing procedure for subcutaneous xenograft implantation into nude mice 
The cryo-tubes, containing the frozen tumor tissues, were transported on liquid nitrogen to the 
specific pathogen free (SPF) area of the animal laboratory. For subcutaneous implantation, the 
tumors where thawed by swiveling the cryo-tubes in warm water (37 °C) as long as the ice 
had been completely melted. Subsequently, the tissue pieces were carefully washed with 
sterile PBS in order to get rid of culture medium and DMSO. Finally, the tumor pieces were 
subcutaneously implanted under the thoracic dermis of nude mice by means of a trocar. Once 
a week, tumorigenicity and the body weight were monitored. 
 
In vivo imaging procedures 
To inspect the effect of freezing and thawing on the activity of luciferase and the functionality 
of Dsred2, tumor-bearing nude mice were imaged by BLI and FLI as described in detail in 
Chapter 5.  
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Figure 2: Details of the temperature registration (optimized freezing protocol) at different 
positions of the technical assembly. The blue curve represents the actual temperature 
within the sample, which shows a rise in temperature at the time of starting crystallization 
(black arrow). Temperature of the chamber at two different positions is shown in red and 
in violet, whereas the turquoise curve shows the programmed temperature profile and the 
green curve the actual course of the temperature during progressive cryopreservation.   
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D Results 
 
Effect of freezing and thawing on the tumorigenicity of selected tumor cells 
To validate the elaborated freezing method, several subcutaneous tumors were selected for 
investigations on their tumorigenicity. Non-frozen tumor pieces, implanted into nude mice, 
served as a control. 
Figure 3 shows the in vivo growth of genetically modified, human colon carcinoma HT-29 
DsRed2 tumors. Whereas frozen and re-thawed tumor pieces showed retarded subcutaneous 
growth, compared to the controls, the take-rates of both groups turned out to be identical. In 
all mice xenograft implantation yielded solid tumors.  
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Figure 3: In vivo growth curves of genetically modified HT-29 tumors. The cells were 
transfected in vitro with the gene encoding the red fluorescent protein DsRed2 (HT-29 
Dsred2 cells). Circles represent the growth kinetics of tumors, serially transplanted  into 
control mice (12th in vivo passage, mean values (±SEM), take-rate 100 %), whereas the 
triangles represent neoplasms that were obtained by implantation of frozen and re-thawed 
tumor pieces (12th in vivo passage, mean values (±SEM), take-rate 100 %)  
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The growth kinetics of subcutaneous HT-29 Luc tumors at different in vivo passages is shown 
in Figure 4. In passage 5 (Figure 4a), both investigated groups showed high take-rates 
(control 83 %, test group 100 %), and the tumors formed in both groups demonstrated 
comparable growth characteristics. Similarly, these properties of HT-29 Luc tumors were also 
observed at higher in vivo passages (Figure 4b and 4c).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: In vivo growth curves of subcutaneous, genetically modified human colon 
carcinoma HT-29 Luc, in different in vivo passages. Circles represent the growth kinetics 
of human xenografts in serially transplanted control mice, whereas the triangles show 
malignancies that were obtained by implantation of frozen and re-thawed tumor pieces. In 
vivo passage 5 (a) (mean values ± SEM, take-rate control mice 83 %, take-rate 
investigational group 100 %); in vivo passage 7 (b) (mean values ± SEM, take-rate control 
mice 100 %, take-rate investigational group 100 %); in vivo passage 8 (c) (mean values ± 
SEM, take-rate control mice 100 %, take-rate investigational group 100 %). 
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Frozen and re-thawed tumor pieces of HT-29 Valt Hyal1 DsRed2 tumors (Figure 5) exhibited 
comparable retardation of subcutaneous tumor progression as previously described for HT-29 
DsRed2 tumors. Nevertheless, freezing and thawing did not affect the take-rates of these 
xenografts (100 % for both colon carcinoma variants).  
 
 
 
 
 
 
 
 
 
Figure 6 shows the in vivo growth kinetics of the human triple-negative breast cancers HCC 
1806 and HCC 1937. The graphs show the 0th in vivo passage, representing tumor formation 
after tumor cell injection, and the 1st in vivo passage of subcutaneous tumors, which was 
obtained by the implantation of frozen and re-thawed solid tumor pieces. The freezing 
procedure did not affect the tumorigenicity of the cells, and the take-rates retained at 
maximum (100 % for both mammary carcinoma variants after implantation of tumor pieces). 
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Figure 5: In vivo growth curves of subcutaneous HT-29 Valt Hyal1 Dsred2 tumors (a). 
Circles represent the growth kinetics of tumors in control mice (6th in vivo passage, mean 
values (±SEM), take-rate 100 %), whereas the triangles represent neoplasms, which were 
obtained by implantation of frozen and re-thawed tumor tissue (6th in vivo passage, mean 
values (±SEM), take-rate 100 %).  
Growth kinetics of subcutaneous HT-29 Sneu Hyal1 Dsred2 tumors (b). Circles represent 
the growth kinetics of tumors in control mice (12th in vivo passage, mean values (±SEM), 
take-rate 100 %), whereas the triangles show malignancies that were obtained by 
implantation of frozen and re-thawed tissue pieces (12th in vivo passage, mean values 
(±SEM), take-rate 100 %).   
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Effect of freezing and thawing on the activity of luciferase and DsRed2 
fluorescence 
 
Since cryopreservation of solid, genetically modified tumors might be interesting for animal 
experiments, the functionality of introduced proteins had to be proven after freezing and 
thawing. For this purpose, the luciferase activity and the DsRed2 fluorescence were 
investigated by BLI and FLI (see Chapter 5).  
 
 
days after cell injection/implantation
0 20 40 60 80 100
tu
m
or
 a
re
a 
[m
m
²]
0
50
100
150
200
250
300
a 
days after cell injection/implantation
0 20 40 60 80 100
tu
m
or
 a
re
a 
[m
m
²]
0
50
100
150
200
250
300
b 
Figure 6: In vivo growth curves of subcutaneous, human breast cancer xenografts in nude 
mice. HCC 1806 tumors (a); circles represent the growth behavior of subcutaneously 
injected cells (0th in vivo passage, mean values (±SEM), take-rate 100 %), whereas 
triangles show the growth kinetics of tumors that were obtained by implantation of frozen 
and re-thawed tissue pieces (1st in vivo passage, mean values (±SEM), take-rate 100 %). 
HCC 1937 tumors (b); circles represent the growth behavior of subcutaneously injected 
cells (0th in vivo passage, mean values (±SEM), take-rate 100 %), whereas triangles show 
the growth kinetics of tumors, obtained after  implantation of frozen and re-thawed tissue 
pieces (1st in vivo passage, mean values (±SEM), take-rate 100 %).  
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Freezing and thawing did not affect the activity of luciferase. The intraperitoneal injection of 
4 mg D-luciferin into nude mice, bearing subcutaneous HT-29 Luc colon carcinoma, resulted 
in strong specific bioluminescence signals, not only when the tumor tissues were implanted 
freshly, but also when frozen and re-thawed tissue samples were used for implantation 
(Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Optical imaging of subcutaneous HT-29 Luc tumors (5th in vivo passage) using 
BLI.  
Bright field image and corresponding bioluminescence signal originating from a “control-
tumor” which had formed after implantation of a fresh small tumor piece into the animal 
(a, b).  
Bright field image and the specific bioluminescence from a tumor, which had grown after 
implantation of a frozen and re-thawed tissue piece (c, d).  
Instrument settings of BLI: stage height h2b, exposure time 90 s, normal gain 0, readout 
rate 1 MHz. at 16 bit. Tumors are marked by blue arrows in the bright field images. 
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Effects of freezing and thawing on the functionality of the red fluorescent protein Dsred2 
were investigated by means of FLI (Figure 8). As observed for the activity of luciferase, the 
freezing did not affect the functionality of DsRed2. Tumors, which had developed after 
implantation of frozen and re-thawed tumor pieces, could be easily visualized by their 
fluorescence.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Optical imaging of subcutaneous HT-29 Dsred2 xenografts (a, b), 6th in vivo 
passage, and HT-29 Sneu Hyal1 Dsred2 double-mutants (c, d), 12th in vivo passage. Tumors 
were generated after implantation of frozen and re-thawed tissue pieces. Blue arrows point 
to the tumors in bright field images. 
Fluorescence images show the overlay of 23 fluorescence images in the range of 580-800 
nm in 10 nm steps, analyzed by the unmixing procedure.  
Instrument settings were as follows: stage height h2, excitation filter 503-555 nm, emission 
580 nm cut off, exposure time 70 ms (HT-29 Dsred2 tumor) and 60 ms (HT-29 Sneu 
Hyal1 Dsred2 tumor).  
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E Summary  
With respect to long-term storage of solid tumor samples, a standard procedure for computer 
controlled rate freezing was developed. Several parameters were optimized in order to reduce 
putative tissue damaging by released heat of crystallization. For validation of the method, 
several human tumor types were investigated with respect to tumorigenicity after controlled 
freezing and thawing. Furthermore, effects of freezing and thawing on the functionality of 
luciferase or the fluorescent protein DsRed2 were inspected by BLI and FLI. 
Tumorigenicity studies showed that in several cases the implantation of cryopreserved tissue 
samples yielded in a slightly retarded growth compared to the implanted freshly dissected 
tumor pieces. Nevertheless, all investigated types of xenografts showed a take-rate of 100 % 
after implantation subsequent to freezing and re-thawing. In addition, the functionalities of 
luciferase as well as the red fluorescent protein DsRed2 were retained during 
cryopreservation. Thus, future tumorpharmacological studies using human xenografts in 
immunodeficient mice will be facilitated a lot by the established automated freezing 
procedure.  
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